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Summary:
Numerous drugs are chiral, generally only one enantiomer is therapeutically active
while the other antipode is completely inactive or shows often undesired and/or toxic
side effects. For this reason, all new chiral drugs are now formulated in enantiopure
form. Non-steroidal anticancer and antifungal drugs contain the same chemical structure
e.g. Bifonazole 6a and non-steroidal aromatase inhibitors such as the Menarini
anticancer drug 18. They are characterized by the presence of single chiral centre in
benzhydrilic position. The present work was aimed at new procedures for the synthesis
of both Bifonazole 6a and the Menarini aromatase inhibitors 18 in enantiomeric pure
form.
In order to prepare enantiopure synthons and final products several synthetic
methods were developed.
A chiral lithium aluminiumhydride complex with (R)-(-)-2-isoindolinyl-butan-1-ol
(R)-(-)-24 as auxiliary was used for the asymmetric reduction of ketones 25a-d and
26a,c in order to obtain the corresponding enantiopure alcohols.
Racemic and enantiopure alcohols 27a-c,g,m and 31a-1 were used as starting
materials in multi-step syntheses for the corresponding N-imidazole derivatives in
racemic and enantiopure forms. Involved are three reaction steps: (a) Mitsunobu
reaction with 4,5-dicyano imidazole to obtain the N-4,5-dicyanoimidazole derivatives
33a-m; (b) hydrolyses of the N-imidazole-4,5-dicarbonitrile derivatives 33a-m to the
corresponding diacids 34a-m, (c) thermic decarboxylation of the diacids  34a-m to
the final N-imidazole derivatives 35a-d.
This synthetic procedure was exceptionally well suited for the production of
enantiopure N-alkyl imidazole derivatives 34a,b, instead gave high chemical yield but
complete racemic products with benzylic alcohols 31d and benzhydroles 27a-c.
  Using a modified Marckwald procedure starting from chiral amines (S)-(+)-44
and (S)-(+)-51 it was possible to synthesize the imidazole ring and to obtain the
corresponding enantiopure (S)-(+)-1-(2-octyl) imidazole (S)-(+)-35a and (S)-(+)-1-
phenyl-1-ethyl imidazole (S)-(+)-54. (S)-(+)-35a presented an identical specific rotation
as the corresponding compound obtained from the three step synthesis discussed
above and proved the inversion of the configuration during the Mitsunobu reaction.
In order to obtain the enantiopure aryl-2-benzo[b]furan methanols 27 a new
synthetic method was considered instead of the asymmetric reduction of the
corresponding ketones that lead to poor results. The use of the lipase SAMII allowed
the synthesis of enantiopure 1-aryl-2-propyn-1-ols (R)-(-)-58a-c,e,h-l in high
enantiomeric excesses and good chemical yields via hydrolysis of corresponding
racemic acetates 60a-c and chloroacetates 61a-l (Scheme 7.4).
The racemic and enantiopure 1-aryl-2-propyn-1-ols 58 a-l were cyclized with 2-
iodophenol to the corresponding aryl-2-benzo[b]furan carbinols 27g-h and 63a-d and
with 2-N-Mesyl iodoaniline to aryl-2-(N-mesyl)indol carbinols 64a-g using Pd(0) as
catalyst. Both products were obtained in high e.e. and chemical yield. These constitute
the first applications of Pd catalyses with enantiopure arylpropynols.
The reaction conditions were optimized in order to maximize chemical yields and
enantiomeric excesses. Finally an hypothesis for the mechanism of cyclization was
formulated. The first step is the Pd0 catalyzed addition of the acetylenic compound to
the 2-iodophenol leading to 62; the second step is the CuI catalyzed cyclization to
benzo[b]furane derivatives 27 or to N-Ms-indol derivatives 64.
In conclusion the present work led to advances in the stereoselective synthesis of
antifungal agents such as bifonazole 6a and the aromatase inhibitors 18; in fact the
application of the described methodology to an enantiopure amine may probably lead
to the target molecule in enantiopure form.
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Chapter 1 1
1.Introduction
1.1. Chiral Drugs
A large fraction of the many thousand drugs on the market are chiral
compounds (Fig1.)1. Due to economic factors, but also for traditional
reasons, many of them are marketed as racemates. Depending on the
number of asymmetric centres, they can exist as two or more enantiomers
(2n, where n is the numbers of chiral centres). For long time it was assumed
that their manufacture in enantiomerically pure form was too expensive and
difficult to perform due to the lack of synthetic methods for their
preparation.
Drugs
1675
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Semisynthetic
475
Non chiral
6
Chiral
469
Sold as single enantiomers
461
Sold as racemate 
8
Synthetic
1200
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Sold as single enantiomers
Sold as racemate 
720
480
58
422
Figure 1.1: Chiral drugs: applications as single enantiomers or as racemic mixtures.
Stereoselective syntheses and techniques for the separation of
diastereoisomers are now available and have reached economic feasibility,
thus the situation is changing  rapidly. Similar arguments are valid for the
use and synthesis of agrochemicals (Fig 1.2.).
Chapter 1 2
Pesticides 550
Natural products
Synthetic
537
Non chiral
Chiral
sold as single enantiomers
Sold as racemate 
447
83
Chiral sold as single enantiomers13
1313
7
Figure 1.2: Chiral pesticides and their application as single enantiomers or as racemic
mixtures.
All life processes are characterized by a high level of dynamic
organization requiring an intricate regulatory network for inter- and
intracellular communication and for communication between living
systems and their environment. Conveyance of information is largely
controlled by messenger molecules that  selectively interact with
particular sites of enzymes, receptors, carrier molecules, etc., which are
essential components constituting the basis of life. Drugs, pesticides and
pheromones can be regarded as exogeneous messengers. They are
designed for particular functions and are "released" under particular
conditions . Like endogenous messengers, they usually act on specific sites
such as receptors or enzymes. Endogenous and exogeneous messengers
can be subject to activation and/or inactivation by metabolic conversion.
Examples are prodrugs, prehormones and propesticides.
The selectivity - the discriminatory capacity of the specific sites for
messenger molecules and substrates - is based upon complementary
chemistry. This can be visualized as the key and lock principle, not as a
static but as a dynamic process of mutual adaptation, an "embracement"
between substrate and enzyme, or messenger molecule and receptor. The
complementary principle concerns the distribution of charge at the
interface of interacting molecules and the spatial structure of the
interactions. Stereoselectivity of biological systems and stereospecificity
in the action of chiral bioactive xenobiotics is a "natural" matter.
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The concept of stereochemistry and stereoselectivity in biological
processes dates back to Pasteur and van't Hoff-Le Bel, about 100 years
ago. The four valences of carbon imply that, if four different groups are
attached to one carbon atom, the spatial arrangement results in a centre of
asymmetry and thus the occurrence of stereoisomers, such as enantiomers
having a mirror image relationship. Based on the concept of a three point
interaction, the eutomer3,4  may bind to its site of action a, b, g, via three
groups, A, B, and C. The antipode, frequently called the distomer, in
contrast can only fit with two groups (e.g. A B with a and b), with group C
being in the wrong position w , (Fig. 1.3).
C
D
g
w
A B
a b
w
g
ba
C
D
A
B
Figure 1.3: Three-point interaction of enantiomers with a receptor (schematic).
The distomer therefore will have a low affinity. It may be totally
devoid of action or only "inactive" regarding the desired activity. It can
however act in another sense e.g. in causing undesired side reactions or
even antagonize the active isomer. In general, it is possible to assume that
the two enantiomers of a particular compound can have a) equal
pharmacological activity, b) one may be inactive, or c) one may be toxic,
or d) the two might have unequal degrees of various kinds of activities.
In the past, medicinal chemists had been content to develop mostly
racemic forms of chiral drugs, under the assumption that both
enantiomers were equally active or one enantiomer was inactive and
innocuos. The extra steps and expensive chemicals needed to synthesize
enantiomers meant much higher production cost. However, a number of
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trends have developed an irresistable wave of prospects for new chiral
drugs to be developed as single enantiomers. There is also a strong
movement towards so-called "racemic switches"- single enantiomers
derived from older chiral drugs originally marketed as racemates.
The development of chiral drugs as single enantiomers received a big
boost from the American  Food and Drug Administration (FDA)
communication in the summer of 1992 due its its long - awaited guidelines
for the marketing of these drugs. The issue to be decided was whether drug
companies may market such compounds as racemic mixtures or whether
they must develop them as single enantiomers. FDA's position is that drug
companies have the choice of whether to develop chiral drugs as racemates
or as single enantiomers. But the interpretation of guidelines will rest with
individual FDA reviewers considering particular cases. And under the
guidelines, drug companies will have to furnish rigorous justification for
FDA approval of racemates. So, in order to avoid unpleasant surprises,
most drug companies have decided to develop only single enantiomers.
Several have also issued instructions to their research departments to avoid,
whenever possible, chiral molecules.
This evolving regulatory climate in the development of chiral drugs
presents many opportunities to drugs firms and their suppliers. The main
beneficiary will be the chemist, because the resolution of racemates,
asymmetric synthesis, and the determination of enantiomeric purities are
chemical activities.
Many chemists are seeing an advantage in "racemic switches", the
redevelopments of drugs, already approved as racemate, as pure
enantiomers. Patents of many racemic drugs are expiring or running out,
and drug companies, in order to defend themselves against competition
from generic drug producers can patent pure enantiomers of the racemic
drug.
In this case fewer biological tests are needed for an enantiomer to be
approved.
In fact, many older racemic drugs are being switched by third party
firms under the very noses of the original discoverers and/or principal
marketers. One attraction for these third party entrepreneurs in
discovering unexpected and thus patentable properties of enantiomers; or
patenting the most economical production process. One of these racemic
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switches is in the area of analgesics. Thus Menarini (Italy) has collaborated
with the British Company Chiros, ( Cambridge, England) to develop (S)-
(+)-Ketoprofene 1 (Fig 1.4). Discovered by Rhone-Poulenc  it was sold in
the U.S. as racemate under the name Orudis, while the enantiomer has been
registered by Menarini in Spain. The (S)-(+) enantiomer is an analgesic/anti-
inflammatory drug whereas the (R)-(-) isomer shows activity against bone
loss in periodontal disease5.
O
Me
CO2H
1
*
Figure 1.4: (±) Ketoprofene 1 (±) 2-(3-benzoylphenyl) propionic acid
The discovery of two different pharmacological effects for opposite
enantiomers is a common driving force for a racemic switch.
Nebivolol, producted by Janssen Pharmaceuticals, is an example for
different pharmacological actions in two enantiomers. It had been
developed as a b-blocker for hypertension. But, whereas (+)-Nebivolol is a
b-blocker, the (-) enantiomer is a vasodilating agent. Thus, by alleviating
hypertension by two different mechanisms of action, the racemate may be
considered superior to either enantiomer5.
There is also a hypothetical case of a chiral drug that is degraded by
metabolic reactions at a site distant from the asymmetrically substituted
carbon atom. This way both enantiomers would be inactivated at the same
rate. Therefore, an inactive enantiomer may serve as a sacrifical substrate
for degradation of the enzyme, thus prolonging the residence time of the
active enantiomer in the body. To achieve the same therapeutic benefit, the
patient would have to take the same dose of expensive enantiomers as of
the cheaper racemate.
Clearly, all industrial observers believe that if the potency of an active
and inactive enantiomer is such that the dose can be cut in half, the patient
will benefit.
Candidates for racemic switches are also antifungal agents, non
steroidal inhibitors of aromatase (anticancer), cardiovascular drugs, non
steroidal anti inflammatory drugs (NSAIDs), central nervous system
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agents, antihystaminica, and prescription drugs being considered for
eventual over the counter sale (OTC's).
This thesis will focus on the synthesis of antifungal agents and  non
steroidal inhibitors of aromatase.These two classes of drugs share general
chemical structures and mechanisms of action. In fact both inhibit two
different cytochrome P-450 dependent enzymes having a protoporphyrin
heme as catalytic site. They present (Fig. 1.5) an heterocyclic moiety such
as an imidazole or triazole in a benzylic or benzhydrilic position.
Furthermore the asymmetric centre is the benzhydrilic or benzylic carbon
wich is the core of the molecules connecting all other parts of the molecule.
Aromatic Moiety Aromatic Moiety
Imidazole or Triazole
Benzylic or Benzhydrylic 
Chiral Centre
Figure 1.5: General structure of antifungal agents and non steroidal aromatase inhibitors.
Even though these classes of drugs have very simple structures, they
have never been synthesized in enantiopure form.
1.2. Enzymes containing the Cofactor Cytochrome  P-450.
Cytochrome P-450 dependent enzymes constitute a family of enzymes
which catalyze the oxidation of a large range of biological substrates. The
P-450 dependent enzymes are divided into 10 groups and 18 subgroups
based on sequence alignment with groups sharing greater than 30%
sequence homology and subgroups with homology greater than 46%6,8.
The enzymes bind dioxygen and through a stepwise cleavage of the O2
double bond incorporate one oxygen atom into non activated C-H
Chapter 1 7
-bonds9. It is now widely accepted that some enzymes of the P450
subgroup (notably aromatase and lanosterol 14-a-demethylase) in
extension to their role in hydroxylation and related oxygen insertion
reactions can catalyze a sequence of reactions leading to C-C bond
cleavage8,9. Cytochrome P-450-dependent lanosterol 14-a-demethylase
(P-450 DM) catalyzes the first step of the biochemically important
conversion of lanosterol to cholesterol by removal of the 14-a-methyl
group of lanosterol to give the D 14-15 desatured sterol10, or ergosterol.
Both cholesterol and ergosterol are essential constituents of the cell
membranes in mammals and fungi, respectively.
HO
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Aromatase 
14-a-Demethylase
Figure 1.6: Site of action by Aromatase and 14-a-Demethylase
The aromatase Cytochrome P-450 is involved in the specific
recognition and binding of C-19 steroid substrates and catalyzes the
multistep oxidative reaction sequence leading to aromatization of the A ring
of the steroid 72. In figure 1.6 the reaction sites of the Aromatase
Cytochrome P-450 and the Lanosterol 14-a-demethylase (P-450 DM) are
shown.
1.2.1. Inhibitory Activity of Antifungal Agents   on 14-a-
Demethylase.
Ergosterol 2 is the main structural component of fungal cell
membranes (Fig.1.7).
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2
Figure 1.7: Ergosterol 2
 Diminuition of ergosterol 2 is believed to be the primary mechanism
by which many fungicides inhibit fungal growth.
HO
3 HO 3a
Figure 1.8: Lanosterol 3 and 24-methylenedihydrolanosterol 3a.
An early precursor in the synthesis of ergosterol 2 is mevalonic acid
which is condensed via several steps into squalene. The cyclization of
squalene oxide leads to lanosterol 3 and 24-methylene-dihydrolano-
sterol11,12 3a ( Fig. 1.8). 3a accumulates in drug treated cells because of
the inability of these cells to remove the C-14 methyl group. In contrast,
demethylation would lead to 4,4-dimethylfecosterol, the next sterol along
the biosynthetic pathway leading to ergosterol.
The specific action of fungicides in preventing demethylation at C-14
is controlled by a Cytochrome P-450 enzyme involved in the
demethylation process. It is believed to involve the association of a
heterocyclic nitrogen atom with the protoheme of Cytochrome P-
45013,17. The demethylation at C-14 of the sterol nucleus involves three
reaction steps, shown in Scheme 1.1.
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CH3
OH
14
O2 NADPH
Cyt P-450 DM
OH
Cyt P-450 DM
O2 NADPH
Cyt P-450 DM
O2 NADPH -CO2
Scheme 1.1: Demethylation of Lanosterol 3 by 14-a-Demethylase
Inibitors prevent the first step of the reaction14.The inhibition of C-14
demethylation is thought to be due to the binding of a heterocyclic nitrogen
atom in an azole to the protoheme iron atom which in turn would prevent
the activation of oxygen that would normally take part in the reaction. The
non heterocyclic portion in the antifungal agents binds to the lipophilic sites
of Cytochrome P-45015.
Under normal conditions, azole (N-substituted imidazole and triazole)
antifungal antibiotics cure mycoses by inhibiting the fungal P-450 DM at
concentrations which are not expected to affect the corresponding host
enzyme16. The accumulation of 14-a-methylated sterols in azole-treated
fungal cells affects the membrane structure and their function, resulting in
the inhibition of fungal growth 16, 18.
Differential inhibition of this cytochrome P-450 enzyme between
pathogenic fungi and humans is the basis for the clinically important activity
of azole antifungal agents. The analogous differential inhibition of the
enzyme between fungi and plants is also responsible for the utility of azole
derivatives as agricultural antifungal agents16. The specificity of the
inhibitors is determined by the differential complementarity between the
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structure of the agent and the active sites of the fungal and host enzymes19.
One of the reasons to continue the search for better antifungal agents is to
increase their specificity towards fungal enzymes. This is an important goal
especially under pathological circumstances, where the immune system is
compromised to a great extent (AIDS pathology, major surgery intervention
follow by an infection) and the side effects (inhibition of the host P-450
DM) due to overdosage of the azole compounds may eventually cause the
death of the patient20, 21.
1.2.2 Antifungal Agents on the market.
Since the advent of the antifungal imidazoles in 1969 several of these
compounds have been successfully developed and marketed. Many of
these compounds are limited in their use due to their intrinsic toxicity and
scarse solubility. Nevertheless, they positively contribute in the area of
antifungal chemotherapy. A brief survey of some more widely used
antifungal imidazoles is given below. All antifungal agents can be classified
into three major classes: Ketoconazole 4a  and its analogues  4b-c ( Fig.
1.9), Miconazole 5a and its analogues 5b-d ( Fig. 1.11) and Bifonazole 6a
and its analogues 6b-d ( Fig. 1.12).
In the Ketoconazole series 4a-c ( Fig. 1.9) the azole moiety is not
directely connected to the chiral centre. The second class is  represented by
the Miconazole series 5a-d ( Fig. 1.11) having  the imidazole or triazole ring
in a homobenzylic position, while the chiral atom is in the benzylic position.
The last group is exemplified by Bifonazole 6a and its analogues 6b-d (
Fig. 1.12). Here the imidazole moiety is in benzhydrylic position which also
constitutes the chiral centre.
1.2.2.1 Ketoconazole and its analogues 4a-c.
The structures of Ketoconazole 4a and its analogues 4b-c are shown
in Fig. 1.9.
At present the best drug in the imidazole class of antifungal agents is
Ketoconazole22,244a. It was synthesized and developed by Janssen
Pharmaceuticals in 1977; Ketoconazole (cis-1-acetyl-4-[[2-(2,4-dichloro-
phenyl)-2 (1H-imidazol-1-ylmethyl) -1,3-dioxolan-4-yl] methoxy] phenyl]
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piperazine) is also the most extensively documented antifungal
imidazole25,26.
Cl
Cl
OO
R'
R
O N N OAcR'=4a R= Imidazole
 4b R= 1,2,4 Triazole O N NR'=
4c R= Imidazole S NH2R'=
4d R= Br R'=
O
O
4 a-d
Figure 1.9: Structures of Ketoconazole 4a and its analogues 4b-c, and together with the key
intermediate for the enantioselective synthesis 4d.
Ketoconazole 4a has been shown to have in vitro  activity against a
broad spectrum of fungi including the three genera of dermatophytes,
yeasts, dymorphic fungi and a variety of others. In vivo studies with
several animal species demonstrated a broad spectrum of activities against
superficial as well as systemic fungal infections.
The United States Food and Drug Administration approved 4a in
1981 for the treatment of candidias, chronic mucocutaneous candidias,
oral candidias, candiduria, coccidiomycosis, histoplasmosis, chromomy-
cosis and paracoccidiomycosis27-29. One of the salient characteristics of
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Ketoconazole 4a is that it was the first orally active antifungal agent of the
imidazole class after clotrimazole.
Ketonazole 4a, as compared with amphotericin B and miconazole, is
well tolerated although certain problems in its use in therapy are reported in
the literature (nausea, vomiting or anorexia, abdominal complaints)30.
Gynecomastia has been reported to occur in 3-8% of patients receiving
ketoconazole and this may result in a direct effect of the drug on the breast
tissue31. Another adverse reaction associated with ketoconazole is hepatic
toxicity. 4a has also been shown to have a similar inhibitory effect on the
enzyme responsible for the conversion of lanosterol to cholesterol in
mammals and has been demonstrated to lower cholesterol levels in
humans32,33. In addition, it inhibits a number of other cytochrome P450
enzymes involved in steroidal biosynthesis and drug metabolism. It has also
been shown to block adrenal steroidogenesis by inhibition of the corticoid
11-b-hydroxylase34. For these properties it has been utilized to treat
prostate cancer and Cushing's syndrome35.
Ketoconazole 4a is marketed as racemic mixture of the cis-(2S,4R)
and (2R,4S) enantiomers as illustrated in figure 1.9.
It is one of the few antifungal agents which has also been synthesized
in enantiopure form. Starting from optically pure (R)- and (S)-solketal
tosylate 4e (figure 1.10), by transketalization with apropiate ketones, both
enantiomers of 4a and also the corresponding trans derivatives were
prepared36.
The same chiral building block has been used to synthesize selective
inhibitors of the mammalian 14-a-demethylase in order to reduce the
cholesterol levels in the humans37.
The latest stereoselective synthesis of both enantiomers of
Ketoconazole 4a has been reported in 1995. Starting from commercially
available (R)- or (S)-epichlorohydrine38 4f (Fig. 1.10), (+)-or (-)-4a
Ketoconazole was obtained in nine steps38.
O O
OTs
O
Cl
(S)-4f(S)-4e
Figure 1.10: (S)-solketal tosylate 4e and (S)-epichlorohydrine 4f.
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The four stereoisomers of Ketoconazole 4a were evaluated for their
effectiveness as inhibitors of the cytochrome P450 involved in:
(a) cholesterol biosynthesis and degradation (lanosterol 14-
a-demethylase and cholesterol 7-a-hydroxylase); (b) steroid hormone
biosynthesis (cholesterol side chain cleavage, progesterone 17a,20-lyase,
deoxycorticosterone 11-b hydroxylase and aromatase) and (c) xenobiotic
transformation (lauric acid hydroxylation  and  progesterone
2a -, 6 b -, 15 a -, 16 a -, 21 hydroxylation)36.
It was shown that the cis-isomers are more potent inhibitors of
mammalian lanosterol 14-a-demethylase than the diastereomeric trans-
isomers. The cis-(2S,4R) isomer is three times more active than its
antipode36.
The most important analogues of Ketoconazole 4a are Terconazole
4b, cis- 1,4,2- (2,4-dichlorophenyl) -2- (1-ylmethyl) -1,3 -dioxolan - 4-
ylmetoxyphenyl -4- (methylethyl) piperazine, a triazole ketal synthesized by
Janssen Pharmaceuticals.39
In this case the heterocyclic moiety is a 1,2,4 triazole instead of the
imidazole, and contains a t-butyl group instead of an acetate group in
position 4 of the piperazine.
In 1995, Menarini reported the first stereoselective synthesis of (+)-or
(-)-Terconazole 4b.
The synthesis of both enantiomers of Terconazole employed as
starting material (2R,4R)-(+)-and (2S,4S)-(-)-bromobenzoate 4d (Fig. 1.9)
which have been also used as advanced chiral intermediates for the
synthesis of both enantiomers of ketoconazole40. Another synthesis of the
analogues of Ketoconazole 4c has been reported in 199441.
Terconazole 4b has also been shown to be highly effective in vivo for
the topical treatment of various experimental models of dermatomycosis
and candidiasis. It also shows some oral activity against experimentally
induced superficial mycoses 42.
1.2.2.2 Miconazole and its analogues 5a-d.
Miconazole 5a and its analogues  5b-d are shown in Fig 1.11.
Miconazole 1 - [2,4 - dichloro -b- (2,4-dichloro-benzyloxy) phenyl]
imidazole nitrate 5a is a phenylethyl imidazole derivative synthesized by
Janssen Pharmaceuticals in 1969 43.
Chapter 1 14
Cl Cl
O
N
N
R
5a
5b
5c
5d
R=
R=
R=
R=
Cl
Cl
Cl
Cl
Cl
S
Cl
5 a-d
Figure 1.11: Miconazole 5a, Econazole 5b, Isoconazole 5c , Tioconazole 5d .
 No informations are available in the literature regarding the
stereoselective synthesis of 5a and its analogues 5c-d. Miconazole 5a has
been shown to have a broad spectrum of antifungal activities 44.
Dermatophytes, pathogenic yeasts, dimorphic fungi, Aspergillus
species and several mycetoma-causing agents have been shown to be
susceptible to clinically obtainable concentrations of this compound 45.
Clinically, Miconazole 5a can be administered either intraveneously or
topically. It requires solubilization in polyethoxylated castor oil for
intravenous administration, but this vehicle has been suggested to be
responsible for many side effects within this therapy 46. The role of this
imidazole derivative in the therapy of fungal diseases remains uncertain,
it has never been properly defined. Some authors 47 have reported the
oral use of miconazole in the prophylaxis in neutropenic cancer. Topical
applications to treat dermatophytes appears to be moderately successful.
Fortunately, no side effects resulted from topical treatments48.
Econazole 1-[2-(2,4-dichlorophenyl)-2-(4-chloro benzyloxy) ethyl]
imidazole 5b, an analogue of 5a was also synthesized by Janssen
Pharmaceuticals 49.  In the literature there are no informations regarding
its stereoselective synthesis, but it has been also reported that one of the
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single enantiomers and the racemic mixture virtually showed the same
antifungal activity 50.
The antimicrobial activity of Econazole 5b has been shown to be
similar to that of 5a against dermatophytes, pathogenic yeasts, dimorphic
and filamentous as well as gram positive bacteria 51,52.
Isoconazole 5c, 1- [ 2, 4- dichloro -b- ( 2, 6 - dichloro benzyloxy )
phenylethyl] imidazole nitrate, is an antifugal imidazole structurally related to
both Miconazole 5a and Econazole 5b, produced by Janssen
Pharmaceuticals.
No informations are available on the enantioselective synthesis or
chemical resolution of this compound, neither the antimicotic activity of a
single enantiomer.
Isoconazole 5c has been demonstrated to have a broad activity
spectrum in vitro against dermatophytes, pathogenic yeasts, pathogenic
filamentous fungi , gram positive bacteria and tricomonas 53. It is very
effective in the treatment of experimentally induced infections following
topical application. In fact, this compound has been developed and
marketed for  the topical treatment of vaginal candidiasis53.
Tioconazole, 1-[2-[ (2-chloro-3-thienyl) methoxy]-2-(2,4dichloro
phenylethyl]-1H-imidazole 5d is a substituted imidazole derivate sythesized
by Pfizer. 5d has been shown to be 4 fold more active than 5a against
Candida sp. while it is comparable to 5a in its inhibitory activity against
Aspergillus sp.54 . The main use of this drug is as a topical agent for the
treatment of skin mycose, vaginal candidiasis and tricomoniasis54.
1.2.2.3. Bifonazole and its analogs 6a-d.
Bifonazole 6a and its analogues 6b-d are shown in figure 1.12.
Bifonazole, 1-[(4-biphenyl)phenylmethyl]-1H-imidazole 6a, is an imidazole
derivative synthesized by the Bayer AG in racemic form55. Up to now there
are no reports regarding its stereoselective synthesis.There are also no
pharmacological informations available regarding the activities of the single
enantiomers.
Bifonazole has been shown to have a broad spectrum of antifungal
activity in vitro against many pathogenic yeasts, dimorfic pathogens,
dermatophytes and pathogenic filamentouses fungi56.
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Figure 1.12: Bifonazole 6a and its analogues 6 b-d.
 Generally, Bifonazole 6a was found to be comparable to Clotrimazole
6d in its in vitro antifungal activity, although quantitatively Bifonazole 6a
was somewhat less potent than Clotrimazole 6d. Experimental studies in
vivo have demonstrated that it is effective in treating dermatophitic
infections, this effectivity being attributed to the therapeutically achievable
fungicidal effect on dermatophites and to the long residence time of the
compound on the skin. Pharmacokinetic studies have demonstrated that this
drug is not mutagenic57 and well tolerated. The efficacy of Bifonazole as a
topical antifungal agents has been shown by several clinical studies and it is
equal or superior to the comparable antifungal imidazoles tested. It has
fewer side effects and has the distinct advantage of a single daily dose
treatment58.
Analogues of bifonazole are 6b and 6c in which the biphenyl moiety
was modified. 6c has been shown to be comparable in its activity to
bifonazole against Candida albicans and Candida sp.59, while 6b has a
higher activity than bifonazole in the treatment of these same diseases 60.
Clotrimazole, 1-(O-chloro-a,a-diphenylbenzyl) imidazole 6d, is a
tritylimidazole in which the benzene ring carries a chlorine substituent. It
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was synthesized by the Bayer AG in 1972 61. It has been shown to have a
broad spectrum of antimicrobial activity against dermatophytes, pathogenic
yeasts, filamentous and dimorphic fungi, as well as against some gram-
positive bacteria. Studies have shown that 6d required only a very short
contact time in order to achieve maximum inhibitory activity62 It
substantially inhibits the uptake and intracellular pooling of leucine, lysine
and other aminoacids in the absence of glucose 63.
Clotrimazole 6d was shown to be orally active in early in vivo  studies
but problems with toxicity and side effects directed the development
towards topic applications. The efficacy in the treatment of experimental
fungal infections decreases as a function of time64. A progressive decline in
serum concentrations of the drug after administration over several days has
not been observed. This means a high metabolic stability and a long half
life. Other problems following oral administration 65 are unacceptable high
incidences of gastrointestinal disturbances, as well as hepatic and adrenal
changes.
Clotrimazole 6d has been proven to be effective and safe in the topical
treatment of a variety of fungal infections. It is as effective as hystatin in the
treatment of superficial Candida infections. Clotrimazole 6d has been
shown to be also active in the treatment of oral Candidiasis.
1.3. Inhibitory activity of anticancer drugs on Aromatase.
The biosynthesis of steroids occurs in the gonads where sexual
steroids are produced and in adrenals where glucocorticoids and
mineralcorticoids are synthesized. However, extra glandular production of
some steroids also takes place in peripheral tissues. For example,
aromatase, which converts androgens into estrogens has been identified in a
wide variety of tissues.
A number of clinical situations are documented in which steroid
hormones, either in normal amounts or when produced in excess play a
role in the pathogenesis of diseases. Thus, inhibiton of the steroid-
producing enzymes is a valuable means of treating these conditions. Until
recently, however, there were relatively few inhibitors available that
were specific  for any one steroidogenic enzyme. Most of these
compounds inhibit steroid hydroxylation and interact with the
Cytochrome P-450 component of the enzymes.
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In the last few years, several compounds have been identified that
selectively inhibit aromatase. Since estrogens are important in a variety of
physiological processes and diseases such as gynaecomastia, precocious
puberty, and endometrial and breast cancer - the leading cause of death
among women66 with approximately 40000 deaths per years in the U.S.A.
alone67 , selective inhibitors of aromatase are proving useful for both
investigational and therapeutic purposes 68.
Basic and clinical data suggest that human breast cancers can be
divided into hormone-dependent and hormone-independent subtypes, the
former accounting for one-third of the over 100,000 new cases diagnosed in
the USA each year, and even being more prevalent in postmenopausal
women 69. It was envisaged that an effective inhibition in the biosynthesis
of estrogens may be useful for controlling the amount of circulating
estrogens and, consequently, of estrogen-dependent disorders 70,71.
1.3.1. The Enzyme Complex Aromatase.
The aromatization of C19-steroids (androgens) on the way to C18-
steroids (estrogens) constitutes the last and most important step in the
biosynthetic pathway from cholesterol to estrogens (Scheme 1.2). This is
performed by the enzyme complex aromatase (estrogen synthetase),
consisting of a flavoprotein  NADPH dependent-cytochrome P-450
reductase that transfers electrons from NADPH (nicotinamide adenine
dinucleotide) to the terminal enzyme, and a specific form of the cytochrome
P-450 enzyme system, known as aromatase cytochrome P-450, which is the
protein involved in the specific recognition and binding of C-19 steroid
substrates.
It catalyzes the multistep oxidative reaction sequence leading to
aromatization of the ring A of the steroid 72. Aromatase, along with other
steroidogenic enzymes such as the cholesterol side-chain cleavage enzyme
(desmolase), 21-hydroxylase, 11b-hydroxylase, 18-hydroxylase, 17a-
hydroxylase, and 17,20-lyase, form part of the subgroup of cytochrome
P-450 enzymes.
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Scheme 1.2: Biosynthesis of androgens and estrogen.
These enzymes are characterized by a heme-iron group, which
activates molecular oxygen. A review addressing the mechanicistic aspect
of oxidative reactions catalysed by the P-450 enzymes with particular
relevance to steroidogenesis has been reported73.
Selective inhibition of this ultimate step in estrogen biosynthesis by
specific inactivators of aromatase may soon become a useful therapeutic
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tool for controlling pathological conditions associated with endogenous
estrogens, such as breast and endometrial cancer 74-84, and benign
prostatic hyperplasia 85-87and this by reducing their levels without
affecting production of other physiological steroids.
Aromatase, therefore, has important functions in female
development and reproduction. In humans, it is produced in the ovaries
and here first in the theca cells and then in much greater abundance in the
granulosa cells of the developing follicle 88. During pregnancy, the
enzyme is produced in the syncytiotrophoblast of the placenta. In the
male, aromatase is present in the Leydig cells of the adult testes 89.
Estradiol produced by the testes is thought to be involved in regulating
androgen biosynthesis and the proliferation of the Sertoli and Leydig
cells. In early development, local production of estrogen in the brain has
been shown to be essential for sexual differentiation of the male
phenotype. Central aromatization is necessary for the manifestations of
many kinds of sex behavior, neuroendocrine and developmental responses
of several species.
In addition, aromatase is formed in a number of other tissues
throughout the body. The most important sites of non-gonadal estrogens
are muscle and adipose tissue 90, where production increases with age in
both sexes. Peripheral aromatization is the main source of estrogens in
post-menopausal women 91.
1.3.2. Enzyme properties.
Aromatization of androgens to estrogen occurs via a series of
reactions. The enzyme aromatase catalyzes the formation of aromatic C18
estrogenic steroids (estradiol and estrone) from C19 androgen precursors
(testosterone and androstenedione), containing the 3-keto-D4 grouping in
ring A of the steroid nucleus.
The process (Scheme 1.3) involves three enzymatic hydroxylation
92-96 which are promoted by the ability of the prosthetic group (heme
iron porphyrin complex) of the aromatase to activate dioxygen for
insertion into nonactivated C-H bonds. The first two occur at the C-19
methyl group, followed by the attack at C-4 by an enzyme nucleophilic
group. Endo shift of the C-4 - C-5 double bond and of the peroxy link to
the heme of the cytochrome and elimination of the C-19 methyl group as
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formic acid results in the formation of the enzyme-bound intermediate93.
(scheme 1.3).
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Scheme 1.3: Proposed mechanism for the aromatisation of the C-19 Aldehyde
intermediate via hydroperoxyacetal.
This intermediate collapses to an aromatized product via elimination of
the 1b-H and enolisation of the resulting keto-diene moiety which releases
the estrogen and simultaneously regenerates the unchanged and active free
enzyme95,96.
Whether the third hydroxylation occurs at C-19, C-1 or at C-2 of ring
A (as previously hypothesized) 97-100, is still unclear and the
stereochemical outcome of the elimination of the 1- and 2- hydrogens are
still matters for debate. Recent communications, however, confirm the
intermediacy of the C-19 aldehyde , which is then attacked by the (heme-
iron)-bound hydroperoxy group to give a hydroperoxy acetal, which
collapses to generate the aromatized product and formic acid via the
concerted loss of the 1b-H and the cleavage of the C-10 -C-19 bond,
followed by the enzyme assisted loss of the 2b-hydrogen 101-107.
Regardless which mechanism will eventually emerge as the one best
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describing the aromatization of androgens, any hypothesis which provides
the basis for designing compounds which selectively inactivate this process
will have served its purpose 93.
1.4. Steroidal and irreversible inhibitors 108.
Compounds that interfere with the aromatase enzyme activity may be
classified as reversible or irreversible inhibitors. An attractive approach to
the irreversible inactivation of aromatase is the use of steroidal compounds
possessing latent reactive functionalities which are unmasked at the
enzyme’s active site.
The first selective aromatase inhibitors reported were C-19
steroids109. These compounds were substrates analogues and exihibited
typical properties of competitive inhibitors. They included 1,4,6-
androstatriene-3,17-dione 7 109, 4-hydroxyandrostene-3-17-dione (4-OHA)
8 110 and 4-acetoxyandrostenedione 9 111 (Fig. 1.13)
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Figure 1.13: Irreversible inhibitors of Aromatase.
Interestingly, some of these inhibitors have been found to cause
inactivation of the enzyme112 and appear to be functioning as mechanism-
based inhibitors. While not intrinsically reactive, inhibitors of this type
are thought to compete rapidly with the natural substrate and
subsequentely interact with the active site of the enzyme. They bind either
very tightly or irreversibly to the enzyme and are  thus causing its
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inactivation.113. Because of their binding to the active site, these
inhibitors should be quite specific and should also have lost effects in vivo
as a result of inactivating the enzyme. Thus, the continued presence of the
drug to maintain inhibition is not necessary and the chance of toxic side
effects, therefore, will be reduced. The inactivation of Aromatase by 4-
OHA 8 can be envisaged to result from the redirection of the elimination
reaction by the enzyme-bound intermediate as shown in scheme 1.4 with the
hydroxy group in position 4 ( the latent alkylating group), followed
by rapid protonation and loss of water, instead of the normally departing
enzyme nucleophile. Enolisation then occurs to aromatize the steroid ring
A and inactivation results due to the inability of the enzyme to release the
steroid product (scheme 1.4).
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Irreversible inhibition of aromatase
Scheme 1.4: mechanism of irreversible inhibition of aromatase by 4- OHA 8.
Inactivation of aromatase by the potent inhibitor 8 was demonstrated
following preincubation of the compound for various lengths of time with
microsomes from human placenta or rat ovaries in the presence of
NADPH. After removal of the compound, a time dependent loss of
enzyme activity was observed, which followed pseudo-first order
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kinetics112. This inactivation of the enzyme can be prevented,
if high concentrations of the substrate are present during the reaction. Thus,
binding of [6,73H] 4-OHA 8 to aromatase purified from human placenta
can be prevented by preincubating the enzyme with androstenedione. This
finding also suggests that the inhibitor interacts with the enzyme at the same
site as the substrate and at its active site.
Other steroidal aromatase inhibitors have been shown to cause
inactivation. 7a-substituted androstenedione derivatives have been studied,
several of which cause inactivation of aromatase 114, 115. The covalent
nature of the binding of 7a-(4'amino)phenyltio-1,4 androstadienedione (7a-
APTADD) 10 (Fig. 1.14) to aromatase was demonstrated by several
methods.
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Figure 1.14: Latest generation of irreversible inhibitors of Aromatase
Among several C19 acetylenic analogs of androstenedione designed as
mechanism-based or enzyme-activated inhibitors, the 10-(2-propynyl)estr-4-
ene-3,17-dione (MDL 18962) 11 has been reported being the most potent
aromatase inhibitor 116 (Fig. 1.14). 11 has significant and long lasting
biochemical and pharmacological activity in vivo.
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Two newer compounds which demonstrated biological activity are 6-
methylen-androsta-1,4-diene-3,17-dione (FCE 24304) 12 or
Examestane117 and 4-aminoandrosta-1,4,6-triene-3,17-dione (FCE
24928) 13 118 (Fig. 1.14) which cause inactivation of aromatase.
13, named Minamestane, is an orally active, irreversible aromatase
inhibitor without any intrinsic androgenic activity119. The in vivo  and in
vitro activity of 13  has been compared to that of FCE 24304 12
(exemestane) and 4-OHA 8 (formestane). No effect was observed on the
5a-reductase and cholesterol side chain cleavage activity and the
compound showed no significant affinity for androgen and estrogen
receptors.
1.5. Non-steroidal and reversible inhibitors.
The number of structurally distinct non-steroidal Aromatase
inhibitors is rapidly growing, and the biggest class still are the azole
containing analogues. The diversity of active structures contaning the
azole moiety continues to expand, thanks to the ingenuity of chemists and
the tolerance of the target enzyme for alternate substrates.
Aromatase is inhibited by non-steroidal compounds such as
aminoglutethimide  3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione 14a
(AG) and its analogues 14b-d (Fig. 1.15).
This compound was first introduced as an anticonvulsant but its use
was restricted when it was realized that the drug causes adrenal
insufficiency. Aminoglutethimide 14a was the first aromatase inhibitor
used in the treatment of metastatic breast cancer120 in post menopausal
women but it is far from being an optimal drug121-123.14a has a chiral
center at C(3) of the glutarimide ring. The R-and S- enantiomers have
very different activities toward aromatase inhibition, the R-isomer being
36 fold more active124-125.
AG 14a  is also an inhibitor of another P-450 enzyme, responsible
for the cholesterol side chain cleavage (desmolase)126 and thus the
conversion of cholesterol into pregnenolone. Its inhibition thus reduces
the level of corticosteroid production. Patients treated with AG 14a must
therefore receive hydrocortisone replacement therapy in order to
counteract this effect. AG 14a shows effects to the central nervous system
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(NCS) producing drowsiness and ataxia. To overcome these side effects,
many others analogues have been synthesized as shown in figure 1.15.
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Figure 1.15: Aminoglutethimide 14a and its analogues 14 b-d.
The 4-pyridyl analogue (R)-3-ethyl-(4-pyridyl)-piperidine-2-6-dione
14b has been developed as a selective inhibitor of aromatase 127. It does
not inhibit desmolase and does not produce the CNS side effect of AG
14a 128. It is now in the last step of clinical trials in the U.K.
Recently other analogues of AG 14a  possessing an improved
selectivity profile and enhanced potency e.g. (S)-(+)-3-(4-aminophenyl)-
3-cycloexyl-piperidine-2,6 dione 14c 129 and (1R,5S)-(+)-1-(4
aminophenyl)-3-cycloexylmethyl-3-azabicyclo-[3;1;0]-hexane-2,4-dione
14d130 appeared in the literature as possible back-up for AG 14a.
1.5.1. Fadrozole 15.
Fadrozole hydrocloride 15 [4-(5,6,7,8-tetrahydroimidazo[1,5-a]
pyridin-5-yl) benzonitrile] monohydrocloride 15, is a drug developed by
Ciba Geigy (Fig. 1.16).
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15 is an advanced representative of the new class of azoheterocyclic
inhibitors of aromatase currently under clinical evaluation131.
N
N
H
CN
15
Figure 1.16: (S)-(-) Fadrozole 15.
 The pharmacological evaluation of Fadrozole hydrocloride 15 proves
this drug to be a very potent inhibitor which effectively inhibits aromatase in
vivo with an ED50 = 0.03 mg/kg132 leading to a significant reduction of
estrogen levels. The excellent selectivity for aromatase over desmolase
supports the working hypothesis that the strong binding to iron is
responsible for the higher potency of the imidazoles and that the
complementarity of the inhibitor with the steroid binding site - while
enhancing this potency- more importantly provides selectivity for aromatase
over desmolase and other cytochrome P-450 enzymes133.
Fadrozole 15 has a chiral centre in the benzylic position; the two
enantiomers have been separated by chiral HPLC and the absolute
configuration has been assigned by X-ray analysis of its corresponding salt
with D-(-)-tartaric acid134. The S - configuration was assigned to the (-)-
enantiomer that was shown to be responsible for the high aromatase
inhibitory activity of fadrozole 134.
The cyano function in the para position of the phenyl ring it is an
essential structural requirement for the high inhibitory activity in fadrozole
and its analogues 133. In fact it seems possible that this polar group might
mimic one of the carbonyl functions of the steroidal inhibitors, either that of
the A or that of the D ring 134.
Ciba Geigy further developed the 1,2,4 - triazole derivatives CGS
20267 16135, the most potent aromatase inhibitor in vivo  reported by the
end of 1993 (Fig. 1.17).
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Figure 1.17: CGS 20267 16
It is important to note that, in this case the heterocyclic moiety is
directly linked to benzhydrilic position.
1.5.2. Vorazole 17.
Vorazole, 6-[(4-chlorophenil)(1H-1,2,4-triazole-1-yl)]-1-methyl-1H-
benzotriazole] 17 has been recently developed136 as a non steroidal
aromatase inhibitor, (Fig. 1.18).
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Figure 1.18: Vorazole 17.
In vitro and in vivo studies with animal models demonstrated high
potency and specificity and thus its potential clinical usefulness in humans.
It has also been demonstrated that almost all aromatase activity resides in
the dextroenantiomer (R83842). The (+)-and (-)-enantiomers were separated
by chiral semipreparative HPLC column. Studies both in animals and
humans showed an almost complete inhibition of in vivo human aromatase
activity138.
In May 1994, Janssen Pharmaceuticals patented the synthesis of both
enantiomers139. The procedure is based on the classical resolution of
17a139 (±)-6- [(4-chlorophenyl- hydrazinomethyl) -1-methyl- 1,4-
benzotriazole] using a chiral acid (Scheme 1.5) and subsequent
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transformation of the appropriate, enantiomerically pure hydrazine
intermediate into (+)-Vorazole 17 139.
NHNH 2
N
N
NCl
NHNH 2
N
N
NCl
(+)-7a
Chiral acid
(±)-7a
Scheme 1.5: resolution of (±)-6-[(4-chlorophenyl-hydrazinomethyl)-1-methyl-1,4-
benzotriazole] 17a using a chiral acid.
1.5.3. Derivatives of 1[(benzo(b)furan-2-yl)-arylmethyl] 
imidazole 18.
Substituted 1[(benzo(b)furan-2-yl)-phenylmethyl]imidazoles have been
demonstrated to be new potent, selective inhibitors of female rat aromatase
in vitro and in vivo  by Menarini, Florence140. The general structure of 18
is shown in figure 1.16.
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N
N
R
18
R = Halides, CN,Me.
Figure 1.16: General structures of Menarini Aromatase inhibitors 18.
These compounds with an IC50 <10 nM show very similar potency as
the best existing non-steroidal reversible aromatase inhibitors, such as
fadrozole, vorazole and CGS 20267. Furthermore 18 was shown to be
about 3 orders of magnitude more potent that AG 14a.
 In table 1 some of this compounds with their relative activity140 are
reported.
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In vivo tests of compounds 18a-g proved to reduce the estradiol level
from 98% to 82% and also to have higher activities than AG 14a.
Compoun
d
R IC50(nM) Relative Potency
18a 4-CN 3 2436
18b 4-Cl 7.7 949
18c 4-F 7.3 1001
18e 2-Me 7.9 925
18d 4-Me 8.8 831
18e 2-Cl 19.5 375
18f 4-Ph 242 30.2
14a AG 7310 1
Table 1.1: relative potencies of compounds 18a-g in comparison with the AG 14a.
The 4-fluoro derivatives 18c have been separated by analytical chiral
HPLC into the two enantiomers and their activity has been tested: the (+)-
enantiomer was 15 fold more active than the (-)-enantiomer141a, and the 4-
cloro derivative 18b has been separated in single enantiomers by fractional
crystallization of their dibenzoyltartrate salt, and also for this molecule the
(+)-enantiomer was 15 fold more active than the (-)-enantiomer141b.
Molecular Modelling using the approches of Furet et al.142 for the
study of the binding of fadrozole to Aromatase  provided a satisfactory
explanation for these observations141.
1.6. Aim of this thesis.
Aim of the thesis was the synthesis of enantiopure benzhydryl azoles.
This target was chosen both for its industrial importance where products of
this kind are under development as racemates, and because it is considered
a chemistry field not yet explored in depth. In order to achieve this goal
three different strategies were chosen (Fig. 1.17):
1) Synthesis and separation of diasteroisomers.
2) Enantioselective synthesis
3) Crystallization of diasteroisomeric salts.
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Enantioselective syntheses and the separation of diasteroisomers were
investigated in greater detail as compared to the crystallization of
diasteroisomeric salts.
Enantioselective Synthesis
Classical Resolution by Crystallization of Diastereoisomeric Salt
CHIRAL TARGETS
Synthesis and sepation of diasteroisomers
Figure 1.17: Synthetic approaches to enantiopure compounds.
The described work was focused on two different classes of drugs: (a)
bifonazole 6a and its analogues (antifungal agents) and (b) the Menarini
anticancer drug 18 (aromatase inhibitor) (Fig 1.18).
O
N
N
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Figure 1.18: Bifonazole 6a and Menarini anticancer drugs 18.
Neither enantioselective syntheses nor general methods to obtain these
classes of compounds in enantiopure form are reported in literature; with
the exception of a patent for Vorazole 17a139.
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These apparently similar two classes of compounds showed a
completely different chemical behavior during our investigation as will
become clear in the following chapters. Structurally quite simple, these
compounds contain only one chiral centre in form of a  tertiary carbon
bound to three different aromatic substituents. The system is prone to form
very stable carbocations143 under acidic conditions, furthermore the
molecules do not posses any site of functionalization which would allow the
formation of separable diasteroisomers. The following paragraphs will show
the consequences of these features on the employed general strategies.
1.6.1. Approaches based on diasteroisomers.
This approach consists in the synthesis of molecules having a
"removable anchor" group, such as a carboxylic acid, amine or alcohol,
that could be bound to another molecule with defined chirality in order to
form a pair of diasteroisomers. The different physico-chemical properties
of the diasteroisomers can be used to separate them by chromatography or
by crystallization. After the separation it is necessary to remove the anchor
group and to generate the molecule with the defined chiral centre under such
mild conditions  as to avoid any possible racemization of the single isomer
obtained from the separation. The last step is the removal of the anchor
from the molecule to generate the free enantiomer of the drug. Again it is
necessary to find the mildest conditions in order to avoid racemizations of
the final compouds (Fig. 1.20 ).
Our target molecules are unfunctionalized and we have designed two
different functional groups to be introduced as anchors, either on the
aromatic moieties or on the imidazole ring (Fig. 1.19).
Ar
N
N
R
Ar
N
N R
Ar=  Biphenyl, Benzofurane R = NH 2,COOH,OH.
Figure 1.19: Possible positions of anchor groups.
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R,S DRUG ANCHOR R MOLECULE DIASTEROISOMER COUPLE RS,RR
SEPARATION OF 
DIASTEROISOMERS
R R RS
CLEAVAGE
R S
CLEAVAGE THE ANCHOR
R S
ENANTIOPURE  FORM
Figure 1.20: Generic procedure used for the production of single enantiomers from a racemic
mixture via the separation of diasteroisomers.
1.6.2. Approaches towards Enantioselective Synthesis.
Retrosynthetic analysis (Scheme 1.6) of the target molecules based on
the easiest synthetic and general pathways results in  two possible key
intermediates:
1) Enantiopure Alcohol A.
2) Enantiopure Amine B.
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Scheme 1.6: Retrosynthetic analysis
The enantiomerically pure targets could be synthesized using two
possible enantiopure precursors such as the alcohol A or the amine B.
Starting from the enantiomerically pure alcohol A a clean SN2 reaction with
imidazole would lead to the final product. Enantiomerically pure amine B
could be synthesized from the enantiomerically pure alcohol A by an SN2
reaction of the appropiate synthons or by asymmetric reduction of the
prochiral oxime C. Amine B is a key intermediate since the imidazole can be
synthesized directely from it. The real general precursor for all of the above
strategies however is the achiral ketone D which by asymmetric reduction
would lead to the enantiomerically pure alcohol A.
1.6.3. Resolution of Diasteroisomeric Salts by Crystallization .
This is the oldest method to produce enantiopure compounds. It is
also the most useful procedure used in industry to produce enantiopure
chemicals. A classical example is the resolution of amines with
enantiopure tartaric acid, the industrial methodology to produce
enantiopure amines. The method is apparently  easy: the racemic amine is
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solubilized in hot ethanol or an other appropriate solvent in presence of the
resolving agent (chiral acid). The diasteroisomeric salts are formed, and if
the choice of solvent and resolving agent is correct, only one
diasteroisomeric salt will precipitate. After separation of the
diasteroisomeric salt by filtration, followed by decomposition with aqueous
base, the free enantiomer is usually extracted in organic solvents. This
procedure, only apparently easy, is often called "art" because the best
solvent and resolving agent can not be predicted a priori.
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2. Theoretical Discussion of Techniques.
2.1 Synthesis of enantiopure alcohols by asymmetric 
reduction of prochiral ketones
2.1.1.Introduction
The reduction of carbonyl groups in aldehydes and ketones to the
corresponding alcohols is ubiquitous in organic synthesis. Since the first
report of such a reduction by diborane more than half a century ago, metal
hydride reagents have became of major importance as reagents of choice
for these synthetic transformations. The opportunities for variations in the
metal, ligands, counterions and reaction conditions have helped to
overcome most problems encountered regarding the stereo-, regio-or
chemo-selectivity in these reactions.
2.1.2. Stereoselectivity.
The origin and magnitude of stereoselectivity observed in the reduction
of chiral carbonyl compounds has long been an area of intense theoretical
and practical studies. Efforts have concentrated largely on the 1,2-
asymmetric induction that occurs in the hydride addition to a carbonyl
group flanked by an asymmetric centre. Cram's rule was formulated to
rationalize the results of nucleophilic addition to aldehydes and ketones
contaning non polar groups1. The most stable conformation A ( Scheme
2.1 ) was assumed to arise by minimization of the interaction between the
largest group RL and the carbonyl group which was coordinated to the
approaching reagent. Addition then occured preferentially from the side of
the smallest substituent RS rather than the larger medium sized group RM.
The outcome of the reduction of ketone A to alcohol B following Cram's
rule is illustrated in Scheme 2.1. This rule enabled a large body of
experimental results to be correlated, however its theoretical base was
subsequentely shown to be flawed.
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Scheme 2.1: Reduction of ketones: Cram's rule.
The results in the reduction of a-halo-ketones or aldehydes were
anomalous and led to Cornforth's dipolar model C (Scheme 2.2), in
which the dipoles of the carbonyl group and the carbon-halogen bond
were in an antiperiplanar arrangement. Reduction then proceeded from
the less hindered side of the ketone C leading to alcohol D2 (Scheme 2.2).
RLRs
O
Cl R
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R
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Cl RCl
OHRL
HRs
H-
Cornforth
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C C D
Scheme 2.2: Reduction of ketones: Cornforth model.
The possibility of chelation in case the a-substituent X was an
hydroxy, alkoxy or amino group was covered by Cram's cyclic or chelate
model E 3(Scheme 2.3). The chelating group X and the carbonyl group
were eclipsed and coordinated to the metal M. The reduction occurs again
from the less hindered side. This model has been widely used to
rationalize the diasteroselectivity in reduction of ketones E when
chelation is important, depending on the nature of the substituent X and
the metal ion M (Scheme 2.3).
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M
Scheme 2.3: Reduction of ketones: Cram's chelate model.
Informations regarding the ground state conformation of carbonyl
compounds demonstrated that the conformation in which one bond is
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eclipsing the carbonyl group is energetically favored. This led Karabatsos to
propose an alternative model4. Calculation suggested that the most favored
conformation G ( Scheme 2.4) would have the medium size group RM of
the ketone G eclipsing the carbonyl group, and addition of the hydride
would occur from the side of the less bulky substituent RS to give  the
alcohol H ( Scheme 2.4 ).
RL
Rm O
Rs
R
O
R
Rm
Rs
RL
Rm
Rs
RL
H
R
OHH
-
KarabatsosH-
G G H
Scheme 2.4: Reduction of ketones: Karabatsos model.
A comparison of the other possible transition state with this
conformation allowed the magnitude of diasteroselectivity to be correlated
with the experimental results.
The most influential contribution towards the interpretation of 1,2
asymmetric inductions in carbonyl group reductions was that of Felkin5.
Attention was directed for the first time to the structure of the transition
state, which was assumed to be very similar to that of the substrate.
Torsional strain caused by interactions between the partially formed
hydride-carbonyl bond and the full bonds at the adjacent centre was
assumed to cause attack perpendicular to the carbonyl group plane and
staggered to the largest or more electronegative group RL. The angle of
approach was later revised by the Burgi-Dunitz trajectory 6a-c, derived from
crystallographic studies. It placed the incoming hydride much closer to the
substituent RS. This interaction was decisive for the selection of this
transition state over the alternative one, in which the position of the small RS
and the medium RM would be exchanged.
Importantly and in agreement with the Felkin model, if two alkyl
substitutions are present, the more stable conformation has the larger group
perpendicular to the carbonyl group and points the remaining alkyl group
away from the incoming nucleophile.
2.1.2.1. Cyclic Carbonyl Compounds.
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The stereochemistry and the mechanism of reduction in cyclic ketones
by metal hydride reagents provided an unique opportunity for the
comparison of experimental results with theoretical expectations. The
models proposed by Cram, Cornforth and Karabatsos described above
were inadequate for explanations of the stereochemical results. The effect
of steric influences, torsional and electronic factors in the reduction, its
stereochemical outcome and position of the transition state have also been
intensely reviewed.
Felkin identified torsional effects in the cyclohexanone 19 whose
reduction accounted for the observed stereoselectivity. Minimization of this
torsional effect in the absence of steric hindrance led to the predominance
of axial attack ( Scheme 2.5 )7.
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Scheme 2.5: Reduction of cyclohexanones 19.
The eclipsing interactions between the incoming nucleophile and the
bond a to the carbonyl group are more important, for any given trajectory,
for an equatorial direction of attack.
The differences are clearly illustrated in the Newman projection of
cyclohexanone 19 ( Figure 2.1 ).
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Figure 2.1: Newman projection of cyclohexanone 19.
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The dramatically enhanced axial selectivity demonstrated in the
reduction of cyclohexenone as compared to cyclohexanone was explained
by the different internal dihedral angle which is reduced from 510 in
cyclohexanone 19 to 220 in cyclohexenone 20. This in turn produced a
dramatic change in torsional interaction regarding both the axial or
equatorial attack, as clear from the Newman projection 20 ( Fig. 2.2 ).
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Figure 2.2: Newman projection of cyclohexenone 20.
This conformation explained also the absence of stereoselectivity in
the reduction of conjugated cyclohexenones.
2.1.3. Chiral Reducing Agents.
The reduction of prochiral ketones to optically active alcohols is one
of the most useful asymmetric reactions.The alcohols produced by such a
process may serve as chiral building blocks at the beginning of a
synthesis, or they may serve as the desired end products. In either case,
the proper selection of the asymmetric reducing reagent is critical, and
several factors may influence the choice of reagent. In choosing an
asymmetric reducing agent, one often seeks to mimic the action of
enzymes.Thus one would like to use reagents that are catalytic, selective,
yield products with high enantiomeric purity and behave predictably with
other functional groups. In addition to the selectivities often associated
with enzymes, it is also desirable to employ reagents that are effective on
a wide range of substrates and allow the convenient isolation of the
products which should be available in both enantiomeric forms. Clearly
no single reagent can be expected to have all these desirable properties.
Thus much efforts have been focused towards developing reagents that
provide useful compromises.
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An asymmetric reducing agent need not be catalytic if it is inexpensive
and can be easily obtained. The cost factor may be further reduced if the
chiral ligand can be recycled. Chiral modifications of metal hydride reagents
with a wide variety of chiral auxiliaries for the asymmetric reduction of
carbonyl compounds have been studied intensively during the last three
decades. However, asymmetric reducing agents developed in the early stage
of this programme commonly provided only low optical induction in the
asymmetric reduction of prochiral ketones8a-c. A wide variety of asymmetric
reducing agents has now become available for such application.
Unfortunally, no one particular reagent is effective for all the different
classes of ketones.
Presently there are more than twenty promising reagents9, however
only during the last decade some of these have found a wide application.
At the moment, only five of them are extensively used in asymmetric
reduction: ( Figure 2.3 ):21a diisopinocamphenyl-chloroborane, IPC2BCl,
(DIP-ChlorideTM); 21b B-isopinocampheyl -9- borabicyclo - [3.3.1]
nonane, (Alpine-BoraneTM);  21c oxazaborolidines; 21d aluminium
complexes derived from optically active 1,1- Binaphthyl-2,2'-diol, such as
BINAL-H; and 21e  BINAP-Ru complexes.
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Figure 2.3: Chiral Complex 21a-e for the asymmetric reduction of prochiral ketones.
Chapter 2 42
Brown's DIP-Chloride 21a, Midland's Alpine-Borane 21b and Noyori's
Binal-H 21d are used in stoichiometric quantities whereas Corey's
Oxazoloboridines 21c and Noyori's Binap-Ru complexes 21e are used
catalytically.
2.1.3.1. Mechanism of Asymmetric Reduction of Prochiral   Ketones.
It is interesting to point out that every chiral reducing agent forms a
different chiral complex or transition state with the corresponding prochiral
ketones. The proposed mechanism for the reduction of prochiral ketones
with 21a (DIP-chloride) and 21b (Alpine-borane) is similar10. Midland
proposed that the reduction proceeds via a bimolecular, six membered
cyclic, boat like transition state in which the tertiary b-hydrogen (in syn-
planar B-C-C-H conformation) eclipsed with the boron atom, is transferred
to the carbonyl carbon. In the transition state, the smaller alkyl group RS is
in the axial position and syn-facial with the methyl group of pinene, while the
bulky alkyl group RL prefers an equatorial position far away from the
pinanyl methyl group (Scheme 2.6).
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Scheme 2.6: Mechanism and transition state for the chiral reduction of ketones with DIP
chloride 21a
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This approach clearly explains the formation of the S-isomer from the
(-) - DIP chloride 21a and the R-isomer from the (+) - DIP chloride 21a
unless the steric bulk of the carbonyl moiety is changed, as in the case of t-
butyl phenyl ketone or in the case of acyl silanes.
A different mechanism has been proposed for Corey's
oxazaborolidines1121c. It constitutes an alternate chair transition state
assembly to explain the origin of the observed enantioselectivity in
oxazaborolidine catalyzed reductions of prochiral ketones.
According to this model ( Scheme 2.7 ), the 1,3 diaxial interaction
between the RL and RS substituents of the ketones and the oxazaborolidone
methyl group differentiates between the two diasteroisomeric transition
states 22a and 22b, leading to the major R-product and the S-enantiomers
as minor products12.
Corey's oxazaborolidines can be used in catalytic amounts (5% molar
with respect to the ketone); the source of hydride is BMS or BH3 -THF in
an equimolar ratio with the ketone. A complete investigation of the reaction
conditions has been reported by the Merck Sharp and Dohme department
of process research12.
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Scheme 2.7: Mechanism and transition state for the chiral reduction of ketones with
Oxazaborolidine 21c.
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Chiral phosphine complexes of late transition metals in a low oxidation
state catalyze enantioselective reductions in a homogeneous phase. Noyori
developed an interesting approach for the enantioselective reduction of
prochiral a-substituted ketones employing an enantiopure Ru (II) complex
with 2,2'-Bis-(diaryl phosphino) 1,1'Binaphtyl (BINAP) 21e/d.
These organometallic catalysts are endowed with functionality and
axial chirality and allow a differentiation between diasteroisomeric transition
states differing in energy of only 10 KJ/mol. Such molecular catalysts are
not only able to accelerate the reaction rate, but also to control the
stereochemical outcome of the reaction in an absolute sense.
BINAP 21e, a fully arylated, C2 symmetrical chiral diphosphine, is one
of the most effective chiral ligands that have been designed13 (Fig. 2.4).
BINAP ligands can accommodate a wide variety of transition metals to
form conformationally unambiguos seven membered chelate rings
containing only sp2 carbons.
PAr2
PAr2
PAr2
PAr2
(R)-BINAP (S)-BINAP
Figure 2.4: R- and S-BINAP 21e.
The single crystal X-Ray analysis of certain square planar or
octahedral BINAP complexes indicates that the seven membered rings have
a higly skewed configuration that provides a distinct chiral microenviroment
in which the phosphophenyl groups are oriented into axial and equatorial
directions14 ( Fig. 2.5 ).
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Figure 2.5: Orientation of posphophenyl groups in BINAP
Thus, spatial characteristics exert a significant influence on the
substrate coordination sites allowing for exceptional efficiency in BINAP
catalysis.
A wide variety of functionalized ketones can be converted into their
respective optically pure alcohols via homogeneous hydrogenation in the
presence of halogen-containing Ru-BINAP catalysts in alcoholic media.
The reaction proceeds in a higly enantioselective and predictable fashion. A
general mechanism which describes this selective process involves initial
coordination of the carbonyl oxygen and the a or b adjacent heteroatom
(such as nitrogen, oxygen or halogen) to create a five to seven membered
metal chelated ring complex prior to hydrogen transfer.
In the BINAP-Ru catalyzed reaction, diverse polar functionalities
facilitate the hydrogenation of the neighboring carbonyl group and allow the
efficient enantioface differentation. The halogen containing complexes of
type RuX2-BINAP, the dimeric triethylamine complex or dicarboxylate
complex, Ru(OCOR)2-Binap, may be used as catalyst, depending on the
ketonic substrates. Methanol or ethanol are the solvents of choice.
The reaction with a substrate:catalyst molar ratio of 2200:230 proceeds
with a reasonable rate at room temperature using an initial hydrogen
pressure of 40-100 atm.
Noyori, in 1979, reported also the use of optically pure 2,2' dihydroxy-
1,1'- binaphthyl as LiAlH4 chelating agent. The 1,1' Binaphthol itself has an
axial asymmetry and possesses an extremely high ability of chiral
recognition15.
BINAL-H 21e is prepared by modification of LiAlH4 with (R)- or (S)-
binaphthol and one equivalent of ethanol (Scheme 2.8).
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Scheme 2.8: Formation of BINAL-H 21e.
Complex hydride reagents of the type LiAlHn(OR)4-n are known to
exist in a complicated equilibrium with a variety of disproportionated and
aggregated species16. However, the stereochemical outcome arising from
the rigid, unique chiral conformation of this reagent is most economically
rationalized by the mechanism involving a six membered, chelating transition
state17. For example, in the transition state of the reaction of acetophenone
and (R)-BINAL-H containing an ordinary R' group, the R'O oxygen acts as
bridging atom because of its highest basicity among the three oxygens
bound to Al. Therefore the chair conformation with axial-methyl and
equatorial-phenyl groups 23a is favoured over the diastereomeric transition
state 23b in accordance with the observed enantioselectivity16 (Fig.2.6).
O
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O
Ph
Me
Et
O
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Al
O
O
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repulsion
DISFAVORED
23a 23b
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Figure 2.6: BINAL-H transition state 23a/b in the acetophenon reduction.
The BINAL-H is one of the best chiral LiAlH4 complex reported;
many other examples are reported in the literature such as: LAH-Darvon-
Alc (Alc=2S,3R-(+)-4dimethylamino-3-methyl-1,2-diphenyl-2-
butanol)18a-d , LAH-MEP-ArOH ( MEP = N-Methyl ephedrine; ArOH =
3,5-dimethylphenol)19a-b, LAH-diamine[diamine(S)-2-(2,6xylidimethyl)-
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pyrrolidine ]20, LAH-aminobutanol [ (S)-4-anilino-3-( methyl amino) -1
butanol21, LAH-DBP-EtOH[DBP=(S)-(-)10,10'dihydroxy,9,9'biphenylan-
thranyl]22, LAH-MEP-NEA (MEP=N-Methylephedrine,NE AN-
ethylaniline)23, LAH-MEP-EAP ( MEP = N-Methyl ephedrine, EAP = 2-
ethylamino aniline24.
All the classes of chiral reducing agents shown above are used for the
reduction of a wide variety of different classes of prochiral ketones.
Unfortunally, however, none of them has never been used for the reduction
of prochiral benzophenones or diaryl ketones.
In these ketones, both moieties linked to the carbonyl group have
roughly the same size. Therefore, the chiral reducing agent fails to
discriminate between the two faces.
To the best of our knowledge, only a small number of methods are
reported in literature for the synthesis of enantiopure benzhydroles or diaryl
methanoles. In particular: (a) asymmetric reduction by Rodoporidinium
toruloides25, (b) resolution of diasteroisomeric acetyl mandelate esters26, (c)
nucleophilic addition of aryl groups to aromatic aldehydes by
organotitanium chelating agents 27. A much more interesting approach has
been reported by E. Brown in 199128describing the use of the very
interesting LAH complexing agent, (R)-(-)- (2)- (isoindoliny) butan-1-ol 24 (
Fig.2.7) which will be described later.
The major advantages of this chiral complexing agent are that the chiral
amino alcohol is very cheap and available in both enantiopure forms.
N
OH
 24
Figure 2.7: (R)-(-)-2-(2-isoindolynil) butan-1-ol 24, Brown's chiral amino alcohol for the
asymmetric reduction of benzophenones.
An ortho-substituent in one of the aromatic rings seems to be essential
for a good stereoselection in the asymmetric reduction of prochiral
benzophenones with this chiral LAH complex. The ortho
bromobenzophenone 25b was reduced to the ortho-bromobenzhydrol 27b
with an enantiomeric excess > 95% e.e.and a chemical yield of 100%
(Scheme 2.8).
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OBr Br OH
LAH1,5(OR)2,5
dry Ether
e.e. > 95%, 100% Yield25b 27b
Scheme 2.8: Chiral reduction of ortho bromobenzophenones 25b by the Brown procedure.
The best molar ratio between LAH and the chiral ligand 24 is 1 to 2.5;
no mechanistic hypothesis regarding the absolute stereochemistry of the
alcohol has yet been reported by Brown.
2.2 Synthesis of enantiopure alcohols by enzymatic resolution
2.2.1. Introduction
Enzymes are proteins, which catalyze numerous biological
transformation in vivo . They are constructed from twenty natural amino
acids. The relationship between the amino acid sequence and its catalytic
activity is still impossible to predict. It is clear that enzymes represent a
valuable class of catalysts for organic transformations and numerous
organic reactions can be catalyzed in their presence. For organic synthesis it
has to be decided whether an enzymatic approach towards the solution of a
particular synthetic problem is more practical than a non-biological
approach. In many instances enzymatic transformations represent only one
alternative or improvement as compared to an existing chemical
methodology. In some cases, however, enzymatic processes are more cost-
effective than non biological methods and thus have clear advantages.
Several large scale enzymatic processes used in industry (resolution of
amino acids with acylase, transformation of pig insuline to human insulin
catalyzed by trypsin, preparation of penicillin analogues with penicillin
acylase, synthesis of optically pure fine chemicals etc) have demonstrated
that enzymatic catalysts can be the best route to fine chemicals.
2.2.2. Enzyme kinetics.
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Enzymatic reactions are as a  whole multistage processes. The
substrate S initially binds non-covalently to the enzyme E at a special site
called the active site. The reversible complex of substrate S and enzyme E
is called the Michaelis-Menten complex. It provides the proper
combination of reactant and catalytic groups in the active site of the
enzyme (equation 1):
E+S ES
K1
K-1
Equation 1
In the active site, after the formation of the Michaelis-Menten
complex, the chemical reaction step takes place and the enzyme substrate
complex breaks down in a slower second step to yield the free enzyme E
and the reaction product P (equation 2):
ES
K2
K-2
E+P
Equation 2
In this model, the second reaction is slower and therefore is rate
limiting for the overall reaction. From this it follows that the overall rate
of enzyme-catalyzed reactions must be proportional to the concentration
of the ES complex. At any given instant in an enzyme catalyzed reaction,
the enzyme exists in two forms, the free or uncombined form E and the
combined form, the ES complex. At low [S], most of the enzyme will be
in the uncombined form E. Under these conditions the rate will be
proportional to [S] because the equilibrium of equation 1 will be shifted
towards the formation of more ES as [S] is increased. The maximum
initial rate of the catalyzed reaction (VMAX) is observed when virtually all
of the enzyme is present as ES complex and the concentration of E is
extremely small. Under those conditions, the enzyme is "saturated" with its
substrate, Further increases in [S] will not cause any increase in rate. After
the ES complex breaks down to give the product P, the enzyme is free to
catalyze the transformation of another substrate molecule. The
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saturation effect is a distinct characteristic of enzyme catalyzed reactions
and is responsible for the plateau observed in figure 2.8.
V
VMAX
[S]
Figure 2.8: Reaction rate as a function of substrate concentration
When the enzyme is treated with a large excess of substrate, there is a
phase called "pre-steady state". During this short period of time the
concentration of the ES complex builds up, but the pre-steady state is usual
too short to be easily observed. The reaction quickly achieves a steady
state in which [ES] (and the concentration of any others intermediates)
remains approximately constant over time. The measured V generally
reflects the steady state even though V0 is limited to the early part during the
course of the reaction. To study quantitatively the relationship between
substrate concentration and enzymatic reaction rate, it is necessary to make
the following assumptions:
1) The breakdown process of ES is considered to be almost
irreversible (K2>>K-2) and during the early part of the reaction the
concentration of the product [P] is negligible and thus the simplifying
assumption can be made that K-2 is very small. The overall reaction thus is
reduced to equation 3:
E+S ES
K1
K-1
K2
E+P
K-2
Equation 3
From this assumption the rate of product formation is ( equation 4):
v = K2 [ES]
Equation 4
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As [ES] in equation 4 can not be a measured experimentally, [E]0 is
introduced representing the total enzyme concentration ( bound and free
enzyme); [S] is considered costant because the amount of substrate bound
to the enzyme at any given time is negligible as compared to the total
concentration of S.
The steady state assumption proposes that the rates of formation and
breakdown of ES are equal ( equation 5 ):
 K1 [E] [S] =K 2[ES]+K1 [ES]
Equation 5
Where [E]= [E]0-[ES].
Equation 5 is resolved leading to an expression for [ES] (equation 6):
 [E] 0 [S]
K2 + K  -1 
K1 
+ [S]
 [ES] =
Equation 6
The value K2+K-1/K1 is the Michaelis-Menten constant Km, and
equation 6 becomes equation 7:
 [E] 0 [S]
+ [S]
 [ES] =
Km 
Equation 7
Now it is possible to change the [ES] in eq. 4 with the expression in
the eq.7 leading to equation 8:
 K 2   [E] 0  [S]
+ [S]Km 
v  =
Equation 8
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This equation can be further simplified because the maximum velocity
will occur when the enzyme is saturated and [ES]=[E]0. VMAX can then be
defined as K2[E]0. Substitution into eq.8 leads to the Michaelis-Menten
equation 9:
VMAX [S]
+ [S]Km 
v =
Equation 9: Michaelis-Menten equation
The Michaelis-Menten equation 9 expresses the rate equation for the
enzyme catalyzed transformed of one  single substrate.
2.2.3 Specificity
Selectivity constitutes  the major synthetic value of enzyme catalysts.
Because enzymes are large chiral molecules with a unique structure at the
active site, they can be highly selective for certain types of substrate
structures and reactions. Useful types of enzyme catalyzed reactions
include the chemoselective reaction of defined functional groups in a given
molecule. The reactions are:
Regioselective
Enantioselective with racemic substrates
Enantioselective with prochiral substrates
Diasteroselective
All such selective reactions occur because during the reaction the
prochiral or chiral reactants form diasteromeric enzyme transition state
complexes that differ in transition state energy (G#).
2.2.3.1. Kinetic resolution of a racemate
In the kinetic resolution of a racemate the two enantiomeric substrates
are competing for the same active site of the enzyme E. If A and B are two
enantiomers, the reaction scheme is as follows (Scheme 2.9):
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E+A EA
K 1A
K -1A
K 2A
E+P
E+B EB
K 1B
K -1B
K 2B
E+Q
Scheme 2.9:
In figure 2.9 the transformation for two enantiomers is represented.
They obviously have different transition state (G#) energies. If the
difference in DG # is high, the enantioselection will be high.
DG*
DG* A
DG* B
E+P
E+Q
E+A+B
DDG*
Reaction coordinates
Figure 2.9: Reaction profile for the kinetic resolution of enantiomers.
The steady state or Michaelis Menten equation can be used to
describe each reaction rate (equation 10 and 11):
 K CAT  vA  =
Km
[E] [A]
A
 K CAT  vB  =
Km
[E] [B]
B
eq.10
eq.11
Equation 10 and 11: reaction rates for two enantiomers.
The ratio of eq. 10 and eq.11 is therefore (equation 12):
 KCAT 
Km
 [A]
A
 KCAT 
Km
 [B]
B
vA 
v B
=
Equation 12: ratio of reaction rates.
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This analysis shows that the ratio of specifity constants
(KCAT/Km)A/(KCAT/Km)B determines the enantioselectivity of the reaction.
These specificity constants are related to free energy terms expressed by
G0=- RT ln K.
The enantioselectivity of the reaction is related to the difference in
energy of the diastereomeric transition states (see Fig.2.9) by equation 13:
DDG*=( DGA*-DGB*) = -RT ln [(Kcat/Km)A / (Kcat/Km)B]
Equation 13
In an enzyme-catalyzed kinetic resolution which proceeds irreversibly,
the ratio of specificity constants also known as enantioselectivity value E
can be further related to the extent of conversion C and the enantiomeric
excess e.e. as shown30 in equation 14. The parameter E is commonly used
in characterizing the enantioselectivity of an enzyme catalyzed resolution.
E=
ln [(1 - C) (1 + ee A)]
ln [(1 - C) (1 - ee A)] ln [1 - C (1 + ee P)]
ln [1 - C (1 - ee P)]
=
Equation 14: Expression of E value.
The conversion C is expressed as C= 1 - A+B / A0+B0 and the
enantiomeric excess eeP = P-Q / P+Q; the concentrations are in Mol%.
Experimentally, equation 14 can be used to determine one of the three
parameters if two are known from experiments. If the E value is known the
equation can be used to predict the ee of the product or the remaining
substrate at a defined degree of conversion.
In a graphic representation the enantiomeric excess (ee%) of product
and substrate is shown as a function of the conversion C (%) for a given E
value. In a normal experiment it is possible to follow both enantiomeric
purities and to calculate with the equation 14 the E value. Generally, in
order, to have a perfect kinetic resolution which can give enantiopure
products and starting material at 50% conversion, the E value must be
higher than 100. In cases of lower E values, only one enantiomer (always
the remaining one) can be obtained enantiomerically pure.
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2.2.4 Lipases.
Most lipases are classified as serine proteases which catalyze the
hydrolysis of lipids to fatty acids and glycerol31. Unlike esterases, which
show a normal Michaelis Menten behaviour, lipases display only little
activity in aqueous solutions in presence of soluble substrates. A sharp
increase in activity is observed when the substrate concentration is
increased beyond its critical micellar concentration32a-c. The increased lipase
activity at the lipid-water interface led to the suggestion that soluble lipases
might undergo a conformational change -interfacial activation- at the oil
water interface33. This conformational change at the interface is supported
by the X-Ray structures of human34a,b and Mucor miehei35a-c lipases,
phospholipase A236a-b and their complexes with inhibitors where the shift of
a loop called "lid" over the active site is clearly shown.
OH
OR'
O-EnzR
R O
O
Enz
RCO2R' + Enz-OH
RCO2H + Enz-OH
H2O
a) ester hydrolysis 
b) esterification 
c) transterification
d) acyl transferR"OH
RCO2R" + Enz-OH
tetrahedral intermediate
- R'OH
Figure 2.10: The four reactions catalyzed by ester hydrolases
Generally lipases catalyze four different reactions involving carboxylic
esters (figure 2.10):
a) Ester hydrolysis
b) Esterification
c) Transesterification
d) Acyl transfer
Although not in all cases proven beyond doubt, it is generally accepted
that the catalytic mechanisms are similar to those of serine proteases which
have been studied in great detail.
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The generally accepted mechanism of serine dependent lipase is shown
simplified in scheme 2.10:
O-
O
N
N O
H
R OR'
O
H
H H
OH
O
NH
N O
R OR'
O-
H H
OH
O
NH
N O
R O
OH
O
NH
N OH
R
O
OH
His
Ser
Oxyanion hole
Asp
His
Ser
Oxyanion hole
Asp
-H2O
His
Ser
+H2O
Asp
Ser
His
Asp
Scheme 2.10: hydrolysis mechanism of serine lipases.
The reaction proceeds via  nucleophilic attack on the carbonyl group
of the substrate ester RCO2R' by the activated primary hydroxy group of
the serine in the active site. The tetrahedral intermediate is stabilized by
formation of hydrogen bonds between the negative charge on the ester
oxygen and the amino acids of the oxyanion hole present in the protein
backbone as shown in scheme 2.10.
There are several examples of X-Ray crystal data which support this
hypothesis 37.
The tetrahedral intermediate is then stabilized by elimination of R'OH
leading to an activated ester termed acyl-enzyme. This is the central
intermediate in all four esterase-catalyzed reactions.
In aqueous media the acyl group of the acyl enzyme is transferred to
the nuclephilic H2O, present in large excess; the equilibrium is shifted
towards the hydrolysis product.
In non aqueous systems the reverse reaction is possible and ester
synthesis occurs (reaction b and c figure 2.10). Esterifications via
enzymatic acyl transfer (reaction d figure 2.10) are particularly attractive for
synthesis because no water is involved. If the acyl doner, which often
serves also as solvent, is used in excess the acyl group from the acyl-
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enzyme intermediate can be transferred also to other nucleophiles such as
R''OH leading to new esters RCO2R''. The success of such acyl transfer
reactions largely depends on the nucleophilicity of the acceptor alcohol
R''OH. Upon inspection of reaction d (figure 2.10) it is evident that the
desired transfer can be achieved only if the initially eliminated alcohol R'OH
is less nucleophilic than R''OH.
This enzymatic process, however is reversible and often requires long
reaction times and a large excess of ester as acyl doner to form the acyl-
enzyme in order to achieve a reasonable degree of conversion38ac.
The application of vinyl or isopropenyl esters as acylating agents for
lipase catalyzed esterifications 39ac offers an effective solution of this
problem because the end side product of the esterification is immediately
converted irreversibly into acetaldehyde or acetone, respectively. (scheme
2.11):
OAcR OH
O O
HOR
Lipase
++
Scheme 2.11: Esterification of alcohol by lipase with vinyl acetate
The only nucleophile present in solution is the alcohol that will be
esterified.
The enantioselectivity E of lipase catalyzed reactions in aqueous
solution, water organic solvent mixtures, and anhydrous organic solvent
follows the classical competitive equation 14 30,39.
2.2.4.1 Active site model for interpreting and predicting the 
specificity of lipases.
The previous absence of a complete set for X Ray data of lipases has
led to the development of simple models for interpreting and predicting the
specifity of enzymatic kinetic resolutions. On the basis of substituent sizes
at the stereocenter, rules, allowing a prediction which enantiomer of a
secondary alcohol is favoured in a kinetic enzymatic resolution have been
developed by analysis of the data reported in the literature and were
confirmed by subsequent experiments. This strategy has been applied to
Chapter 2 58
three different enzymes40 (cholesterol esterase CE, Pseudomonas cepacia
PCL, Candida rugosa  CRL).
A more detailed model has been developed for Pig Liver Esterase
(PLE) based on cubic space descriptors that form the active site41. For this
model, approximately 100 methyl esters with representative structures were
identified and the results of their PLE catalyzed hydrolyses on a preparative
scale were analyzed collectively. This has led to a model consisting of five
binding loci, where the serine region is considered as a sphere with a
diameter of 1 Å. The binding regions controlling specificity are represented
by two hydrophobic and two more polar pockets. The two hydrophobic
sites, which interact with the aliphatic or aromatic hydrocarbon portions of
substrate, have a volume of approximately 33 Å3, and 5,5 Å3 respectively.
Polar groups, such as hydroxy, amino, carbonyl, nitro funtions etc, are
excluded from this area. The hydrophobic pockets can, however,
accommodate less polar groups such as ether or ketal groups, if necessary.
The remaining two sites accept groups that are more polar or
hydrophilic. They are located at the front and back of the active site.
A model accounting for enantioselective esterifications42 catalyzed by
Pseudomonas species has been also developed. Also in this case, from the
literature data, a working hypothesis has been developed assuming that the
alcohol is resolved most efficiently if it has one small and one relatively
large group, the latter slightly removed from the asymmetric center (Fig.
2.11) carrying the hydroxy group.
 
LargeSmall
OHH
Figure 2.11:Simple model for predicting the resolution of secondary alcohols via acylation
This study has led to the development of a model for the lipase
Pseudomonas AK which seems to be effective for the resolution of
molecules with near planar structure. It is not suitable for the resolution of
substrates carrying relatively bulky moieties close to the hydroxymethine
center, or which are unable to adopt low energy planar conformations
around the hydroxy group. The active site is envisaged as a near planar
pocket with a hydrophilic canopy for the alcohol functionality
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projecting above the plane. The depth of this active site area is sufficient to
accomodate at least the terminal methylene group of an allene (>1.8Å). The
model is described in figure 2.12:
2.3Å
2.0Å
3.6Å
2.8Å
5.8Å
5.1Å
3.1Å
Figure 2.12: Two dimensional  representation of the enzyme active site of Pseudomonas AK.
Many other well defined substrate structure/enzyme activity
relationships are emerging. For instance, numerous resolutions of a-aryl
alcohols mediated by SAM II lipase have been reported, allowing to
establish that this is a good enzyme preparation for resolution of these
substrates, and that the R-enantiomer of the alcohol is acylated preferentially
in most cases43-47.
The SAM II lipase shows more than 75% homology with the lipase
from Pseudomonas cepacia, but no X-Ray structure is available at present
in the Cambridge Brookaven Structures Database or has been published.
Hence only qualitative models have been reported48 essentially consistent
with that shown in figure 2.11.
2.2.5. Enzymatic kinetic resolution of propargyl alcohols.
Several enzymes (lipases) are able to resolve racemic mixtures of
propargyl alcohols (esters) into the pure enantiomers by a) esterification
or b) hydrolysis.
Thus, the highly enantioselective esterification of secondary
propargyl alcohols by Pseudomonas sp. has been reported in great
detail42,49. The substrates used in these studies are characterized by the
presence of two substituents of largely different bulkiness, but in no case
an aromatic ring is attached directly to the hydroxymethine group.
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Another example is the resolution of tertiary propargylic alcohols in
presence of Candida cylindracea50 where, however, only low enantiomeric
purities where obtained.
2.3 Mitsunobu reaction: mechanisms and applications.
The Mitsunobu reaction, pioneered by Mitsunobu and coworkers in
196751, has proven useful in a wide variety of synthetic applications
involving alcohols. From the first applications the Mitsunobu reaction has
evolved into one of the primary synthetic tools for inverting alcohol
stereochemistry as evinced by over 1100 citations of Mitsunobu's 1981
review on the subject52. Furthermore, it is a very versatile method for the
condensation of alcohols ROH and various nucleophiles (or acids) HA
leading to the product RA ( Scheme 2.11. ).
ROH + HA
Mitsunobu reaction  
conditions
RA
Scheme 2.11: Mitsunobu reaction.
2.3.1. Reaction Mechanism.
A search of the literature indicated that the mechanism of this reaction
has been the subject of only few investigations 53a-d. The Mitsunobu
reaction takes place in three steps as outlined in scheme 2.12.
'RO 2C N N CO2R' 'RO 2C N N H
CO2R'
+PPh3
'RO 2C N N 
H
CO 2R'
+PPh3
RO +PPH3
Step 1: Adduct formation
PPh3 + + AH
HN CO2R'
Step 2: alcohol activation
ROH +
A-
A -  +
RO +PPH3
2
Step 3: S N2 reaction
+  A -  RA  + O=PPh 3
Scheme 2.12: mechanism of the Mitsunobu reaction.
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2.3.1.1. Step 1: Adduct Formation.
The general procedure for the Mitsunobu reaction encompasses the
addition of dialkyl diazodicarboxylate to a solution of a carboxylic acid, an
alcohol and triphenylphosphine, the usual solvents being dichloromethane
or tetrahydrofuran. In these media, formation of the betaine adduct A
(Scheme 2.13) from dialkyl diazodicarboxylate and  triphenylphosphine
occurs within seconds at -20 °C, as evidenced by bleaching of DEAD upon
addition.
'RO2C N N CO2R' 'RO2C N N CO2R'
+PPh3
PPh3 +
A
-
Scheme 2.13: Betaine adduct formation.
The formation of the betaine originally has been proposed by
Morrison54 and was later substantiated by Bunn and Huisgen55. It has been
generally assumed that the betaine is formed by a Michael type nucleophilic
attack of the phosphine on the nitrogen, the reaction has been shown to be
irreversible56. In the absence of solvent, a deep red solution is produced in
an exotermic reaction, this color was first noted by Mitsunobu57 who
suggested that radical or radical ions might be present and this suggestion
was subsequently confirmed by Jenkins through EPR studies58.
2.3.1.2. Step 2: Alcohol Activation.
The second step of the Mitsunobu reaction entails transfer of the
PPh3+ group from the DEAD-PPh3 adduct A (Scheme 2.14) to the alcohol.
'RO 2C N N CO2R'
+PPh3
RO PPh3
+
A
+   DEADH + A -+ ROH + A-
B
H
Scheme 2.14: formation of the oxyphosphonium intermediate B.
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Three different factors control the rate of this transfer:
A) The basicity of the counterion (A-)generated in the formation of 
the DEAD-PPh3 adduct A.
B) The extent of hydrogen bonding to this counterion
C) Substituent effects in the phospine
Before discussing these effects, first a note regarding the structure of
the oxyphosphonium intermediate. Mitsunobu originally hypothesized  a
phosphonium salt as an intermediate akin to structure B ( Fig. 2.15.), where
the phosphorus has a positive charge and tetrahedral geometry. However,
several recent papers have presented evidence for a neutral phosphorane
structure C (Fig. 2.15.) that contains two molecules of alcohol per molecule
of phosphine53c-d.
OR
PPh3
PPh3P
Ph3P
Ph3P P
PPh3
PPh3
OR
OR
B C
+
Figure 2.15.: Oxyphosphonium structures.
Generally, a neutral phosphorane is formed in the absence of acidic
compounds. The adduct B is stable at -20° C but it rapidly decomposes at
room temperature. Therefore, formation of the oxyphosphonium
intermediate in the presence of the acid component is the best way to
prevent undesirable side-reactions.
2.3.1.2.1. Effect of the basicity of the counterion.
The rate of transfer of the PPh3+ group from the DEAD-PPh3 adduct
A to the alcohol (Scheme 2.14) is highly dependent on the basicity of the
counterion generated in forming the DEAD-PPh3 adduct A as well as on the
extent of hydrogen bonding to this counterion. These effects have been
studied by Hughes53d in connection with the substitution of hydroxy groups
in the side chain of b-lactames.
Generally, this consideration indicates the role of the counterion as a
base for alcohol deprotonation, which in turn must occur before PPh3+
transfer takes place (Scheme 2.16.).
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'RO 2C N N H
CO2R'
+PPh3
RO PPh3 'RO2C N N H
CO2R'
+ ROHA-
A
B
RO -    +   AH
+
-+
+    RO-
Scheme 2.16: oxyphosphonium intermediate B.
Hughes10 studies confirmed this hypothesis. In fact he observed that,
when the DEAD-PPh3 adduct A is prepared in presence of p-TsOH,
formation of the oxyphosphonium intermediate B does not occur due to the
weak basicity of p-TsO- which cannot appreciably deprotonate the alcohol.
However addition of a stronger base to the same reaction, such as
triethylamine (TEA), does catalyze the formation of the oxyphosphonium
intermediate B. This demonstrated that the oxyphosphonium intermediate B
is formed at a rate wich is dependent on the AH/A- ratio and on the basicity
of A-.
In summary, the reactivity of A- as a base and as a nucleophile in the
first two steps of Mitsunobu reaction must be carefully controlled in
solution. This means that if A- is a strong base and a poor nucleophile the
oxyphosphonium B adduct forms, while in the opposite situation, when A-
is a poor base but a strong nucleophile, it competes with DEAD-PPh3
adduct B in reaction with the alcohol.
However, the reaction has a serious limitation regarding the acidity of
HA, which must have a pKa <11 in order for the reaction to proceed
satisfactorily. If HA has pKa >11, the chemical yield of RA is lowered
considerably and with HA having pKa > 13 the reaction does not occur at
all. It is also possible to carry out the Mitsunobu reaction with acids having
pKa >11 if the normal redox system is changed from DEAD/PPh3 or
DIAD/PPh3 (diisopropyldiazodicabrboxylate) to ADDP [(1-1'
azodicarbonyl) dipiperidine] in association with tributyl phosphine60,
because in this system:
A) The phosphine shows increased nucleophilicity in the formation 
betaine A;
B) The positive charge is localized on P thus facilitating the 
nuclephilic attack of RO-
C) The negative charge is localized at the azo nitrogen thus 
increasing its basicity in the betaine A.
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2.3.1.2.2. Effect of Substitution in the Triarylphosphine 
moiety on the Rate of Alcohol Activation.
Hughes studied the effect of substitution in the triarylphosphine on the
rate of alcohol activation and found, as expected, that electron withdrawing
groups, such as chlorine in positions 2 or 4 increase the electrophilicity of
phosphorus. In table 2.1 the relative rates of formation of the
oxyphosphonium intermediate A at 0 °C with substituted triarylphosphines
in CH2Cl2 solution are summarized.
Substituent Relative Rate
m - Cl 6200
p - Cl 3600
H 780
m - Me 300
p - Meo 1
Table 2.1 :Effect of substituents on the rate of formation of the oxyphosphonium intermediate
A.
The strongly desactivating effect of the 4-MeO group suggests that a
significant dp-pp overlap may occur between the aryl ring and phosphorus
as shown in figure 2.13.
P- O+CH3
Ph
Ph
Figure 2.13: dp-pp  overlap
2.3.1.2.3. The SN2 Reaction.
The final step of the Mitsunobu reaction is the SN2 reaction of the
anion A- with the oxyphosphonium intermediate B. Generally the reaction
proceeds with complete stereochemical inversion. However, for particular
substrates, this general rule is not respected, indicating that an SN1
component becomes relevant. Another side- and competitive reaction is the
E1 elimination that in some cases can become the major reaction.
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There are various effects which can influence the rate of SN2
substitution. One of them is the effect of the carboxylate basicity when the
nucleophile is an acid. In contrast to the alcohol activation step, there is
only a slight dependence of SN2 rates on the carboxylate basicity. This
indicates that the SN2 transition state has to some extent SN1 character, with
a small incidence of bond formation and a large incidence of bond
breaking. This is not unexpected, since carboxylates are weak nucleophiles,
while triphenyl phosphine oxide is an excellent leaving group due to the
formation of the strong P=O bond.
The influence of acidity on the SN2 reaction has been also studied for
aryl substituted acids61 and it has been demonstrated that less acidic (more
basic) carboxylate species dictate a slow SN2 reaction. However, with more
acidic (less basic) species, the rates of alcohol activation and SN2
displacement  (step 2 and 3 respectively) became comparable.
In summary the Mitsunobu reaction is dramatically influenced by the
acid component. It appears that there is a relationship between the
dissociation constant of the acid and the overall efficiency of the reaction,
whereby more acidic species generally provide a higher yield of inverted
product.
It is also apparent that synthetically useful yields are dependent on a
variety of electron withdrawing substituents on the aryl carboxylic acid.
2.4 Synthesis of heterocycles by transition metal catalysis.
Organotransition metal chemistry is rapidly becoming an important tool
for organic synthesis and during the past three decades enormous advances
have taken place in our understanding of the structure and reactivity of
organotransition metal compounds. These insights have opened the way for
applications of these compounds to ever burgeoning, fields of organic
synthesis, both as stoichiometric reagents and as catalysts. We were
interested in the synthesis of chiral 2-substituted benzo[b]furanes and 2-
substituted indoles from alkynes and aryl halides mediated by transition
metals(scheme 2.17).
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X
YH
R
R' Y
R
R'
M+
X= Br, I
Y= O, NMs
R= H, Alkyl, Aryl, Esters, alcohols
R'= H, Alkyl, Aryl, Esters, Alcohols
Scheme 2.17: Annulation of triple bonds mediated by transition metals.
Three differents methods are reported in the literature for the synthesis
of these compounds mediated by transition metals:
1) Castro's procedure.
2) Cacchi's procedure.
3) Larock's procedure.
For the first methodology copper(I) was used, for the second and the
third Pd catalysts were employed; all of them were applied to racemic or
achiral compounds.
2.4.1 Annulation of triple bonds by Castro's procedure.
Castro and coworkers62a-d. were the first to discover and study the
substitution of o-halophenols and 2-haloanilines with copper(I) acetylide
followed by cyclization to the 2-substituted benzo[b]furanes and 2-
substituted indoles in the presence of a base (scheme 2.18).
X
YH
Cu
R Y
H
R
Base+
X= I
Y= O, NH, NMs,NTs
R= H, Alkyl, Aryl, Esters, alcohols
Solvent, T.
Solvent = DMF, Py.
Scheme  2.18: Castro's procedure for the synthesis of benzofuranes and indoles.
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The reactions were found to be strongly dependent on the solvent, in
particular on its ability to afford a homogeneous reaction medium. This
aspect is very important for the synthesis of 2-substituted indoles. When
the reaction was carried out in a homogeneous medium (pyridine as solvent)
the ortho amine tolane was obtained (no cyclization to indole occurred),
while in heterogeneous medium (DMF as solvent) 2-substituted indoles
were synthesized 62b,d (scheme 2.19).
I
NH2
Cu
Ph N H
H
Ph
DMF
80°C
NH2
Ph
+
DMF,CuIPyridine
Scheme  2.19: Influence of the solvent in Castro's procedure.
The Castro procedure has found very good applications in the
syntheses of novel adenosine A1 receptor ligands63.
A limit of this procedure was the fact that the copper(I) acetylides had
to be prepared separately and isolated. Also some of them are known to be
shock sensitive and explosive. Furthermore, many functionalized copper(I)
acetylides cannot be synthesized and isolated in the usual manner, because
they are soluble in, or reactive towards, the reaction mixture used for their
preparation. To circumvent these problems a modification of Castro's
procedure was reported in 1989 by Owen64, where the copper (I) acetylide
was generated in situ  from the acetylenic compounds and Cu2O in
presence of base, followed by coupling and cyclization to 2-substituted
benzo[b] furanes (scheme 2.20).
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I
OH
R
H
O
R
R= Alkyl, Si(Me) 3, Ph.
Cu2O
Py, reflux,N 2
Scheme 2.20: Modification of Castro's procedure by Owen
In all these methods the copper(I) was used in equimolar amounts or in
excess depending on the substrate.
2.4.2 General procedure for the synthesis of 2-substituted 
benzo[b]furanes and 2-substituted indoles via Palladium 
catalyzed heteroannulation of triple bonds.
Simultaneously, Cacchi and Yamanaka developed a procedure for  the
synthesis of 2-substituted benzo[b]furanes and 2-substituted indoles,
respectively, by Palladium catalyzed heteroannulation of alkynes (scheme
2.21).
X
YH
H
R Y
H
R
Pd°+
X= Br, I
Y= O, NMs
R= H, Alkyl, Aryl, Esters, alcohols
Scheme 2.21: Cacchi and Yamanaka procedure for the synthesis of 2-substituted
benzo[b]furanes and 2-substituted indoles
2.4.2.1 Yamanaka's procedure for the synthesis of 2-
substituted indoles via  a Palladium catalyst.
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Yamanaka and coworkers have studied65a-c an approach to the
synthesis of 2-substituted indoles in presence of a Copper-Palladium
catalyst. Essentially, this procedure allowed the use of copper (I) in
catalytic amounts and did not require prior preparation and isolation of
copper(I) acetylide. Palladium then catalyzed the coupling between the aryl
iodide and the copper (I) acetylide. Conditions to achieve only the coupling
reaction or both coupling and cyclization have been studied in depth
showing the important role of the R group on the aniline (scheme 2.22).
I
NHR
H
R'
N 
R
H
R'
NHR
R'
N 
H
H
R'
PdCl 2(PPh3)2
+
CuI, TEA, 120°
sealed tube
EtO-Na+
R=CO 2Et
R=Ms
R=  Ms, CO 2Et
R= Alkyl, Aryl.
Scheme 2.22.: Influence of activating groups in the Yamanaka cyclization.
In particular, when R is a mesyl group, 2-substituted indoles can be
directly obtained, while with less electron withdrawing R groups, such as
CO2Et the reaction affords the intermediate, uncyclized coupling product.
This, in turn, can be transformed into the heteroannulated compound by the
action of a base.
2.4.2.2. Cacchi's procedure for the synthesis of 2-substituted 
benzo[b]furanes using Palladium catalyst.
Cacchi and coworkers66 reported a procedure for the synthesis of 2-
substituted benzo[b]furanes from 1-alkynes using a Copper-Palladium
catalyst. The reaction of 2-hydroxyaryl or 2-hydroxyheteroaryl halides with
several 1-alkynes in the presence of a base, bistriphenylphosphine Pd (II)
diacetate and Copper (I) iodide in DMF at RT or 60° C leads to 2-
substituted benzo[b]furanes in usually good yields (scheme 2.23).
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A X
OH
R1
R2 H R3+
Pd(OAc)2/CuI
Piperidine/RT or 60°C
A
O
R3
R1
R2
A = N, CH. 
X =I,Br. 
R1 =H, CH3,CHO. 
R2 =H, OCH3. 
R3 =Alkyl,CH(OH)Akyl or Aryl,Esters
Scheme 2.23: Synthesis of benzofuranes according to Cacchi's procedure.
A short communication published in 1992 from Kundu N.G.67a,b
represented our most important reference. This paper described the
synthesis of 2-benzo[b]furanyl carbinol by coupling and cyclization of 1-
phenyl 2-propyn-1-ol with o-iodophenol(scheme 2.24).
The molar ratio between propargylic alcohol and 2-iodophenol was 2:1
and the yield was calculated on the basis of the conversion of o-iodophenol
as 66%. It is important to emphasize that all of the above described
procedures were reported with achiral or racemic acetylenic compounds
while our investigation is related to the possibility of applying these
methodologies to chiral alkynes.
I
OH
H+
O
Ph
OH
Ph
OH
PdCl2(PPh3)2
TEA , CuI 80°C
Scheme 2.24: Kundu's procedure for the synthesis of arylbenzofuranylmethanols.
To our knowledge, these are the best conditions reported to date for
the synthesis of 2-substituted benzo[b]furanes.
2.4.2.3 Larock's procedure for the annulation of internal 
alkynes to various heterocycles.
Larock R.C.68 and coworkers in 1995 reported a very good
procedure to synthesize aromatic heterocycles via Palladium catalyzed
annulation of internal alkynes. Syntheses of various heterocycles,
including 1,2-dihydroquinolines, benzofuranes, benzopyranes and
isocumarines are reported in this article. Generally, 5% molar Pd(OAc)2,
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sodium or potassium carbonate as base, lithium chloride or  nBu4NCl as
chloride source are employed in DMF as solvent with 5% molar
triphenylphosphine sometimes added to the reaction mixture.
Temperatures ranging from 80° C to 140° C were necessary to effect
the annulation within a reasonable time. The regiochemistry followed the
general trend with the aryl group being added to the less hindered end of the
alkyne and the Palladium catalyst to the more hindered one (scheme 2.25).
I
OH
Me tBu
O
tBu
Me
PdCl2(PPh3)2
nBu 4NCl, KOAc 
100°C, 24h.
+
Scheme 2.25: Regioselectivity  in the palladium catalyzed cyclization of asymmetrically
substituted alkynes.
The heteroannulation using o-iodophenol has been found to be more
difficult than the analoguous reaction using o-iodoaniline. Generally, higher
temperatures were required for the cyclization of o-iodophenol, thus
reducing the regioselectivity of the process. For example, the annulation of
ethylphenylpropynate afforded a 2:3 mixture of regioisomers (scheme 2.26).
I
OH O
CO2Et
Ph
CO2EtPh
O
Ph
CO2Et
PdCl2(PPh3)2
LiCl K 2CO3
135°C, 24h.
+
ratio 2:3
Scheme 2.26: Anullation of ethylphenylpropynate
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3. Synthesis of Substrates.
3.1. Synthesis of Ketones.
Ketones are the starting materials for antifungal agents like bifonazole
and also for antitumor agents such as 18 (Menarini's compounds).
3.1.1. Synthesis of Ketones 25a-f by Friedel-Crafts Acylation-
Starting Materials for further studies on Bifonazole.
Benzophenones are ideal precursors for bifonazole and its analogues.
Unfortunately they are not commercially available, with the exception of
benzophenone itself.
Friedel-Crafts acylation1,2 is the most important method for the
preparation of aryl ketones.The reagents usually employed are acyl halides,
carboxylic acids, anhydrides, or ketenes3. The general scheme of the
reaction is shown in scheme 3.1.
R
O
X R'
+ R
O
R'
Lewis acid
R = Alkyl, Aryl.
R' = Alkyl, Aryl, Hydroxy, Alkoxy, Halides 
X = I, Br, Cl, F.
Scheme 3.1: Friedel-Crafts acylation, general scheme.
R may constitute either an aryl or an alkyl group. Since the RCO group
is deactivating, the reaction stops cleanly after one group is introduced. All
four acyl halides can be used, although chlorides are the most commonly
employed, the order of reactivity is usually I>Br>Cl>F4. Catalysts are
Lewis acids such as AlBr3, AlCl3, GaCl3, FeCl3, SnCl4, BCl3. For the
acylation a little more than 1 mole of catalyst is required per mole of
reagent, because the first mole is coordinated to the oxygen of the
reagent5,6.
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The reaction is quite successful for many types of substrates,
including compounds containing ortho and para directing groups such as
alkyl, aryl, hydroxy, alkoxy, halogen and acetamido groups. They are easily
acylated and lead mainly or exclusively to the para acetylated products,
because of the relatively large size of the acetyl group. Friedel-Crafts
acylation is usually prevented by meta directing groups. The mechanism of
this reaction is not completely understood, but at least two mechanisms
could operate, depending on conditions7. In most cases the attacking
species is the acyl cation, either in its free form or as ion pair8 (scheme 3.2):
RCOCl + AlCl3 C O
+R  + AlCl4
-
R = Alkyl, Aryl.
Scheme 3.2: Formation of acyl cation.
If R is a tertiary group, RCO+ may loose CO to give R+, so that the
corresponding alkylarene ArR is often a side product or, sometimes, also
the main product. In the other mechanism an acyl cation may not be
involved, in this case the 1:1 complex can attack directly9,10 (scheme 3.3).
ArH 
R
O
X
AlCl3
-
+
+
H
X
O
R
AlCl3
-
+ R
O
R'
AlCl3
-
+
Scheme 3.3: Direct acylation of complex.
A free-ion attack is more likely for sterically hindered groups R11.
The CH3CO+ has been detected (by IR spectroscopy) in the liquid
complex between acetyl chloride and aluminium chloride, dissolved in a
polar solvent such as nitrobenzene. In non polar solvents such as
chloroform, only the complex without the free ion is present12. In any case,
1 mole of the catalyst certainly remains complexed to the product at the end
of the reaction.
Prochiral Ketones 25a-f were prepared via  Friedel-Crafts reaction as
shown in scheme 3.4..
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O
Cl
R
R'
O
R'
R+
AlCl3
25 a-fA a-f
Scheme 3.4: Synthesis of prochiral ketones 25 a-f by Friedel-Crafts acylation.
Only commercially available aroylchlorides were considered as
starting materials, the choice was based on the possible synthetic
approaches describe in chapter 1.6.
Six different, substituted benzoyl chlorides Aa-f were chosen to
acylate biphenyl and benzene (time, yields and reaction conditions are
summarized in table 3.1).
Product R R' T [°C] Time h Yield %
25a H Ph 0-reflux 28 97
25b 2-Br H 0-reflux 16 96
25c 2-Br Ph 0-reflux 18 98
25d 2-F Ph 0-reflux 18 97
25e 4-NO2 Ph 0-50 16 90
25f 3-NO2 Ph 0-50 12 90
Table 3.1: Prochiral ketones 25a-f by Friedel Craft acylation.
Aroyl chlorides A a-f were reacted in 1,2 dichloroethane ( in benzene
for 25b) in presence of AlCl3 as Lewis acid with biphenyl. Compounds
25a-f represent suitable intermediates for the preparation of the targets via
the  strategies described in chapter 2, such as:
1) 4-Phenyl benzophenone 25a would be  the precursor of 
bifonazole;
2) 25e-f bearing nitro groups in positions 3- and 4- of the aromatic 
ring could be transformed to the corresponding amines which could 
be coupled with an enantiopure acid to form a separable mixture of 
diasteroisomers;
3) 25b-d with halogens in the 2-position of the phenyl ring were
used for the asymmetric reduction to chiral benzhydroles using
Brown's method25,26. 2-Bromo benzophenone 25b was synthesized
with the purpose of validating this method25,26 reported in
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literature as the best substrate for this kind of asymmetric reduction.
2-Bromo-4'-phenyl benzophenone 25c can be considered as
precursor of bifonazole. The ortho substituent is required for good
enantioselectivity during the Brown asymmetric reduction, while the
para phenyl group is required for the bifonazole structure. The para
phenyl group on the aromatic moiety of the molecule does not
interfere with the process of chiral recognition by the chiral LAH
complex.
The Friedel-Craft's acylation of the biphenyl moiety with all aroyl
chlorides Aa-f proceded with high regioselectivity, biphenyl was only
monoacylated in the para position with respect to the second aromatic ring.
Reactions were followed by both GC-MS and 1H-NMR after work up
without any purification.The chemical yields were always very high.
3.2. Synthesis of Aryl-2-Benzo-[b]-Furanones 26 a-e: Prochiral 
Ketones for the Menarini Anticancer Drugs 18 via the 
Rap Stormer procedure.
The synthesis of Aryl-2-benzo-[b]-furan ketones 26a-e was achieved
via the Rap Stormer  procedure. For this the w -bromo-acetophenones A 1-
5 were condensed with salicyl aldehyde B under basic conditions (scheme
3.5) leading to the ketones 26a-e.
O
X
R
OH
O
H
O
OR
+
EtO-Na+
26 a-e
EtOH 60°C
X = Cl, Br.A 1-5 B
Scheme 3.5: Synthesis of Aryl-Benzo[b]furan Ketones 26 a-e.
The required w -Bromo-acetophenones A1,3-5 were commercially
available, while A2 was prepared from the corresponding 4-
cyanoacetophenone by bromination with molecular bromine in chloroform
at room temperature in high (88%) yield (Scheme3.6).
Chapter 3 76
NC
O
NC
O
BrBr2 ; CH2Cl2
A2
Scheme 3.6: Bromination of 4-Cyano acetophenone .
The crude reaction product was used directly without any further
purification in the following Rap-Stormer synthesis leading to the
corresponding 4-cyano-2-benzo[b]furanone 26b.
In table 3.2 the different w -bromoacetophenones used as substrates
for the condensation to aryl-benzo[b]furan ketones 26a-e are listed,
together with reaction times and obtained chemical yields.
Substrate X R Time h Product
Yield (%)
A1 Br H 12 26a (56)
A2 Br 4-CN 16 26b (66)
A3 Cl 2,4-Cl 16 26c (88)
A4 Br 4-F 14 26d (68)
A5 Br 4-Cl 15 26e (72)
Table 3.2: Synthesis of aryl-benzo[b]furan ketones 26a-e by the Rap Storner procedure.
The chemical yields are moderate. In the case of w -bromo-4-
cyanoacetophenone A2 the chemical yield was calculated based on the
corresponding 4-cyano acetophenone.
All compounds 26a-e are precursors for the most active Menarini
Aromatase inhibitors (see table 1.1, chapter 1 for the activities of the
corresponding compounds). It is interesting to point out that in the literature
no examples for their asymmetric reduction are reported.
3.3. Reduction of Prochiral Ketones 25a-f and 26a-e to
Racemic Alcohols (±) 27a-m using NaBH4.
NaBH4 is one of the most useful reducing agents for ketones. It is easy
to handle, generally reacts under mild conditions, does not require
Chapter 3 77
dry solvents and, is cheap. The general mechanism of the reduction is
shown in scheme 2.714:
O H BH3
- O R
H
R OH RO- + HO H BH3OR
-+
Scheme 2.7: General mechanism of ketone reduction by NaBH4
The Na+ seems not to participate in the transition state (as does Li+ in
LiAlH4 reductions15) but kinetic evidences showed that an OR group of the
solvent seems to be involved in the reaction and remains attached to the
boron 16.
Both classes of prochiral ketones 25a-f and 26a-e were reduced to racemic
alcohols 27a-m with NaBH4. A 1:1 mixture of ethanol and THF was used
as solvent to achieve a perfect solubilization of the ketones at low
temperature (scheme 3.8.):
R
O
R
OH
'R 'RNaBH4
25 a-f and 26 a-e 27 a-m
THF/ EtOH
Scheme 3.8: Synthesis of racemic aryl-phenyl methanols (±)27a-f and aryl-2-benzo[b]furan
methanols (±)27g-m.
High yields were obtained and no side products were detected neither
during the reactions nor after the work up. Products, experimental
conditions and chemical yields are reported in table 3.3.
(±)-27a-m were used as reference materials for the determination of
the enantiomeric excess in the enantiomerically enriched products.
Furthermore they were used as starting materials in all the new synthetic
routes in order to prove the feasibility of the strategy. Finally also for the
synthesis of separable diasteroisomers.
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Product R R' T °C Yield %
(±)-27a Biphenyl H 0 95
(±)-27b Ph 2Br 0 94
(±)-27c Biphenyl 2-Br 0 95
(±)-27d Biphenyl 2-F 0 94
(±)-27e Biphenyl 4-NO2 -15-0 98
(±)-27f Biphenyl 3-NO2 -15-0 95
(±)-27g 2Benzo[b]furan H 0 93
(±)-27h 2Benzo[b]furan 4-CN -15-0 97
(±)-27i 2Benzo[b]furan 2,4-Cl 0 93
(±)-27l 2Benzo[b]furan 4-F 0 94
(±)-27m 2Benzo[b]furan 4-Cl 0 95
Table 3.3: Reduction of prochiral ketones 25a-f and 26a-e to racemic alcohols (±)-27a-m by
NaBH4.
3.4. Asymmetric Reduction of Prochiral Ketons.
The most widely used chiral agents for the reduction of prochiral
ketones to enantiopure alcohols were reported in chapter 2. It was also
emphasized that the procedure25,26  described by E. Brown should be
considered the only promising method for our purpose, since all other
methods work only very well for ketones having two different substituents
either in  size (very large-very small) or in structure (aliphatic-aromatic).
3.4.1 Synthesis of (R)-(-)-2-(2-isoindolinyl) butan-1-ol (-)-24. An
optically active ligand for the asymmetric reduction of
prochiral benzophenones.
Brown and coworkers did not report the experimental procedure for
the preparation of the (R)-(-)-2-(2-iso indolinyl) butan-1-ol (-)-24. The
synthesis was achieved by alkylation of 1,2-dichloroxylene or 1,2-
dibromoxylene with R-(-) -2-aminobutan-1-ol in presence of dry K2CO3 as
base (scheme 3.9).
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X
X
N
OH
H2N
OH Dry K2CO3
Dry CH3CN
X = Cl, Br. reflux (-)-24
+
Scheme 3.9: Synthesis of (R)-(-)-2-(2-isoindolinyl)butan-1-ol (-)-24.
Both substrates were used in small scale syntheses (one gram) but 1,2-
dichloroxylene was chosen also for the scale up (150 grams) because it is
more safe in comparison with 1,2-dibromoxylene which has very irritating
properties. The synthesis of (R)-(-)-2-(2-iso indolinyl) butan-1-ol (-)-24 was
performed at different temperatures and in different solvents such as
acetone and acetonitrile. Reactions in acetone were always incomplete even
under reflux for more than 24 hours. Acetonitrile was found to be the
superior solvent for the reaction but only under refluxing conditions. In fact
all experiments carried out at lower temperatures led to mixtures of
products, mainly the N-monoalkylated-2-amino-1-butanol (uncyclized
product) in mixture with the desired product (-)-24. Generally high dilution
conditions were required in order to favour the intramolecular cyclization
instead of intermolecular alkylation. Dry potassium carbonate was used as
base in all cases. Purification was achieved via  repeated high vacuum
distillation of the crude solid reaction product.
3.4.2 Asymmetric reduction of prochiral benzophenones 25 a-d 
by a complex between (R)-(-)-2-(2-isoindolinyl)-butan-1-ol 
(-)-24 and LiAlH4.
The first experiment was performed with 2-bromobenzophenone 25b
(scheme 3.10). This substrate was described by Brown in its papers25,26
and was shown to be the best substrate for this kind of asymmetric
reduction. The experiment was done in order to validate the reproducibility
of the method.
The reaction was carried out under the reported experimental
conditions: a diethyl ether solution of LAH was added to a solution of 2.5
equivalents of (R)-(-)-2-(2-isoindolinyl)-butan-1-ol (-)-24 in dry diethyl
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ether at 0°C, under an inert atmosphere in order to form a complex with the
gross formula of LiAl(OR*)2,5H1,5; After 45 min. the reaction mixture was
cooled to -15°C and a solution of 2-bromobenzophenone 25b in dry
diethyl ether was added dropwise. The asymmetric reduction led to the
ortho-(+)-Bromobenzhydrole (+)-27b (scheme 3.10). After quenching and
work up the optically rotation was compared with the value reported in the
literature and an identical rotation was found ([a]D= +46.6; c=1.3 in
acetone), corresponding to an enantiomeric excess of higher than 95 %e.e.
(table 3.4.). The reaction was then repeated with the prochiral
benzophenones 25a-d (scheme 3.10).
OX
R
N
OH
OHX
R
(-)24
LiAlH 4
(±) 27a  X=H    R=Ph 
(+) 27b  X=Br   R=H 
(+) 27c  X=Br   R=Ph 
(+) 27d   X=F     R=H
25a  X=H   R=Ph 
25b  X=Br  R=H 
25c  X=Br  R=Ph 
25d  X=F    R=Ph
Dry ether
Scheme 3.10: Synthesis of chiral benzhydroles (+)-27b-d and racemic (±)-27a
Some modifications of the original procedure were introduced.
Especially regarding the reaction work up a procedure was chosen which
allowed the recyclisation of the chiral auxiliary and the improved recovery
of the pure product. The optimal molar ratio of 2.5 equivalents of (R)-(-)-2-
(2-isoindolinyl)-butan-1-ol (-)-24 for one mole of LAH which corresponds
to the gross formula LiAl(OR*)2,5H1,5 was not changed. It was assumed to
be the optimal condition also for the prochiral benzophenones 25a-d. The
chiral reducing complex reagent led to very good enantiomeric excesses
only with ortho substituted benzophenones, while meta substituted
benzophenones gave markedly lower enantiomeric excesses.
The reason for this remains unclear. Obviously an o-substituent on
the phenyl ring must be present in order to achieve good enantioselection.
Speculations can be based on the results reported by Brown. Due to the
chemical nature of the substituents it seems reasonable to exclude that
electronic effects are involved in the recognition process between the
chiral LAH complex and the ketone. Probably the steric effects of the
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substituents are the most important factors governing the enantioselection
of the reduction. It is in fact possible that, due to the presence of the ortho
substituent, the prochiral benzophenone presents the two aromatic moieties
in different planes. The ketone can be almost coplanar with the
unsubstituted aromatic ring to form a flat moiety while the aromatic ring
bearing  the ortho substituent is out of the plane (Fig 3.1).
O
R
Fig.3.1: Conformation of ortho substituted benzophenones.
2-Bromo-(4'phenyl) benzophenone 25c, reduced under identical
experimental conditions as used for 2-bromobenzophenone 25b gave (+)-2-
bromo-4'phenyl-benzhydrol (+)-27c with an enantiomeric excess of higher
than 95% e.e. (scheme 3.10; table 3.4) and with 98% of chemical yield. It is
interesting to note that in this substrate two substituents are present on the
two aromatic rings. The presence of a phenyl ring in the para position did
not lead to any loss of stereoselectivity in the chiral reduction probably
because this did not change the overall geometry of the prochiral ketone.
The enantiomeric excess was determinated by examining the carbinolic
proton in the 1H-NMR spectrum (200 MHz) in the presence of the chiral
shift reagent tris [3-(heptafluoropropylhydroxy methylen)] camphorato
europium 3 [Eu(hfc)3], and also confirmed by chiral HPLC ( Chiracel OD).
The procedure was repeated for 4'-phenyl benzophenone 25a and led
to the racemic 4'-phenyl benzhydrole (±)-27a in 98% of chemical yield
(scheme 3.10; table 3.4). 2-Fluoro-4'-phenyl benzophenone 25d was
reduced to (+) 2-fluoro 4'-phenyl benzhydrole (+)-27d with 80%
enantiomeric excess and 98% of chemical yield (scheme 3.10; table 3.4).
The loss of enantiomeric excess could be attributed to the reduced steric
hindrance of the fluorine atom in comparison to the bromine. The
enantiomeric excess was determined by chiral HPLC (Chiracel OD), while
all attempts to examine the carbinolic proton in the 1H-NMR spectrum
recorded in presence of the above chiral shift reagent failed.
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Product X R Yield % e.e. % [aD]
(±)-27a H Ph 95 0 0
(+)-27b Br H 97 >95 + 46.6
(+)-27c Br Ph 98 >93 + 65.6
(+)-27d F H 98 80 + 57.5
Table 3.4.: Enantioselective reduction of prochiral ketones 25a-d.
Enantioselective reduction of 25a with DIP-chloride was also tried in
order to obtain directly the enantiopure benzhydrol 27a. However this
reduction only led to the racemic alcohol (±)-27a.
3.4.3. Synthesis of enantiomerically enriched 2[benzo(b)furan] 
phenones by asymmetric reduction.
To the best of our knowledge no examples for the asymmetric
reduction of 2 [benzo(b)furan] phenones are reported in literature, and no
synthetic strategies for the preparation of the 2-[benzo(b)furan]-aryl
methanols in enantiopure form are known.
Asymmetric reductions of these types of prochiral ketones were
investigated using the above chiral complexes as reducing reagents. It was
expected that the difference between the two aromatic systems would be
recognized by the chiral reducing reagent (scheme 3.11), in the hope that the
benzo(b)furane oxygen could be coordinated by the aluminium of the
reducing agent.
R'
R
O
HO H
R'
R
O
O
26a   R=R'=H
26c  R=R'=Cl
27g   R=R'=H
27i   R=R'=Cl
N
OH
(-)-24
LiAlH4
Dry ether
Scheme 3.11 : Asymmetric reduction of prochiral ketones 26a and 26c.
This hypothetical coordination should give a stereofacial
discrimination in the ketone 26a. Another hypothesis is that the repulsion
between the oxygen of the ketone and the oxygen of the benzofuran
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induces a rotation of the bond between these two moieties and the system
becomes not as coplanar as in the case of the ortho substituted
benzophenones decribed in the previous paragraphs.(R)-(-)-2 (2
isoindolinyl) butan-1-ol (-)-24 was again used as chiral complexing agent of
LiAlH4. For this class of prochiral ketones no previous informations
regarding the use of this ligand were available. Many experiments were
carried out using different molar ratios of the chiral auxiliary and LiAlH4.
(1:1; 2:1; 2,5:1; 3:1 molar ratio). While all chemical yields were very high, all
reductions led only to racemic alcohols (±)-27g (Table 3.5.). Clearly, our
hypothesis regarding the coordination of aluminium by the benzofuran
oxygen or the possibility of recognition of the two different conformations
of the ketone were incorrect.
2-Benzo[b]furan-2',4'dichlorophenone 26c, in contrast, contains an
ortho substituent which seems to be essential for this kind of asymmetric
reduction. Again four different reactions were carried out using different
molar ratios between chiral auxiliary and LiAlH4 (1:1; 2:1; 2,5:1,0; 3:1)
(Table 3.5.). The reduction of 26c, using a ratio  of chiral auxiliary to
LiAlH4 = 2.5:1 led indeed to higher enantiomeric excess (66% e.e.) with
96% chemical yield.
Substrate R;R' (RO)nAlH4-n Product ee % aD(CHCl3) C
26a H,H n = 1 (±)-27g 0 0 1,55
26a H,H n = 2 (±)-27g 0 0 1,45
26a H,H n = 2,5 (±)-27g 0 0 1,49
26a H,H n = 3 (±)-27g 0 0 1,56
26c Cl,Cl n = 1 (±)-27i 30< + 11,01 1,70
26c Cl,Cl n = 2 (±)-27i 54 + 18,03 1,31
26c Cl,Cl n = 2,5 (±)-27i 66 + 18,98 1.42
26c Cl,Cl n = 3 (±)-27i 51 + 18,01 1,36
Table 3.5: Study of the asymmetric reduction of the prochiral ketones 26a and 26c.
The different behaviour of the ortho substituted benzophenones
27e,d as compared to 2-benzo[b]furan-2',4'dichlorophenone (26c) is
difficult to rationalize, especially considering the fact that the phenyl-2-
benzo[b]furan-ketone (26a) gave the racemic alcohol 27g under identical
conditions. It could be considered that for some reason, the chlorine by
electronic repulsion interacts with the oxygen of the benzofuran moiety
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leading to a distortion of the active conformation. Since the reduction of
ketones proved to be unsuccessful, this class of enantiopure alcohols was
obtained by a different procedure described in the next paragraphs.
The enantiomeric excess of the above compounds was determinated
by 1H-NMR with the corresponding esters formed with (S)-(-)-1-camphanic
chloride. The method of analysis will be described in detail in the next
paragraph. Analysis by chiral HPLC (Chiracel OD) of the free alcohols led
to identical results. It is interesting to note that all first attempts to determine
the enantiomeric excess were, as in the case of the chiral benzhydoles, done
by NMR and using shift reagents. Unfortunately none of the many tried
reagents was able to resolve completely the signals in the spectrum. For this
reason it was necessary to synthesize the corresponding camphanic ester.
3.4.3.1. Determination of the enantiomeric excess in (+)-27i 
by 1H-NMR.
The enantiomeric excess of (+)-27i was determined by 1H-NMR
after esterification of (+)-27i with (S)-(-)-1-camphanic chloride. The
principle is based on the known property of diasteroisomers to produce
different NMR spectra, next to different physical properties. Calculation
of the relative diasteroisomeric ratios in the 1H-NMR was done with the
crude product mixture in order to avoid a possible loss of a single
diasteroisomer or partial racemization during sample processing.
The crude 1H-NMR spectrum of the reaction products of (±)-27i
and (S)-(-)-1-Camphanic chloride showed only one perfectly resolved
signal, allowing integration: the b proton in the furane ring of the
benzo[b]furane moiety.
The 1H-NMR of the free alcohol (±)-27i showed the b-proton of
the furan ring at 6.46 ppm and the carbinol proton at 6.28 ppm, the latter
being frequently a doublet because of the coupling between this proton
and the alcoholic proton at 2,76 ppm (Fig. 3.2). Generally, if water was
present in the sample, due to the low exchange rate between water and the
alcoholic proton, this resulting signal was broad and the carbinolic proton
appeared as a singlet (the coupling constant is very small and it is not
detectable); the same effect was found at high concentrations of the NMR
sample. In the absence of these two effects the doublet signals appeared
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very sharp and it was possible to calculate the coupling constant, which
was found to be 3.16 Hz.
Cl
Cl
O
HO H
H
b Proton of benzo(b)furanes  
6,46 ppm
Carbinolic proton 
6,28 ppm(±)-27i
Hydroxy proton  
2,76ppm
Figure 3.2: Chemical shifts of the protons involved in the determination of the enantiomeric
excess.
When the alcohol (±)-27i was acylated with (S)-(-)-1-Camphanic
chloride, the carbinolic proton was shifted by more than 1 ppm into the
aromatic region where it could not be detected as a single signal. On the
contrary, the b proton of the furane ring in the benzo(b)furane moiety
remained at is normal position, and was split in to two well separated
singlets (each one belonging to a single diasteroisomer).
The first experiment was done with racemic (±)-27i. The signal of the
two diasteroisomers at 6.62 and 6.58 ppm showed the typical 1:1 ratio of a
racemic mixture. The experiment was repeated for each  asymmetric
reduction and the enantiomeric excess produced was calculated in all cases
from the relative ratio of the b proton of the furane ring and the
benzo(b)furane moiety. The experiment was developed into a routine
procedure, and the acylation was directly performed in deuterated
chloroform in presence of triethyl amine as base. This was possible since
the region of the spectrum needed for the determination of the e.e. was not
obscured by any other signal resulting from the base, salt or small excess of
the camphanic chloride.
All attempts to separate the diasteroisomers by normal or reverse
phase TLC failed. An enrichment of one diasteroisomer was achieved by
preparative silica TLC, in collecting the product from the higher part of the
spot. The resulting enantiomeric excess was 82% e.e.
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3.5 Dehalogenation of alcohols containing halogenated aryl 
groups.
In order to obtain the benzhydroles and phenyl-2-benzo[b]furan
methanole without substituents, the aryl dehalogenation of (±)-27c , (+)-27c
and (±)-27i was studied.
Dehydrohalogenations or dehalogenations are a kind of reduction that
can be accomplished using a large variety of reducing reagents27. The most
common one is lithium aluminum hydride (scheme 3.12).
RX + LiAlH4 
X= Cl, Br.
RH
Scheme 3.12: Dehydrohalogenation by LiAlH4.
This reagent reduces almost all types of alkyl28 and aryl29,30 halides.
Removal of halogen from aromatic rings can also be accomplished by
various other reducing reagents, such as nBu3SnH31, Ph3SnH32, metallic
Zn in acid or base33, catalytic hydrogenolysis34, NaBH4 and a catalyst35,
Nickel-Raney  in alkaline solution36. Not all of these reagents operate by
electrophilic substitution mechanisms, some are involved in nuclephilic
substitution and others in free radical processes.
3.5.1 Aryldehalogenation of (±)-27c, (+)-27c and (±)-27i.
Various reagents and experimental conditions were used for the aryl
dehalogenation of (±)-27c and (+)-27c. Originally all the different
procedures were carried out on the racemic material in order to obtain
informations regarding the chemical behavior during these transformations.
Raney Nickel in methanol (scheme 3.13) was found to be unselective.
A mixture of the desired product and the dehydroxylated side product 28
was found in the reaction mixture after a few hours. Both temperature and
reaction times were changed but no selective reaction conditions were
found.
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OH Br R H
 Raney Nickel
MeOH; reflux
(±)-27c R = OH (±)-27a
R = H          28
Scheme 3.13: Dehydrohalogenation of (±)-27c by Raney Nickel.
At room temperature the reaction did not occur at all and under reflux
the ratio between the two products (±)-27a and 28 was 1:1. If the reaction
was carried out for extended times mainly 28 was recovered. Identical
reactions carried out with the benzofurane derivative (±)-27i gave a
complex mixture of unknown products. However, from the crude NMR it
was clear that the benzofurane ring was distroyed.
A second attempt was made with n-tributyltinhydride in dry THF,while
AIBN was used to initiate the radical process. After twenty four hours
under reflux only the starting material was detected by TLC.
Dehydrohalogenation of  (±)-27c by LiAlH4 was found to be
exceptionally selective, and the side product 28 was not detected.
OH Br OH H
LiAlH 4
(±)-27c;, (+)-27c
THF refflux
 (±)-27a ; (+)-27a
Scheme 3.14:  Dehydrohalogenation of  (±)-27c and (+)-27c by LiAlH4.
The reaction was also performed with enantiopure (+)-27c (e.e.>93%)
and enantiopure (+)-27a (>93%e.e.) was obtained. Thus, no racemization
occured during the reaction. The e.e. was determinated by chiral HPLC
(Chiracel OD). Under completely identical reaction conditions using  (±)-
27i no desired product was detected by TLC. Only unreacted starting
material and a series of side products were found.
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4. Stereospecific Synthesis of 1-Alkylimidazole 
Derivatives via Mitsunobu Reaction.
The Mitsunobu reaction was considered to be a good method for the
synthesis of 1-alkyl imidazoles.To the best of our knowledge the only
information (no experimental details were reported) in this regard involved
the reaction of both imidazole and 2-methyl-4,(5)- nitroimidazole 29 with
either methanol or 1-phenyl-1-ethanol. Imidazole itself is unreactive under
the normal reaction conditions probably because of its pKa (higher than
11). The nitroimidazol derivative reacts as expected to give a mixture of N-
alkyl-2-methyl-4-nitroimidazole 30a and the corresponding 5-nitro isomer
30b (Scheme 4.1):
N
H 
NMe
NO2
N
NMe
NO2
N
NMe
NO2
R
R
29
+   ROH
  R=Me 
  R=1-phenyl-1-ethyl 30a
dry THF
DEAD / PPh3
30b
+
Scheme 4.1: Mitsunobu reaction with 2-methyl-4,(5)- nitroimidazole 29.
4.1. Alkylation of Imidazole derivatives via Mitsunobu reaction.
In order to perform the alkylation with alcohols 31a-f and 27a-c,g,m
via Mitsunobu reaction, commercially available 4,5-dicyano imidazole 32
was chosen as substrate.
This choice has a number of advantages. First, the presence of the
two cyano groups decreases the pKa of the imidazole ring to well below
11. This means that the 4,5 dicyano imidazole 32 is a suitable substrate for
the alkylation via Mitsounobu reaction. Second, 32 has a C-2 symmetry,
consequently the two nitrogens of the imidazole moiety are identical and
the N-alkylation leads to a single product. Thirdly, it is commercially
available and cheap. Fourth, the cyano groups can be removed from the
final product in two steps: by hydrolysis followed by decarboxylation.
Twenty racemic and enantiopure alcohols were used to study the
 Mitsunobu reaction with 4,5 dicyanoimidazole 32. Alkylated products
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33a-m were hydrolysed to the dicarboxylic acid derivatives 34a-m with
NaOH and finally 34a-m were converted via a decarboxylation step into the
final imidazole products 35a-m (Scheme 4.2).
OH
R1 R2
N
R1 R2
N
CN
CN
N 
H
N
CN
CN
N
R1 R2
N
CO 2H
CO 2HN
R1 R2
N
DEAD PPh 3
31a-i,27a-c,g,m 33 a-m
32
Hydrolysis
Decarboxylation
34a-m35a-m
Scheme 4.2: Synthetic pathway, Mitsunobu reaction-Hydrolysis-Decarboxylation.
The racemic and enantiopure alcohols 31a-f and 27a-c,g,m were used
as alkylating agents in order to establish the stereochemical outcome of the
Mitsunobu reaction with 4,5 dicyanoimidazole 32. Alcohols 31 a-f are
commercially available both in racemic and enantiopure form. Alcohols
27a-c,g,m (entries 11-19 tab 4.1) were synthesized as reported in chapter 3.
Results are summarized in Tab. 4.1.
31a-f and 27a-c,e,g,m were chosen in order to obtain a complete
picture of the potential and limits of this methodology; the substrates are
primary, secondary, aliphatic, homobenzylic, benzylic, and benzyhydrilic
alcohols. Tertiary alcohols such as t-butanol are unreactive. The results
were very interesting indeed because it was now possible to understand the
real limits of the methodology. Special attention was dedicated to the
stereochemical control rather than the chemical yield.
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Entry Substrate Config.
(ee%)
R1 R2 Product
(Yield%)
Config. Pro
(% ee)
1 31a - H H 33a (45) -
2 31b - H nC7H15 33b (98) -
3 (±)-31c - Me nC6H13 (±)-33c(70) -
4 (-)-31c R (99) Me nC6H13 (+)-33c(65) S (97)
5 (+)-31c S (99) Me nC6H13 (-)-33c(67) R (97)
6 (±)-31d - Me Bn (±)33d(40) -
7 (-)-31d R (99) Me Bn (+)33d(39) S (98)
8 (±)-31e - Et Ph (±)-33e(55) -
9 (+)-31e R (99) Et Ph (-)33e(55) S (41)
10 31 f - Ph Ph 33f (94) -
11 (±)-27a - Ph 4PhC6H4 (±)-33g(96) -
12 (+)-27a nd(>95) Ph 4PhC6H4 (±)-33g(96) R,S (0)
13 (±)-27b - Ph 2BrC6H4 (±)-33h(81) -
14 (+)-27b nd(>95) Ph 2BrC6H4 (±)-33h(96) R,S (0)
15 (±)-27c - 2BrC6H4 4PhC6H4 (±)-33i(82) -
16 (+)-27c nd(>95) 2BrC6H4 4PhC6H4 (±)-33i86) R,S (0)
17 (±)-27g - 2Benzo[b]
furane
Ph (±)-33l(10) -
18 (±)-27m - 2Benzo[b]
furane
2,4C6H3 (±)33m(5) -
19 (+)-27m nd>60 2Benzo[b]
furane
2,4C6H3 (±)33m(5) R,S (0)
Table 4.1: Mitsunobu reaction of alcohols 31a-f and 27a-c,e,g,m with 4,5-dicyanoimidazole.
The experimental results led to the following, very important
informations:
1) The reaction did not occur when a tertiary alcohol (e.g. t-butanol)
was used as substrate, even if an excess of reagent was used.
2) When the diaryl methanoles (entries 10-16) were used as substrates
longer reaction times and an excess of reagents (4:1 molar ratio
reagents/substrate) were required in order to achieve complete conversion.
When in this class of compounds one aromatic ring was substituted with 2-
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benzo[b]furane (entries 17-19 Tab 4.1), the reaction led to very low
conversions (5/10%). The starting material was always recovered also when
the reaction time was very long (>24 hours) and a large excess of reagents
was used (molar ratio reagents / substrate 5/1).
3) The reaction showed pure SN2 mechanism with secondary aliphatic
alcohols. Enantiomerically pure aliphatic alcohols (-)-(R)-31c, (+)-(S)-31c,
(-)-(R)-31d (entries 4,5 and 7 Table 4.1) gave the corresponding 1-alkyl-
4,5-dicyano imidazoles (+)-(S)-33c,(-)-(R)-33c and (+)-(S)-33d as single
enantiomers ( 97/98% e.e.) with medium to good chemical yields. The
molar ratio between substrate and reagents was always 1:1. In these cases
the reaction conditions were not further optimized towards higher chemical
yields.
4) The reaction had a mixed SN2-SN1 mechanism with the benzylic
secondary alcohol (+)-(R)-31e (entry 9 tab 4.1). The resulting product (-)-
(S)-33e showed an enantiomeric excess of 41% e.e.. Thus more than 50%
of the enantiomeric excess of the corresponding starting material was lost.
In order to establish whether the racemization process occured due to
reaction conditions or due to the inherent "mixed" mechanism three
different experiments were perfomed:
A) Reverse addition of reagents:
In this experiment the betaine complex between DEAD and triphenyl
phosphine was preformed at -20°C in dry THF in absence of alcohol and
4,5-dicyanoimidazole. Then the last two reagents in dry THF were added to
the reaction mixture. After 20 hours, the temperature was raised to room
temperature for 8 hours. Following this procedure the enantiomeric excess
of the product was not increased.
B) Shorter reaction time:
The reaction was carried out for a short time (10') and immediately
interrupted. The resulting chemical yield was lower than in the normal
experiment, however the enantiomeric excess was identical.
C) Lower temperature:
An experiment as described under B was carried out at a lower
temperature. At -25°C the reaction did not occur, at -15°C the chemical
yield was decreased to 4%. The enantiomeric excess was identical to those
obtained in the other experiments.
The results of these three experiments are summarized in Table 4.2.
The substrate was always (+)-(R)-31e, the molar ratio  substrate / reagent
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was 1:1, TLC analysis showed an almost complete comsumption of the
starting material. However it was impossible to obtain higher chemical yields
than 55% after purification by flash chromatography. An unknown side
product was detected by NMR analysis, inseparable from the reduced
DEAD:
Entry R1 R2 Config.
(ee%)
T (°C) Product
yield %
Config.
prod. (ee%)
A Et Ph R (99) 25 (-)-33e(55) S (41)
B Et Ph R (99) 25 (-)-33e(32) S (43)
C Et Ph R (99) -15 (-)-33e (4) S (45)
Table 4.2: Reaction mechanism for (+)-(R)-31e.
5) Diaryl methanoles (+)-27a, (+)-27b, (+)-27c (entries 12, 14, 16,
Tab. 4.1) and the 2-benzo[b]furane-2,4 dichlorophenyl methanol (+)-27m
(entry 19 tab 4.1) led to racemic products because of a completely SN1
reaction mechanism. These reactions were performed using both an
equimolar or excess ratio (4:1) of reagents and substrate. Under the latter
conditions a quantitative yield of the corresponding alkylate 4,5
dicyanoimidazole derivative with diaryl methanoles (+)-3a, (+)-3g, (+)-3e
was obtained.
The use of different phosphines such as n-tributyl phosphine or p-
methoxytriphenyl phosphine did not show any advantages as compared to
the more common triphenyl phosphine. Identical results were obtained in
using either diisopropyldiazodicarboxylate DIAD or ADDP [(1,1'-
azodicarbonyl) dipepiridine)] instead of DEAD.
On the basis of these results it was clear that the Mitsunobu reaction
was not a preferred methodology to obtain our target compounds in
enantiopure form. Nevertheless it can be considered an alternative synthesis
of the final products in racemic form.
4.1.1 N-Alkyl-4,5-dicyanoimidazoles 33c-e,g-i,m: determination 
of enatiomeric excess.
The determination of the enantiomeric excess in the Mitsunobu
reaction products 33c-e,g-i,m was one of the major problems in the
synthetic efforts. These products do not contain functional groups such as
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hydroxy or amine groups, that would allow the synthesis of Mosher or
mandelate esters, amides or generally diasteroisomers which are easily
analyzed by HPLC, GC or 1H-NMR. All attempts using chiral HPLC were
unsuccessful.
The only method that gave reasonable results was the analysis by 1H-
NMR in presence of the chiral shift reagent2 Eu(hfc)3 { europium(III) tris[3-
((heptafluoropropyl)hydroxymethylene)-(+) champhorato}.
Figure 4.1.:1H-NMR spectrum of (±)-33d (above) and (+)-(S)-33d (below) in presence of
chiral shift reagent.
A CDCl3 solution of Eu(hfc)3 of known concentration was prepared
and added to the NMR tube containing the sample in CDCl3 solution.
Various amounts of shift regent were added until the splitting of the desired
signals were observed. The best results were obtained with a molar ratio of
the sample and the chiral shift reagent of 1:1.2 to 1.6.
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The first measurements were carried out with the racemic product in
order to obtain a reference spectrum. The experiment was then repeated
with the chiral product. Two points are of importance to note with this
method. First, the sample purity must be high in order to avoid the presence
of signals that could be coincident with those of the sample. Second, the
signal to be integrated must be completely resolved and as sharp as
possible, in order to allow a perfect integration. It would be best to have
more than one signal for integration and take an average of all values.
The measurements were performed for all racemic and chiral products
reported in table 4.1. In some cases it was not possible to detect any signal
resulting from the minor enantiomer, in these cases the enantiomeric excess
was assigned to be 98% e.e. In figure 4.1 the 1H NMR spectra (300 MHz)
of (±)-33d and (+)-(S)-33d in presence of the chiral shift reagent Eu(hfc)3
are shown the selected signals corresponding  to the proton of the
imidazole (10.28 and 10.70 ppm), the aromatic groups (7.40-7.55 and 7.65-
7.80 ppm), chloroform (7.23 ppm), methylen (3.75-3.95 and 4.0-4.15 ppm)
and methyl moieties (2.25-2.35 ppm) respectively; the spectrum above is
racemic (±)33d and the one below from the enantiopure (ee 98%) (+)-(S)-
33d. The Imidazole proton betweeen 10 and 11 ppm were used for the
integration.
4.2. Hydrolysis and Decarboxylation of N-Alkyl-4,5-
dicyanoimidazoles 33c-g.
As reported in scheme 4.2. of the synthetic pathway the alkylation of
the 4,5-dicyanoimidazole via  Mitsunobu reaction is followed by two
additional synthetic steps: hydrolysis and decarboxylation. The cyano
group is transformed into a carboxylic acid by hydrolysis with 10N NaOH
in ethanol under reflux. These harsh conditions were needed for complete
conversion. Less concentrated NaOH solution resulted in only partial
hydrolysis to the corresponding amide.
The N-Alkyl-4,5-dicyanoimidazoles 33c-g were treated with 10N
NaOH  in ethanol under reflux for 16-24 h. After acidification with 3N
HCl the N-Alkyl-4,5-imidazoledicarboxylic acids 34a-e precipitated out,
(entries 1-4,7-8 Table 4.3) and were recovered by filtration. Only for the
isolation of (±)-33e and (-)-(S)-33e (entries 5,6 Table 4.3) extraction of
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the products with ethyl acetate was necessary since after acidification no
precipitation of the products occured. In all cases the chemical yields were
high.
In table 4.3 the structures and chemical yields of the products of the
hydrolysis are reported.
Entry Substrate R1 R2 Produc (Yield t%)
1 (±)-33c Me nC6H13 (±)-34a(77)
2 (+)-(S)-33c Me nC6H13 (+)-(S)-34a(65)
3 (±)-33d Me Bn (±)-34b (79)
4 (+)-(S)-33d Me Bn (+)-(S)-34b(76)
5 (±)-33e Et Ph (±)-34c (73)
6 (-)-(S)-33e Et Ph (-)-(S)-34c(73)
7 33f Ph Ph 34d (97)
8 (±)-33g Ph 4PhC6H4 (±)-34e (85)
Table 4.3: Hydrolysis of the N-Alkyl-4,5-dicyanoimidazoles 33c-g.
At this stage the enantiomeric excess of the diacids was not measured
because of their low solubility in CDCl3 (the normal solvent used with the
shift reagents). Attempts with other solvents like pyridine-d6 and DMSO-d6
were unsuccessful. After the addition of the chiral shift reagent
precipitations always occured and it was not possible to perform the 1H-
NMR experiment. Thus the synthesis was carried on to the desired final
imidazole derivatives.
 Some of the diacids 34a-e were used to synthesize separable
diasteroisomers by reacting them with enantiopure amines or alcohols as
described in paragraph 4.5.
4.2.1. Decarboxylation of N-Alkyl-4,5-imidazol dicarboxylic acids
34a-e.
Three different methods were tried for the  decarboxylation of the N-
Alkyl-4,5-imidazoldicarboxylic acids 34a-e. The first method involved
chinoline and copper powder at 120 °C. Almost all of the unreacted
starting material was recovered from the reaction mixture. The second
method used copper carbonate in DMF under reflux. This reaction did not
give any desired product, only decomposition products and starting
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material. The third method was purely thermal and was carried out in
diphenyl ether at reflux in an inert atmosphere. The desired product was
obtained in only 10 minutes and purification was carried out by silica gel
filtration with two different solvents: n-hexane to remove the the diphenyl
ether and ethyl acetate to recover the product.
The chemical yields were moderate to very high. For these compounds
it was again possible to calculate the enantiomeric excess using 300 MHz
1H-NMR analysis in presence of the chiral shift reagent Eu(hfc)3 {
europium(III) tris[3-((heptafluoropropyl) hydroxymethylene)-(+)
champhorato} for (+)-(S)-35a and europium(III) {tris(d,d-
dicampholylmethanate)} for (+)-(S)-35b and (±)-35c.
In table 4.4 the chemical yields, the enantiomeric excess and the
absolute configurations of the obtained products are reported.
Entry Substrate R1 R2 Product  (yield %) Con.  (% e.e.)
1 (±)-34a Me nC6H13 (±)-35a (81) -
2 (+)-(S)-34a Me nC6H13 (+)-35a (77) S (97)
3 (±)-34b Me Bn (±)-35b (55) -
4 (+)-(S)-34b Me Bn (+)-35b (53) S (98)
5 (±)-34c Et Ph (±)-35c (33) -
6 (-)-(S)-34c Et Ph (±)-35c (38) R,S (0)
7 34d Ph Ph 35d (90) -
8 (±)-34e Ph 4PhC6H4 (±)-6a (98) -
Table 4.4: Decarboxylation products of N-Alkyl-4,5-imidazoldicarboxylic acid 34a-e.
300 MHz 1H-NMR analysis in presence of chiral shift reagents revealed
an enantiomeric excess higher than 97% e.e. for (+)-(S)-35a and (+)-(S)-
35b. Therefore no racemization occurs during the final steps. Only in the
hydrolysis and the decarboxylation of (-)-(S)-33e the product (±)-35c was
produced in racemic form.
In order to establish where racemization took place in the hydrolysis
and decarboxylation sequence, the intermediate diacid (±)-34c and (-)-(S)-
34c were methylated by an excess of diazomethane to obtain the dimethyl
esters (±)-36 and (-)-(S)-36 (Scheme 4.3).
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(-)-(S)-34c
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(-)-(S)-36
CH 2N2
MeOH
Scheme 4.3: Esterification of (±)-34c and (-)-(S)-34c.
Since the dimethyl ester (-)-(S)-36 showed an e.e. of only 40 % e.e. it
was concluded that the intermediate diacid (-)-(S)-34c racemized during the
decarboxylation process. The dimethyl esters (±)-36 and (-)-(S)-36 were
analyzed again by 1H-NMR in presence of shift reagents in order to
determine the enantiomeric excess.
4.3. Mitsunobu reaction with 4-(5)-ethyl imidazole 
carboxylate 37.
With the aim of avoiding the drastic conditions required in the
hydrolysis and decarboxylation sequence of 4,5-dicyanoimidazole
derivatives the use of another substituted imidazole was investigated.
4.3.1. Synthesis of 4-(5)-ethyl imidazole carboxylate 37.
The synthesis of 4-(5) - ethyl imidazole carboxylate 37 was reported at
the end of the last century3 without any experimental conditions or  physical
constants.
The synthesis involved the acetylation of ethyl glycine ester using
acetyl chloride in presence of triethyl amine leading in quantitave yield to the
acetyl glycine ethyl ester 38. a-alkylation of 38 with ethyl formiate in dry
benzene and sodium ethoxide as base led to the intermediate 39 which was
not purified or characterized. The reaction mixture appeared as a white solid
after 24h at 0°C. The crude product was dissolved in water and acidified
with hydrochloric acid and cyclized to 2-mercapto-4(5)-ethyl
imidazolecarboxylate 40 using KCNS. Finally 40 was desulfurated by
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HNO3 and NaNO2 at 0°C leading the 4(5) ethyl imidazole carboxylate 37
( Scheme 4.4).
H2N
OEt
O
AcHN
OEt
O
AcHN
OEt
O
H O-Na +
N
H 
NHS
O
OEt
CH 3COCl/ NEt 3
CH 2Cl 2
N
H 
N
HCO 2Et
EtO -Na +
O
OEt
KCNS/ HCl  
H2O 
70°C
38
Benzene T<15 °C
39
4037
HNO 3 /NaNO 2
Scheme 4.4: Synthesis of 4(5)-ethyl imidazol carboxylate 37.
4.3.2. Mitsunobu Reaction with 4(5)-ethyl-imidazole carboxylate 37.
The Mitsunobu reaction with 4(5)-ethylimidazole carboxylate 37 was
carried out under the normal conditions reported in paragraph 4.2. The
alcohols (±)-27a, (±)-27c and (+)-27c were chosen as substrates because
they are the natural precursors of bifonazole. Since the imidazole derivative
37 was unsymmetrical the reaction led to a 3:1 mixture of the regioisomers
(±)-41a and (±)-41b wich were separated by flash chromatography. When
the reaction was performed with the enantiopure benzhydrole (+)-27a, the
resulting products (±)-41a,b were, also in this case, racemic (scheme 4.5.).
The relative ratio of the regioisomers was 3:1.
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N 
H
N
CO2Et
OH N
N
CO2Et
(±)-41a  = 5 Substituted  
(±)-41b  = 4 Substituted 
relative ratio (±)-41a /(±)-41b  3:1
DEAD/ PPh 3
(±)-27a 
(+)-27a 
37
Scheme 4.5: Mitsunobu reaction with 4(5) ethyl imidazole carboxylate 37.
The structural assignment of the two regioisomers (±)-41a,b was
achieved by monodimensional 1H and 13C-NMR and two dimensional one
bond 1H-13C correlation spectra. From these experiments it was possible
to assign the benzhydryl and the imidazole methynes, while long range 1H-
13C-correlation spectra were used to assign the position of the carboethoxy
group on the imidazole ring (Fig. 4.2).
N
N CO2Et
Benzhydrylic proton A
Imidazole proton and carbon D
Imidazole proton and carbon C
Imidazole methyne proton B
Carbethoxy group
Figure 4.2: representative protons and carbons of 41a,b for the assignment of regiochemistry.
In the case of (±)-41a the benzhydrylic proton (proton A fig.4.2)
showed a long range correlation only with one of the imidazole methynes (
position B and C fig.4.2). For (±)-41b the correlation was found with both
the methynes of the imidazole ring ( position B or C fig.4.2). These results
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indicated that the carbethoxy group was at position 5 in (±)-41a and at
position 4 in (±)-41b. The diagnostic resonances are listed in table 4.5.
Position (±)-41a dH (±)-41a dC (±)-41b dH (±)-41b dC
A 7.57 63.5 6.6 65.3
B 7,85 138.0 7.5 138.0
C 7,40 141.7 - -
D - - 7.55 125.7
Table 4.5: chemical shifts (ppm) of the diagonstic protons and carbons in (±)-41a,b.
(±)-41a,b were also synthesized using another strategy. For this the
alcohol (±)-27a was converted into the corresponding bromo derivative
(±)-42 using bromo triphenylphosphine in carbon tetrabromide which,
without isolation was treated with 37. An equimolar mixture of the two
regioisomers was obtained in 32 % overall yield (scheme 4.5)
OH Br
N 
H
N
CO 2Et
PPh3Br 2/ CBr 4
N
(±)-27a 
N
(±)-42
CO 2Et
(±)-41a  = 5 Substituted  
(±)-41b  = 4 Substituted 
relative ratio (±)-41a /(±)-41b  1:1
37
Scheme 4.5 : Alternative synthesis of (±)-41a,b.
The different ratio of the two regioisomers obtained in the Mitsunobu
reaction can be explained by the different basicity (pKa) of the two
nitrogens in 4(5)-ethyl imidazol carboxylate 37.
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As already outlined above (chapter 3, paragraph 3.1.2.1) one of the
most important requirement for the Mitsunobu reaction is the pKa value. In
this case, the two nitrogens have a different pKa, the one next to the
carboxy ethyl group is more acidic (more reactive in the Mitsunobu reaction
conditions) because of the electron withdrawing effect of the COOEt
group. Probably this effect is stronger than the resonance effect on the
nitrogen.
In the bromine substitution (scheme4.5) the pKa is not as important an
parameter as the nucleophilicity of the two nitrogens. In the light of the
previous considerations the expected experimental results could be
opposite to those resulting from the Mitsunobu reaction.
In fact, the nitrogen in the a position of the ester is less nucleophilic
than the other, but the experimental results clearly indicate that
regioselection did not occur during displacement of the bromine. It is also
interesting to note that the reaction is apparently not affected by steric
influences on the imidazole ring.
4.3.3. Synthesis of Bifonazole (±)-6a from (±)-41a.
(±)-41a was hydrolyzed to the corresponding acid (±)-43 in high yield
with 10% LiOH in a mixture of ethanol / water 1:1 at 0°C for two hours
(scheme 4.6). The reaction conditions were very mild in comparison to the
previously reported one for the hydrolysis of dicyano imidazoles derivatives
33c-g.
Unfortunately, all attempts to decarboxylate (±)-43 under mild
conditions were unsuccessful. The only reaction producing the desired
product (±)-6a was again the thermal decarboxylation by heating the acid
(±)-43 under reflux in diphenyl ether (scheme 4.6).
In conclusion, the monosubstituted imidazole 4(5)-ethyl imidazol
carboxylate 37 can be used in the Mitsunobu reaction but a mixture of
regioisomers was obtained. The reaction led to a racemic product when the
enantiopure benzhydrylic alcohol (+)-27a was used as starting material.
While the reaction conditions for hydrolysis of the ester groups are milder
than those used for the dicyanoimidazole, unfortunately no mild conditions
were found for the decarboxylation step. Thus, this new strategy did not
have any advantages over the previously reported method using 4,5-dicyano
imidazole.
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N
N
CO2Et N
N
CO2H
N
N
(±)-41a (±)-43
LiOH 10%
EtOH H 2O
(Ph) 2O 
reflux
(±)-6a
Scheme 4.6: Hydrolysis and decarboxylation  of N-alkyl ethyl imidazole carboxylate (±)-41a.
The acid (±)-43a however offered an opportunity to synthesize
separable diasteroisomers as described in paragraph 4.5.
4.4. Stereochemical Assignment of the Mitsunobu Reaction 
with Imidazole Derivatives.
The stereochemical assignment of the Mitsunobu reaction was another
point elucidated in the present work. In the literature there are no data
available on these enantiopure compounds. It was the goal to find an
alternative synthetic pathway for enantiopure N-1-alkylimidazoles and to
compare their specific rotation with the products obtained from the
Mitsunobu reaction, followed by hydrolysis and decarboxylation as
described in the above paragraphs and to assign the correct
stereochemistry.
In the literature several polysubstituted imidazoles were obtained
starting from an amine by construction of the imidazole ring4.
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(+)-(S)-2-octylimidazole (+)-(S)-35a was chosen as target compound
for the alternative synthetic pathway and (+)-(S)-2-octyl amine (+)-(S)-44
(not commercially available) as starting material.
The synthesis of (+)-(S)-2-octyl amine (+)-(S)-44 is shown in scheme
4.7. For this the commercially available (-)-(R)-2-octanol (-)-(R)-11c was
converted by Mitsunobu reaction into the (-)-(S)-2-octyl phtalimmide
derivative (-)-(S)-45 which by treatment with hydrazine was converted into
the desired (+)-(S)-2-octylamine (+)-(S)-44. Using (+)-(S)-44 the first
synthesis was performed with racemic (±)-31c in order to check the
strategy and also to obtain reference compounds.
OH N
O
O
NH2
(-)-( R)-31c (-)-( S)-45 (+)-( S)-44
NH2NH2
RefluxDEAD, PPH 3 
dry THF
Phtalamide
Scheme 4.7: Synthesis of (+)-(S)-44.
The thus produced (+)-(S)-44 had identical physical constants in
comparison with the data reported in the literature1.
Racemic 2-octylamine (±)-44 treated with aminomalonitrile and triethyl
orthoformiate in acetonitrile was leading the N-1-(2-octyl)-4-cyano-5-
aminoimidazole (±)-465 in good yield. Using the same procedure identical
results were obtained with enantiopure (+)-(S)-2-octyl amine (+)-(S)-44
leading to (+)-(S)-N-1-(2-octyl)-4-cyano-5-aminoimidazole (+)-(S)-46 in
enantiopure form in 52% yield and 98% e.e (scheme 4.8).
The alkaline hydrolysis of the 5-amino-4-cyano-N-1-imidazole
derivatives (±)-46 and (+)-(S)-46 led to the amino acids (±)-47 and  (-)-(S)-
47, respectively. The hydrolysis conditions were identical to those used for
the hydrolysis of the dicyanoimidazole derivative (±)-33a and (-)-(R)-33a,
and no racemization did occur during this step. Compounds (±)-47 and (-)-
(S)-47 were decarboxylated to the N-1-(2-octyl)-5-amino imidazole (±)-48
and (+)-(S)-48. Also in this case thermal decarboxylation was used since
during this step on the compounds (±)-34a and (+)-(S)-34a no
racemization occurred.
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nC6H13
N
N
CN
H2N
H2N
CN
CN
nC6H13
N
N
H2N
CO2H
nC6H13
N
N
H2N
(+)-(S)-44 
nC6H13
N
N
(+)-(S)-46 
Ph2O
CH(OEt)3
NH2
nC6H13
Reflux
NaOH EtOH
(+)-(S)-47 
(+)-(S)-35a
(+)-(S)-48 
Scheme 4.8: First attempt to assign the stereochemistry of the Mitsunobu-hydrolysis-
decarboxylation reaction (in the scheme represented only by the chiral compounds).
Unfortunately the final deaminations of (±)-48 and (+)-(S)-48 by
NaNO2-HCl or isopentyl nitrite were unsuccessful. Therefore using this
synthetic pathway it was not possible to obtain (+)-(S)-2-octylimidazole
(+)-(S)-35a.
Another attempt, based on the same synthetic pathway was tried using
the intermediate N-1-(2-octyl)-4-cyano-5-aminoimidazole (±)-46.
Unexpectedly the deamination with isopentyl nitrite led to N-1-(2-octyl)-4-
carboxy amide imidazole  (±)-49 in 45 % yield (scheme 4.9).
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nC6H13
NH2
nC6H13
N
N
CN
H2N
H2N
CN
CN
nC6H13
N
N
Isopentyl nitrite
nC6H13
N
N
(±)-44 
CO2H
(±)-46 CH(OEt)3
NaOH EtOH
(±)-49 
NH2
O(±)-50 
Scheme 4.9: Second attempt to assign the stereochemistry of the Mitsunobu-hydrolysis-
decarboxylation reaction. This was done  only with the racemic compounds.
Unfortunately all attempts to hydrolize the amide (±)-49 to the
corresponding acid (±)-50 failed and it was thus impossible to obtain the
final target compound using this synthetic pathway.
Next, the strategy was changed in favour of a Markwald procedure3.
For this, the racemic and enantiopure 2-octyl amines (±)-44 and (+)-(S)-44,
1-phenyl-1-ethylamine (±)-51 and (+)-(S)-51 (commercially available) were
alkylated with bromoacetaldehyde dimethylacetal in order to provide the
monoalkylated products 52a (62%  yield) and 52b (70 % yield) in racemic
and enantiopure form. These compounds were cyclized to racemic and
enantiopure N-1-alkyl-5-mercapto imidazoles 53a and 53b respectively
using KCNS in a aqueous HCl/THF solution. In both cases the yield was
84%. The final desulfuration was performed with Raney-Ni and afforded
compounds 2-octylimidazole 35a and 1-phenylethyl-1-imidazole 54 in
racemic and enantiopure form with an enantiomeric excess of higher than
98% e.e. In scheme 4.8 all reaction sequences are shown.
(+)-(S)-35a thus obtained proved to be identical in all respects,
including specific rotation with (+)-(S)-35c derived from (-)-(R)-2-octanol
(-)-(R)-31c via  the Mitsunobu-hydrolysis-decarboxylation sequence.
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R
NH2
R
H 
N
OMe
MeO
Br
OMe
OMe
R
N
N
HS
R
N
N
R = n-Hexyl  (+)-( S)-44; (±)-44 
R = Ph          (+)-( S)-51; (±)-51 
K2CO3 / CH3CN
R = n-Hexyl  (+)-( S)-52a; (±)-52a 
R = Ph          (+)-( S)-52b; (±)-52b 
KCNS / 
HCl THF
Raney Nickel
MeOH
R = n-Hexyl  (+)-( S)-53a; (±)-53a 
R = Ph          (+)-( S)-53b; (±)-53b 
R = n-Hexyl  (+)-( S)-35a; (±)-35a 
R = Ph          (+)-( S)-54; (±)-54 
Scheme 4.8: Synthesis of racemic and enantiopure N-Alkyl imidazoles 35 and 54via  the
Markwald procedure.
It can therefore be implicated that, as expected, the Mitsunobu
condensation proceeded with complete inversion of configuration of the
starting alcohols.
It should be pointed out that this is the first application of the
Markwald procedure to chiral amines. Furthermore this procedure gave
excellent results with the chiral benzylamine (+)-(S)-51 and thus resolved all
problems with racemization of the benzylic alcohol during the Mitsunobu-
hydrolysis-decarboxylation sequence. Obtained was enantiopure (+)-(S)-1-
phenyl-1-ethyl imidazole (+)-(S)-54.
The enantiomeric excess of the final product (+)-(S)-35a, (±)-56 and
the chiral (+)-(S)-56 was determinated for all compounds by 1H-NMR in
presence of chiral shift reagents as described in paragraph 4.1.1.
4.5 Conversion of chiral alcohols to chiral amines.
The success achieved in the conversion of the enantiopure benzylic
amine (+)-(S)-51 into enantiopure benzylic imidazole (+)-(S)-56 led us to
consider the alternative synthetic pathway described in chapter 1.6.2. The
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key step is the conversion of the enantiopure benzhydrilic alcohol to
enantiopure benzhydrilic amine and via the Markwald procedure to
synthesize the imidazole.
Different methodologies were investigated in order to convert the
enantiopure benzhydrylic alcohol into enantiopure benzhydrilic amine, since,
unfortuntaly  no reports for these substrates can be found in the literature.
4.5.1. Conversion of chiral alcohols to chiral amines in three steps.
In general the synthesis of an amine from an alcohol proceeds via three
synthetic steps: (a) activation of the alcohol function by synthesis of e.g. a
tosylate, mesylate, triflate or conversion into halides; (b) displacement of
these leaving groups with sodium azide, phtalamide and (c) conversion of
the resulting function to the primary amine. All attempts to convert the 1-
phenyl-1-biphenyl methanol (±)-27a and 1-(2-bromophenyl)-1-biphenyl
methanol (±)-27c into mesylates, tosylates or triflates failed.
'R
R
OH
'R
R
OMs
'R
R
NHR
I Step II Step
Scheme 4. : general synthetic pathway to amines.
The reactions were carried out under different experimental conditions
by varying temperature, solvent and reaction time and also with different
reagents, such as MsCl, TsCl and bases such as pyridine or triethylamine.
In no case a product was isolated. The reasons for this are not well
understood. Experiments performed in the NMR-tube indicated that the
products were formed but after a few hours they were degraded to
unknown products. The product showed to be very sensitive to water and
after addition of a drop water the starting material was reformed
immediately. After this observation it was tried to displace the mesylate in a
one-pot reaction with NaN3. But also in this case no product was detected.
Due to these unsuccessful experiments the attention was turned to other
strategies where the alcohols could be converted directly to azides or
suitable precursors.
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4.5.2. Direct conversion of chiral alchols to chiral amines via chiral
azides.
The literature provided a number of methods for the conversion of
chiral, electron-rich benzylic alcohols into the corresponding azides thereby
maintaining optical activity. The use of the Mitsunobu displacement6 with
an azide nucleophile appeared to have the best precedence. It was also the
first example in which an amine equivalent was introduced under Mitsunobu
conditions using phtalamide as nucleophile1. Such reactions with C-N bond
formations were extensively reviewed by Hughes7.
Azide was first introduced under Mitsunobu conditions using
hydrazoic acid as azide source8 and this method was recently extended to
chiral a-arylethyl amines9. Alternatives to hydrazoic acid include diphenyl
phosphorazidate (DPPA)10 and zinc azide/bis pyridine  complex11. More
recently Merck researchers reported in a paper12 and expecially in a
patent13 a practical alternative to the Mitsunobu conditions with diphenyl
phosphorylazide (DPPA) and DBU (diazabicycloundecene). Several of
these methods were investigated with the racemic and chiral benzhydroles
and also 2-benzo[b]furane-aryl-methanoles.
4.5.2.1 Mitsunobu reaction with diphenyl phosphorylazide 
(DPPA) as an organic azide source10.
This method was applied to racemic and chiral substrates (±)-27a,(±)-
27c, (+)-27c, (±)-27g, (±)-27m, (+)-27m (scheme 4.12)
OH
R1 R2
N3
R1 R2PPh3, DEAD, (PhO) 2PN3
dry THF, RT
27-a,c,g,m 55-a-d
Scheme 4.12: Synthesis of azides 55a-d using DPPA.
The procedure described by Base10 was modified because under their
conditions the chemical yield was very low. The modification consisted in
the sequential addition of alcohol and triphenylphosphine to a dry THF
solution of diethyldiazodicarboxylate and DPPA at 0° C, similar to a
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reverse addition in the Mitsunobu reaction. The results using this procedure
are shown in table 4.6.
entry substrate R1 R2 product yield% [a]
1 (±)-27a Ph 4Ph C6H4 (±)-55a 53.8 0
2 (±)-27c 2 BrPh 4Ph C6H4 (±)-55b 57.5 0
3 (+)-27c 2 BrPh 4Ph C6H4 (±)-55b 68.5 0
4 (±)-27g 2 benzo[b]furane Ph (±)-55c 15.0 0
5 (±)-27m 2 benzo[b]furane 2,4 C6H3 (±)-55d 13.3 0
6 (+)-27m 2 benzo[b]furane 2,4 C6H3 (+)-55d 10.8 0
Table 4.6: Synthesis of azide 55a-d via Mitsunobu reaction with DPPA.
All reactions were carried out in dry THF overnight with an excess of
reagents. In the case of compounds 27g-m (entries 4-6, table 4.6) large
amounts of starting material were always recovered. With benzhydroles
27a-c (entries 1-3, table 4.6) products were obtained, however, due to
partial decomposition during chromatography yields were low. The
benzhydroles (entries 1-3, table 4.6) led to better results regarding chemical
yields than the benzo[b]furan aryl methanols (entries 4-6). The results are in
good agreement with those obtained in the Mitsunobu reaction with 4,5
dicyanoimidazole using the same substrates. None of the products showed
a specific rotation  neither at the sodium line nor at all Hg lines. This led to
the conclusion that all compounds were racemic. All attempts to measure
the enantiomeric excess directly by chiral HPLC or by NMR in the
presence of shift reagents failed.
4.5.2.2. Direct conversion of alcohols to azides using 
diphenylphosphoroazidate and DBU.
These reactions were carried out by dissolving the alcohols and DPPA
in dry toluene to a final alcohol concentration of about c.a. 0.5-1.0 M. To
the reaction mixture a slight excess of DBU was added (Scheme 4.13). The
procedure was applied to the alcohols reported in table 4.7.
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R R1
N3
R R1
55a-d
DPPA
27a,c,g,m
DBU
Scheme 4.13: Synthesis of azides 55a-d by DPPA-DBU.
entry substrate R1 R2 product yield% [a]
1 (±)-27a Ph 4 PhC6H4 (±)-55a 0 0
2 (±)-27c 2 BrPh 4 PhC6H4 (±)-55b 5.8 0
3 (+)-27c 2 BrPh 4 PhC6H4 (±)-55b 5.2 0
4 (±)-27g 2benzo[b]furane Ph (±)-55c 54.3 0
5 (±)-27m 2benzo[b]furane 2,4ClC6H3 (±)-55d 67.2 0
6 (+)-27m 2benzo[b]furane 2,4ClC6H3 (+)-55d 69.8 +0.5
Table 4.7: Synthesis of azides  55a-d by DPPA-DBU.
The results were quite opposite to those obtained by the Mitsunobu
reaction described in chapter 4.2.2.1. In fact, the benzo[b]furanes (entries
4-6) reacted better than the benzhydroles (entries 1-3) without any
apparent reason. The reaction takes place in two discrete steps, the first
one being the phosphate formation, followed by azide displacement
(Scheme 4.14).
R R1
O
R R1
P OPhO
N
H+ 
N
OH N3
R R1(PhO)2PN3
DBU27a,c,g,m N3
- 55a-d
OPh
Scheme 4.14: reaction mechanism for azide synthesis by DPPA-DBU.
The mechanism was proposed by Thompson13 The reaction has
considerable advantages as compared to the Mitsunobu reaction with
DPPA. The only by-product of the reaction is the DBU salt of
diphenylphosphate. This salt is water soluble and can be removed during
aqueous work up. The other two contaminants were: (a) excess of DBU
which was eliminated by acidic work up and (b) a slight excess of DPPA
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which was eliminated easily by chromatography. Unfortunately, however,
also in this case the reaction proceeded without any stereocontrol. All
products, with the exception of  (+)-55d, showed no specific rotation at
the Na and Hg wavelenght. As in the case of the Mitsunobu reaction with
DPPA measurement of the e.e. of the products was not possible. The last
attempt to synthetize the chiral azide from the chiral alcohols was
perfomed with zinc azide/bis pyridine complexes. Identical conditions as
reported in the literature were used, but no conversion of the starting
material was observed.
4.5.3. Reduction  of the azides 55a-d to the amines.
From the literature several methods for the reduction of azides to
primary amines are known. Two methods (Scheme 4.15) were tried on our
compounds:
A) Reduction by Ph3P/H2O in THF
B) Reduction by SnCl2/MeOH
N3
R R1
55a-d
NH2
R R1
56a-d
method A or B
Scheme 4.15: Reduction of azides (±)-55a-d to amines(±)-56a-d.
In table 4.8 the results of both methods used for the reduction of the
azides 55a-d are reported.
entry substrate R1 R2 product yield % A yield %B
1 (±)-55a Ph 4PhC6H4 (±)-56a 50 83
2 (±)-55b 2BrPh 4PhC6H4 (±)-56b 55 80
3 (±)-55c 2benzo[b]furan Ph (±)-56c 68 87
4 (±)-55d 2benzo[b]furan Ph (±)-56d 38 85
5 (+)-55d 2benzo[b]furan 2,4 Cl2Ph (+)-56d 42 84
Tab 4.8: reduction of azides (±)-55a-d to amines (±)-56a-d.
The best results in terms of chemical yields were obtained with
SnCl2/MeOH. The reactions were carried out with both the racemic and
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enantiopure azides. It was possible to determinate the enantiomeric excess
of the amines by chiral HPLC. As expected, all amines were racemic
except for (+)-56d which showed an e.e. of 20%. Thus, more than 50% of
enantiomeric excess was lost during the conversion of the alcohol (+)-27m
to the amine (+)-56d. Again it was clear that these methods are not
suitable to obtain the target molecule in enantiopure form.
4.6 Synthesis of separable pairs of diastereoisomers from (±)-34e and
(±)-43a.
4,5-imidazoledicarboxylate derivative (±)-34e and 5-imidazolecar-
boxylate derivative (±)-43a were obtained as intermediates in the
"Mitsunobu-hydrolysis-decarboxylation" procedure. They were considered
as an exceptional opportunity to generate pairs of separable
diastereoisomers. The first attempt involved the synthesis of chiral amides.
For this (+)-(R)-1 Naphtyl-1-ethyl amine and (+)-(R)-1-Phenyl-1-ethyl
amine were used , carbonyldiimidazole (CDI) was the coupling reagent
and dry dioxane was the solvent (Scheme 4.16).
N
N
R
R1
N
N
R
R1
H2N-CH-MeR
CDI,dry dioxane
(±)-43a  R=CO2H R1=H 
(±)-34e  R=R1=CO2H
(±)-57a  R=CONH(C*H Me)1Naphtyl R 1=H 
(±)-57b  R=R1=CONH(C*HMe) 1Naphtyl 
(±)-57c  R=CONH(C*HMe)Ph R 1=H 
(±)-57d  R=R1=CONH(C*HMe)Ph
Scheme 4.16: Synthesis of separable diasteroisomeric amides.
Chemical yields were very high (>95%), and no racemization
occurred during the reactions. More than one hundred TLC eluation
systems were tried to separate the diastereoisomers. Finally with
CH2Cl2:MeOH:AcOH 98:1:1 it was possible to separate the
diastereoisomers (±)-57b and (±)-57d while it proved impossible to
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separate (±)-57a and (±)-57c. Compounds (±)-57b and (±)-57d are
sterically very hindered and one hypothesis was that two conformers were
separated instead of the two diastereoisomers. However 1H-NMR spectra
recorded in DMSO at high temperature did not show any interconversion
between the two separated species (+)-57b and  (-)-57b and (+)-57d and (-
)-57d were really pairs of diastereoisomers. Several attempts were made to
cleave the amide bond of the single diastereoisomers in order to recover
the single enantiomers (+)34e or  (-)-34e.  All attempts were unsuccessful,
and sometimes, due to the drastic conditions, the benzhydrylic proton was
racemized. The strategy was abandoned because in the meantime the
racemization of the benzyl product (-)-(S)-33e was observed during the
decarboxylation step in the "Mitsunobu-hydrolysis-decarboxylation"
methodology. It was not possible to overcome this problem.
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5. Synthesis of Aryl propargylic alcohols of high 
enantiomeric purity via Lipase catalysed 
resolution.
The aim of this part of the thesis was the synthesis of aryl propargylic
alcohols in enantiopure form, useful building blocks for the synthesis of aryl
2benzo[b]furane methanoles 27 and the Menarini imidazole derivative 18 in
enantiopure form.
5.1 Synthesis of racemic 1-Aryl 2-propyne-2-ols (±)-58.
Several methods are described in the literature1a,b,c for the synthesis
of racemic ethynyl carbinoles. The most useful procedure is the addition
of various nucleophilic reagents to aldehydes or ketones, monolithium
acetylide being one example. Several methods for the preparation of this
reagent2a,b are reported in literature. One of the procedures involves the
addition of n-butyl lithium to acetylen in dry THF at -78°C followed by
the addition of aldehydes or ketones3a,b. The reported yields of ethynyl
carbinoles are high, but the experimental procedure is very complex.
Furthermore, the use of acetylene bottles in chemistry departments is
regulated by very restricted laws. Lithium acetylide is commercially
available as 0,1 N THF solution, and this was used as nucleophile for the
addition to the benzaldehyde. In the second procedure, ethylenediamine
was used to stabilize the acetylide3b. Both experiments gave very poor
results, only 45% and 42% yield of 1-Phenyl-2-propyn-1-ol (±)-58a,
respectively were obtained (Scheme 5.1).
H
O
SiMe3
OH
SiMe3
H
R R
1)
dry THF -780C
(±)-59 a-g
nBuLi
2) dry THF -78/00C  
Scheme 5.1:Synthesis of 1 Phenyl-2-propyn-1-ol (±)-58a.
The biggest problem encountered with lithium acetylide is its
disproportionation to form dilithium acetylide and acetylene3b. In order
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to avoid this side reaction trimethyl silyl acetylene (TMSA) was used to
generate the stable nucleophile lithium trimethyl silyl acetylide. For this
TMSA in dry THF was cooled to -75°C and n-butyllithium was added
dropwise, leading to lithium trimethyl silyl acetylide. The reaction
mixture was then cannulated dropwise into a solution of the aryl aldehyde
in dry THF at -78°C to form the desired 1-aryl-2-propyn-3-trimethylsilyl
-1-ols (±)-59a-g (Scheme 5.2).
H
O
SiMe3
OH
SiMe3
H
R R
1)
dry THF -780C
(±)-59 a-g
nBuLi
2) dry THF -78/00C  
Scheme 5.2: Synthesis of 1-aryl-2-propyn-3-trimethylsilyl -1-ols (±)-59a-g.
These reactions gave very good chemical yields with seven aryl
aldehydes as reported in table 5.1.
Entry R aldehyde T °C Product Yield %
1 H -15 (±)-59a 98.5
2 4Me -78 / 0 (±)-59b 97.0
3 4F -78 / 0 (±)-59c 98.0
4 4Cl -78 / -15 (±)-59d 96.0
5 4CN -78 (±)-59e 87.0
6 4NO2 -78 (±)-59f 49.0
7 3,4 OMe -15 (±)-59g 96.0
Table 5.1: Reaction conditions and chemical yields for the synthesis of (±)-59a-f.
It is interesting that for the first four compounds (±)-59a-e (entries
1-4) the reactions were so clean that purifications were unnecessary. For
compounds (±)-59e-f, (entries 5,6), it was necessary to keep the
temperature very low (-78°C). Raising the temperature to -15°C caused
complete degradation of both the starting material and the product. It was
impossible to recover the materials. Under these conditions, the cyano
group does not react with the lithium reagent. This procedure led to the
desired ethynyl carbinoles in very good yield with the exception of the
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product resulting from 4-nitrobenzol aldehyde which led to (±)-59f in
only 49 % yield.
5.1.1.Desilylation of Aryl trimethylsilyl propargylic alcohols 59a-d.
1-Aryl-2-propyn-3-trimethylsilyl-1-ols (±)-59a-d constitute for-
mally protected acetylenes. Various desilylation methods were tried in
order to obtain the acetylenic products (±)-58a-g. No reaction occurred
when (±)-59a was treated with 1 N HCl in THF at different
temperatures. Better results were obtained when the alcohols (±)-59a-g
were treated with KF in DMF (scheme 5.3). The results are reported in
table 5.2.
OH
SiMe3
OH
HR R
25-60°C
(±)-59a-g
KF, DMF
(±)-58a-g
Scheme 5.3: desilylation of (±)-59a-g by KF in DMF.
Entry R T °C Product Yield %
1 4H 60 (±) - 58a 87.1
2 4Me 60 (±) - 58b 47.5
3 4F 60 (±) - 58c 96.9
4 4Cl 60 (±) - 58d 93.2
5 4CN RT-60 (±) - 58e 0
6 4NO2 RT-60 (±) - 58f 0
7 3,4 OMe RT-60 (±) - 58g 0
Table 5.2: Reaction conditions and chemical yields for the desilylation of (±)-59a-g using
KF in DMF.
The reaction worked, however,  well only for three substrates: (±)-
59a,c,d (entries 1,3,4), compounds with an unsubstituted aryl moiety or
with one halogen in the para position.The presence of a methyl group on
the aromatic moiety (±)-59b decreased the yield to 47.5% (entry 2).
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Complete degradation of the substrates occurred with compounds (±)-
59e-g carrying nitro, cyano or methoxy groups in the para position
(entries 5-7). The reaction did not work at room temperature, at close to
50°C the reaction took place for compounds (±)-59a-d while for (±)-
59e-g the reaction mixtures became dark and it was impossible to detect
any products.
Also milder conditions than KF in DMF at 60°C were tried for the
desilylation, and TBAF in dry THF was used as an alternative (scheme
5.4).
OH
SiMe3
OH
H
R R
-15/RT °C
(±)-58a,c,e
TBAF dry THF
(±)-59a,c,e
Scheme 5.4: Desilylation of (±)-59a,c,e by TBAF.
This procedure was applied only to three substrates (±)-59a,c,e.
Again (±)-59a and (±)-59c gave the best results, while (±)-59e was
degraded during the reaction. The results for this reaction are reported in
table 5.3.
Entry R T C° Product Yield
1 4H -15/RT (±)-58a 94.8
2 4F -15/RT (±)-58c 96.9
3 4CN -15/RT (±)-58e 0
Table 5.3: Reaction conditions and chemical yields for the desilylation of (±)-59a,c,e
using TBAF in THF.
A last attempt of desilylation was carried out under basic conditions.
A saturated solution of K2CO3 in absolute MeOH was used and the
reaction was tried on (±)-59g (one of the arylpropynoles which
decomposed in presence of the KF). The reaction was very slow and gave
a complex mixture of products. In fact, in order to achieve a complete
consumption of the starting material, five days were required and only
43% of the desired product (±)-58g was recovered after purification.
(Scheme 5.5).
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OH
SiMe3
OH
H
MeO
OMe
MeO
OMe
(±)-58g
RT 
K2CO3 / abs MeOH
(±)-59g
Scheme 5.5: Desilylation of (±)-59g under basic condition.
Unfortunately it was not possible to find one generally applicable
procedure for the desilylation of all aryl propynoles (±)-59a-g.
5.2 Synthesis of Aryl propynols (±)-58 by addition of 
Grignard reagents to aromatic aldehydes.
Grignard reagents were also considered as nucleophiles for the
addition to aryl aldehydes. For this a 1 M solution of magnesiumethynyl
bromide or chloride in dry THF (purchased from Aldrich) was added to
aryl aldehydes (Scheme 5.7).
H
O OH
H
(±)-58a-c,e,h-m
R RMgBrH
Dry THF
Scheme 5.7: Synthesis of aryl-propynols (±)-58a-c,e,h-m by addition of Grignard
reagent to aryl aldehydes.
Usually the aldehydes were dissolved in dry THF, the resulting
solution was cooled to low temperatures (in some cases 0°C was
sufficient) in order to have a very clean and fast reaction. In table 5.4 the
results and reaction conditions are reported.
The use of this Grignard reagent also allowed the synthesis of
1[4cyanobenzyl]2-propyn-1-ole (±)-58e (entry 4). This product could
not be obtained with all the other methods reported in the previous
paragraphs. This arylpropynole was thus obtained in a single step.
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Entry R T °C Product Yield
1 4H 0 (±)-58a 99
2 4Me -15 (±)-58b 98
3 4F 0 (±)-58c 89
4 4CN -78 (±)-58e 90
5 3Me 0 (±)-58h 91
6 3F 0 (±)-58i 78
7 2Me 0 (±)-58l 98
8 2,4Cl 0 (±)-58m 98
Table 5.4: Reaction conditions and chemical yields for the synthisis of aryl-propynols
(±)-58a-c,e,h-m.
The chemical yields were very high, the reaction conditions mild and
all  products could be purified by easy filtration over silica gel. In order
to obtain a colorless liquid it was necessary to distill the crude products
under high vacuum. The cyano group present in 4-cyano benzaldehyde
proved to be unreactive with the Grignard reagent also in presence of a
slight excess.
5.3 Enzymatic resolution of 2-substituted-2-propynyl-1-oles 
(±)-58.
In the literature several methods for the enzymatic resolution of
acetylenic alcohols by hydrolysis or esterification are reported. O'Hagan8
has reported a very good study of the resolution of tertiary acetylene
acetate esters in presence of a lipase from Candida cylindracea. However,
the enantiomeric excesses usually are very low. Much more efficient is the
esterification of secondary acetylenic alcohols in presence of Pseudomonas
(A.K.) in hexane with vinyl acetate9. In these cases e.e.'s higher than 95%
were reported both for the alcohol and the acetate. E values are higher
than 200. Unfortunately, the paper describes only one kinetic resolution
of a secondary propynyl alcohol with an internal triple bond. Only one
example describes a terminal triple bond and this was the worst substrate,
leading to only very low enantiomeric excess. In the master thesis of
Claudia Waldinger6 preliminary results were reported concerning the
enzymatic resolution of four different terminal aryl propynoles by
hydrolysis or esterification in presence of a lipase from Pseudomonas
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fluorescens  (SAM II). The hydrolysis of the acetates gave better results
than the esterification. Only in the case of 1-Phenyl-1-propyn1-ol, the E
value was higher than 100 and a perfect resolution of the two enantiomers
was achieved. In presence of a methoxy group on the phenyl ring the
stereoselectivity decreased dramatically, in fact E values of 1.05 for the
ortho methoxy, 5.7 for the meta - and 2.2 for the para  - methoxy-
compounds were found. These preliminary results opened the possibility
of obtaining aryl propynoles in enantiopure form by enzymatic
 resolution.
5.3.1 Kinetic resolution of aryl propynoles (±)-58: screening
for  useful enzymes.
Lipases are known to catalyse both the enantioselective esterification
of racemic alcohols and/or the hydrolysis of their corresponding esters. In
order to identify the most desirable mode of transformation and the best
suited enzyme for the aryl propynoles, a series of screening experiments
were carried out. Ten different lipases were used in these experiments.
5.3.1.1 Enzymatic esterification of racemic aryl propargylic 
alcohols(±)-58: screening experiments.
Transesterification of aryl propynoles in presence of ten lipases
[from Hog Pankreas, Porcine Pankreas, Aspergillus Niger, Mucor
javanicus, Candida cylindracea, Candida lipolytica, Penicillium
roquefortii, Mucor miehei (Lipozyme), SAMI and SAMII] were carried
out under the conditions of irreversible acyl transfer. They revealed that
only two lipases, those derived from Pseudomonas species (SAMI and
SAMII) were able to catalyze these reactions, albeit with rather low
enantioselectivities and in preparatively unsatisfactory reaction times.
(Scheme 5.6 and table 5.5). The substrate chosen for the screening
experiments was (±)-58e because: (a) it contains a para-substituent on the
aromatic ring and (b) it is the most important precursor for the Menarini
aromatase inhibitors.
Enzymatic esterifications were carried out in MTBE as solvent. The
relative ratio between substrate (±)-58e : enzyme : vinyl acetate was
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2:1:3 in weight. All ten reactions were carried out simultaneously at room
temperature.
OH
H H H
OH HH AcOO
O
+
LIPASE
(+)-(R)-60e(±)-58e (+)-(S)-58e
NC NC NC
Scheme 5.6: Screening of lipases for the esterification of 1(4cyanophenyl)-2-propyn-1-ol
(±)-58e.
The reactions were monitored by GC every twentyfour hours, for a
total of seven days. Only two enzymes were able to catalyze the
esterification of (±)-58e. In table 5.5 the results obtained after 48 and 96
h are reported.
Lipase Acetate48h Acetate 96h Alcohol 48h Alcohol 96h
Hog Pancreas - - + +
PPL - - + +
Aspergillus Niger - - + +
Mucor Javanicus - - + +
Candida Cylindracea - - + +
Candida Lipolytica - - + +
Penicillium Roqueforti - - + +
Mucor Mihei - - + +
SAM I + + + +
SAM II + + + +
Table 5.5: Enzymatic screening of lipases for the esterification of (±)-58e.
All reaction rates were very slow. In fact, after six days SAM I showed
23% of conversion and very poor enantiomeric excess for the alcohol
(±)-58e, while SAMII showed a conversion of 40%. In this case, the
enantiomeric excess of the alcohol (+)-(S)-58e was 37.6% ee and for the
product (+)-(R)-60e 56.5% ee was observed, corresponding to E>5. All
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other batches were checked after 6 days and only PPL showed a low 4%
conversion. In table 5.5 the qualitative results are reported, + and - means
presence of the material (alcohol or acetate) detected by GC analysis of
the crude reaction mixture.
5.3.2 Synthesis of racemic aryl propynyl acetate (±)-60.
In order to study the enzymatic hydrolysis three different
arylpropynols were acetylated. Two different conditions were used as
described in scheme 5.8 (condition A: Py, acetic anhydride, RT; condition
B: AcCl, TEA, CH2Cl2 or THF). Scheme 5.7
OH
H
OAc
H
RR
(±)-58a,b,e (±)-60a,b,e
Conditions A or B
Scheme 5.7: Acetylation of aryl propynols (±)-58a,b,e.
Reaction conditions (A or B), substrates, products and chemical
yields are reported in table 5.6.
Entry Substrate R Reac. Con. Time h Product Yield
1 (±)-58a H A 12.0 (±)-60a 95.5
2 (±)-58a H B 1.0 (±)-60a 98.3
3 (±)-58b 4Me B 1.0 (±)-60b 97.6
4 (±)-58e 4CN B 1.0 (±)-60e 98.0
Table 5.6: Acetylation of (±)-56a,b,e.
Reactions carried out using method B are much faster than those with
method A. Furthermore the work up using method B is very easy.
5.3.2.1 Enzymatic hydrolysis of 1-(4-Cyanophenyl)-2-Propyn-
 1-Acetate (±)-60e: screening experiments.
The identical set of enzymes used for the esterifications were used
also for the screening of the hydrolysis reaction (scheme 5.8). The
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reaction conditions were: room temperature, phosphate buffer pH=7.0
and stirring; the ratio between ester and enzyme was 1:1. The substrate
was always (±)-60e (Scheme 5.8).
OAc
H H H
OAc HH HO
LIPASE
NC NC NC
+
(±)-60e (-)-(S)-60e (-)-(R)-58e
Ph=7; RT
Scheme 5.8: lipase screening for the hydrolysis of 1-(4cyanophenyl)-2-propyn1acetate
(±)-60e
All reactions were monitored by GC after 24 and 48 hours as in the
case of esterification. Unexpectedly, a completely different behaviour was
found for this reaction in comparison with the corresponding
esterification. The qualitative results are reported in table 5.7.
Lipase Acetate24h Acetate 48h Alcohol 24h Alcohol 48h
Hog Pancreas + + + +
PPL + + + +
Aspergillus Niger - - + +
Mucor Javanicus + + - -
Candida Cylindracea - - + +
Candida Lipolytica + + - -
Penicillium Roqueforti - - + +
Mucor Mihei - - + +
SAM I + + + +
SAM II + + + +
Table 5.7: Enzymatic screening of lipases for the hydrolyses of (±)-60e.
Only two lipases (Mucor javanicus  and Candida lipolytica) were
unable to catalyze the hydrolysis and no product was detected by GC after
48 h; three of the enzymes (Aspergillus niger, Candida cylindracea,
Mucor miehei) were too ''efficient''; after 20 hours all the ester was
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converted into alcohol and consequently there was no enantioselectivity
observed. Three other lipases (Hog pancreas, Porcine Pankreas,
Penicillium roquefortii) showed poor conversion, and after 48 h both
acetate and alcohol were present in the reaction mixture in a 95:5 ratio.
SAMI and SAMII were the only promising lipases. After 48 h more than
fifty percent of the ester (±)-60e was converted into the alcohol (-)-
(R)-58e.
The selectivity was not very high. With SAM II after 52 h the
conversion was 67.8%. The e.e. of the acetate (-)-(S)-60e was 86.6 %
e.e. and the e.e. of the alcohol (-)-(R)-58e was 41.2% corresponding to
an E value of 6.
This result appeared to be really promising considering that in the
previous study the presence of para methoxy led to an E value <1.
Therefore, further investigation were carried out only with the lipase of
Pseudomonas fluorescens  SAMII.
5.3.3 Enzymatic hydrolysis of racemic Aryl-2-propyn-1-
              acetates   (±)-60a,b,e   in   presence   of   the    lipase    from 
    Pseudomonas    fluorescens   (SAMII):   effect    of      the 
              cosolvent.
In order to obtain more informations regarding the behaviour of
SAMII towards  the hydrolysis of this class of acetates, compounds (±)-
60a,b and (±)-60e were including in the screening programme. (±)-
60a was used as a standard because it had already been studied by Claudia
Waldinger in her master thesis. Experiments were carried out at RT using
10% in weight of SAMII in respect of the substrate. Phosphate buffer
pH=7 was used as solvent and 1.0 N NaOH as titrating reagent (Scheme
5.9). Results are shown in table 5.8; scheme 5.9.
OAc
H H H
OAc HH HO
R R R
+
SAM II
PH=7; R.T.
(±)-60a,b,e (-)-(S)-60a,b,e (-)-(R)-58a,b,e
Scheme5.9: Enzymatic hydrolyses of arylpropargylic acetates (±)-60a,b,e.
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Entry Substrate R Time h C% Product Yield e.e. E
1 (±)-60a H 4.5 47.3 (-)-(S)-60a 45.2 87.0 100
2 H (-)-(R)-58a 30.5 97.0
3 (±)-60b 4Me 144 60.7 (-)-(S)-60b 57.3 99.5 35
4 4Me (-)-(R)-58b 33.8 64.8
5 (±)-60e 4C
N
52 67.8 (-)-(S)-60e 60.1 86.6 6
6 4C
N
(-)-(R)-58e 31.0 41.2
Table 5.8: Enzymatic hydrolyses of arylpropargylic acetates (±)-60a,b,e.
As reported in table 5.8, SAMII worked perfectly with the acetate
(±)-60a which does not contain any substituent on the aromatic moiety,
the corresponding E value was >100. For the two others esters having a
para- substituent (Me for (±)-60b and CN for (±)-60e) the selectivity
was much lower ((±)-60b E=35, and (±)-60e E=6). In these
experiments (2 mmoles of esters and 10% in weight of lipase Sam II) the
solubility of the substrates became a problem. (±)-60e was insoluble in
the phosphate buffer and appeared as a solid suspension in the reaction
mixture. The inhomogeneity of the reaction mixture led to
unreproducible results for the three sets of experiments. It is well known
that the optimal reaction conditions for lipase catalysed reactions are
those in which the substrates are oil emulsions in buffer since the reaction
occurs at the interface between the two phases. For this reason it was tried
to keep (±)-60e as an oil in the reaction mixture, however already after
few minutes under stirring in the buffer it became solid. The
inhomogeneity of the reaction mixture could be one reason for the low
selectivity of the lipase during the hydrolysis. Therefore, the use of a
cosolvent was considered as a possible solution for this problem (Scheme
5.10).
OAc
H H H
OAc HH HO
R R R
+
(±)-60a,b,e (-)-(S)-60a,b,e (-)-(R)-58a,b,e
SAM II, cosolvent
PH=7; R.T.
Scheme 5.10: Effect of solvent on the enzymatic hydrolyses of (±)-60a,b,e.
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Three different solvents were considered: MTBE, THF and acetone.
THF was found to be the worst solvent; it was impossible to follow the
reaction by GC. Solvents were used in different concentrations as
reported in table 5.9. For clarity and direct comparison the results
obtained without cosolvent are incorporated in the same table.
Entry Substrate R Cosolvent Product C% Time h e.e E
1 (±)-60b 4Me - (S)-60b 60.7 144 >99.5 35
2 4Me - (R)-58b 64.8
3 (±)-60b 4Me MTBE 10% (S)-60b 38.1 47 47.3 12
4 4Me (R)-58b 77.0
5 (±)-60b 4Me MTBE 25% (S)-60b 41.2 40 38.4 5
6 4Me (R)-58b 54.7
7 (±)-60b 4Me Acetone5% (S)-60b 48.2 76 79.5 31
8 4Me (R)-58b 85.4
9 (±)-60e 4CN - (S)-60e 61.8 52 86.6 6
10 4CN (R)-58e 41.2
11 (±)-60e 4CN MTBE 10% (S)-60e 67.7 36 86.6 6
12 4CN (R)-58e 41.2
13 (±)-60e 4CN MTBE 30% (S)-60e 66.0 36 86.8 7
14 4CN (R)-58e 44.7
Table 5.9: Effect of cosolvent in the enzymatic hydrolyses of (±)-60e.
All obtained results were really unsatisfactory. The addition of
MTBE as a cosolvent dramatically decreased the enantioselectivity of the
enzymatic process for (±)-60b. 10% of MTBE gave E = 12 and 25% of
MTBE gave E value = 5 (entries 3-5; table 5.9). Acetone (entry 7; table
5.9) was found to be a much better cosolvent because it did not decrease
the enantioselectivity of the process as compared with the experiment
using no cosolvent (entry1; table5.9).
Its presence did in no way improve the process. The addition of
MTBE with 10% and 30% to the reaction mixture containing (±)-60e
(entries 11,13; table5.9) did not lead to any change of the selectivity as
compared with the experiment without cosolvent (entry 9; table 5.9). It
led to a homogeneous trend of the reaction and the enzymatic process was
much more continuous. The hypothesis that the solid state of (±)-60b,e
was responsible for the low selectivity was not supported by these
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experiments. But it was interesting to find that the addition of MTBE as
cosolvent was a good method to obtain reproducible and homogeneous
results.
5.3.4 Enzymatic hydrolysis of (±)-60b in presence of SAMII:
effect of the temperature.
The last parameter studied was the temperature; here only one
substrate (±)-60b was used in the experiments (Scheme 5-11.)
OAc
H H H
OAc HH HO
Me Me Me
+
(-)-(S)-60b(±)-60b
PH=7; T.
SAM II
(-)-(R)-58b
Scheme 5.11: Effect of the temperaure on the enzymatic hydrolyses of (±)-60b.
Entry Substrate T °C Time h Product C % e.e. % E
1 (±)60b RT 144 (S)-60b 60.7 100 35
2 RT (R)-58b 64.8
4 35 (R)-58b 79.7
5 (±)60b 55 32 (S)-60b 58.1 89.7 14
6 55 (R)-58b 64.8
7 (±)60b 58 19 (S)-60b 51.5 47.3 12
8 58 (R)-58b 77.0
Table5.10: Effect of the temperature on the enzymatic hydrolyses of (±)-60b.
 Three experiments were carried out at 35°C, 55°C, 58°C. The
results were compared with those obtained at room temperature, as shown
in Tab.5.10.
The increased temperature reduced the reaction time but
simultaneously also reduced the E value. Also in this case no improvement
over the original results was achieved, but it is important to note that at
35°C (±)-60b was an oil in the reaction mixture.
3 (±)60b 35 134 (S)-60b 50.4 80.8 22
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5.4 Synthesis of the racemic chloroacetate derivatives (±)-61.
The chloroacetate derivatives (±)-61 of the Aryl propynols (±)-58
were synthesized in order to increase the rate of the hydrolysis. Reactions
were carried out in dichloromethane in presence of chloracetic anhydride
as acylating agent and triethylamine as base (Scheme 5.12).
OH
H
R
Cl
O
O O
H
R
TEA; CH2Cl2
2
(±)-61b,c,e,h-m(±)-58b,c,e,h-m
O
Cl
Scheme 5.12: Synthesis of chloroacetates (±)-61b,c,e,h-m.
In table 5.11 the results of the acetylation are shown . The obtained
yields are very high.
Entry Substrate R Product Yield
1 (±)-58b 4Me (±)-61b 92.8
2 (±)-58c 4F (±)-61c 94.8
3 (±)-58e 4CN (±)-61e 99.8
4 (±)-58h 3Me (±)-61h 99.5
5 (±)-58i 3F (±)-61i 98.4
6 (±)-58l 2Me (±)-61l 93.0
7 (±)-58m 2,4Cl (±)-61m 96.8
Table 5.11: Synthesis of chloroacetates (±)-61b,c,e,h-m.
5.5 Enzymatic hydrolyses of the chloroacetyl esters (±)-61.
Six chloroacetyl esters (±)-61 were hydrolyzed in presence of
SAMII in phosphate buffer pH=7 at room temperature, 1.0 N NaOH was
used as titrating reagent. These are the most extended sets of experiments
carried out with this  class of aryl propyl esters (scheme 5.13).
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O
H H H
O HH HO
R R R
O
Cl
O
Cl
(±)-61b,c,e,h-l
PH=7; R.T.
SAM II
(-)-(S)-61b,c,e,h-l (-)-(R)- 58b,c,e,h-l
+
Scheme 5.13: Hydrolysis of Chloroacetates (±)-61b,c,e,h-l by lipase SAM II.
The observed reaction rates were much faster as compared to the
corresponding hydrolyses of the acetates. In some cases also the selectivity
was increased. All chloroacetate esters (±)-61 were oils in the reaction
mixture. This led to homogeneous reactions and all problems previously
encountered with the acetate (±)-60e were overcome. Table 5.12 shows
the results.
Entry Substrate R C % Time h Product e.e% Yield E
1 (±)-61b 4Me 56.4 10 (-)-(S)-61b 97.8 40.69 36
2 (-)-(R)-58b 75.7 51.0
3 (±)-61c 4F 53.8 11 (-)-(S)-61c 96.8 44.9 45
4 (-)-(R)-58c 83.2 53.1
5 (±)-61e 4CN 53.0 5.5 (-)-(S)-61e 96.6 44.5 50
6 (-)-(R)-58e 85.5 49.5
7 (±)-61h 3Me 51.8 4.5 (-)-(S)-61h 99.2 43.5 >140
8 (-)-(R)-58h 92.1 46.1
9 (±)-61i 3F 52.1 2.8 (-)-(S)-61i 99.4 46.2 127
10 (-)-(R)-58i 91.5 46.3
11 (±)-61l 2Me 53.9 22.0 (-)-(S)-61l 94.0 45.1 39
12 (-)-(R)-58l 80.4 46.9
Table 5.12: Enzymatic resolution of Chloroacetates (±)-61b,c,e,h-l by lipase SAM II
From the comparison of the results obtained in this work and taking
in account the preliminary results from the master thesis of Claudia
Waldinger, it is possible to draw some general conclusions:
1) the esterification of aryl propynoles by SAMII cannot be
considered a good process because of the lack of enantioselectivity and the
incredibly low rate;
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2) the hydrolysis of aryl propynol acetates and chloroacetates in
presence of SAMII can be considered a method to obtain Aryl propargylic
alcohols of high enantiomeric purity. The use of chloroacetate esters is
recommended due to the higher reaction rates as compared to the acetates.
In the case of (±)-61e a higher selectivity (E=50) was also achieved in
comparison to the corresponding acetate (±)-60e (E=6);
3) it is possible to obtain a SAR (Structure Activity Relationship) for
this class of compounds even if the observed selectivities expressed as E
values were proven to be strongly dependent on the substitution pattern of
the benzene moiety, both regarding the type of substituents and their
position on the aromatic ring. The best position for a substitution of the
aromatic ring is the meta position. Higher E values were observed in all
compounds having a meta substituent. No significant differences between
ortho and para position and the E values were detectable. At present the
variety of the substituents is still too small in order to obtain a complete
overview of the stereoelectronic effects. Apparently electrondonors such
as OMe (C.Waldinger's results) decrease dramatically the
enantioselectivity, while electronwithdrawing groups increase the
enantioselectivity (F and CN). Also a small aliphatic group can increase
the enantioselectivity.
5.6 Hydrolysis of enantiopure Acetates (-)-(S)-60a,b,e and 
chloroacetates (-)-(S)-61b,c,e,h-l resulting from the 
enzymatic hydrolysis in presence of the lipase SAMII.
Acetates (-)-(S)-60a,b,e and chloroacetates (-)-(S)-61b,c,e,h-l
resulting from the enzymatic hydrolysis with lipase SAMII had a higher
enantiomeric excess as compared to the corresponding alcohols because of
the extended conversion rates. It was required to use very mild conditions
for the chemical hydrolysis. A saturated solution of potassium carbonate
in methanol at 0°C for 30 min was found to provide the best conditions
(Scheme 5.14).
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H
OH
R
O
X
H
OHH
R
X=H,  (-)-( S)-60a,b,e 
X=Cl,  (-)-( S)-61b,c,e,h-l
(+)-(S)-58a-c,e,h-l
K2CO3; MeOH
0°C
Scheme 5.14: Hydrolysis of enantiomeric acetates or chloroacetates (-)-(S)-60 and (-)-
(S)-61
The reaction proceeds smoothly in almost quantitative yield and
without racemization of the chiral centre; the enantiomeric excess of the
products is identical with that of the starting materials. Purity and
enantiomeric excess were determined by chiral GC. In table 5.13. the
 results of the reaction are summarized.
Entry Substrate X R Product e.e % Yield
1 (-)-(S)-60a H H (+)-(S)-58a 87.0 94.1
2 (-)-(S)-60b H 4Me (+)-(S)-58b 65.0 93.5
3 (-)-(S)-61b Cl 4Me (+)-(S)-58b 97.7 98.9
4 (-)-(S)-61c Cl 4F (+)-(S)-58c 98.8 98.9
5 (-)-(S)-61e Cl 4CN (+)-(S)-58e 95.9 97.9
6 (-)-(S)-60e H 4CN (+)-(S)-58e 86.6 95.8
7 (-)-(S)-61h Cl 3Me (+)-(S)-58h 99.2 99.6
8 (-)-(S)-61i Cl 3F (+)-(S)-58i 98.8 98.7
9 (-)-(S)-61l Cl 2Me (+)-(S)-58l 94.0 98.5
Table 5.13: Hydrolyses of acetates (-)-(S)-60 and chloroacetates (-)-(S)-61.
The low enantiomeric excess for some compounds (entries 1,2,6) was
due to the low enantiomeric excess of the starting material.
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6 Synthesis of Aryl-2-Benzo[b]Furanyl and Aryl-2-
Indonyl Carbinols 27 and 64-a-g of High
Enantiomeric Purity via Palladium-Catalyzed
Heteroannulation of Racemic and Enantiopure 1-
Aryl-1-Propargylic Alcohols 58.
The synthetic methods reported in chapter 2.4 were applied to synthesize
the Aryl-2-Benzo[b]Furanyl and Aryl-2-Indonyl carbinols 27 and 64-a-g
in racemic and enantiopure forms. The synthetic procedures already
known in literature were modified, or in some cases completely changed
from the original protocol in order to obtain products in high chemical
yield. This work, to the best of our knowledge, is the first application of
palladium catalysed heteroannulation of enantiopure 1-Aryl-2-Propyl-1-ol
alcohols 58 to obtain enantiopure aryl-2-benzo[b]furanyl 27 and aryl-2-
indolinyl carbinols 64-a-g.
6.1   Application of Castro's procedure for the cyclization of 
       racemic or enantiopure 1-phenyl-2-propyn-1-ol 58a with 
        2-iodophenol.
Castro's procedure uses a preformed copper (I) acetylide as
alkylating reagent of 2-iodophenol. The synthesis of this reagent is
performed using CuSO4.5H2O and NH4OH in a mixture of ethanol, THF
and water in presence of the acetylenic compound. This experimental
procedure failed when applied to 1-phenyl-2-propyn-1-ol (±)-58a: it was
impossible to isolate the product from the reaction mixture by
crystallization because of its high solubility in the reaction mixture. In
order to decrease the solubility of the Copper (I) acetylide of 1-phenyl-2-
propyn-1-ol (±)-58a 1-phenyl-2-propyn-1-acetate (±)-60a was used
under identical reaction conditions as described above. Unfortunately, also
in this case it was impossible to recover the product by crystallization
(Scheme 6.1). For these reasons Castro's procedure was not further
applied and it was necessary to use the modified procedure of Owen1.
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OR
H
OR
Cu
 CuSO4.5H2O,NH4OH
H2O, THF, EtOH
 R = H, Ac(±)-58a R = H 
(±)-60a R = Ac
Scheme 6.1: Attempts to form the copper (I) acetylide using Castro's procedure.
The experimental conditions allowed the synthesis of copper (I)
acetylide in presence of 2-iodophenol in situ. The reaction was carried out
in dry pyridine as solvent under reflux in an Argon atmosphere, the
copper source was Cu2O, and the molar ratio between Cu2O/2-
iodophenol/1-phenyl-2-propyn-1-ol (±)-58a was 0.7:1:1 (Scheme 6.2).
OH
H
OH
O
Py, reflux, argon
2-Iodophenol, Cu2O
(±)-58a (±)-27g
Scheme 6.2: Synthesis of Aryl-2-Benzo[b]Furanyl carbinol (±)-27g using Owen's
procedure.
Aryl-2-Benzo[b]Furanyl carbinol (±)-27g was obtained only with a
low chemical yield of ca. 10%. Identical reaction conditions were applied
to the enantiopure (-)-(R)-1-phenyl-2-propyn-1-ol (-)-(R)-58a. The
harsh experimental conditions and the long reaction time (18h) led to
partial racemization of both the unreacted starting material and the
product. The reaction was followed by chiral HPLC and it was clear that
the amount of racemization was proportional to the reaction time.
Futhermore, the product was much more prone to racemization than the
starting material. Both attempts demonstrated that Castro's procedure and
its modification are not useful for the synthesis of enantiopure aryl-2-
benzo[b]furanyl carbinoles 27.
6.2 Application of Kundu's procedure to cyclize racemic (±)-
58a and enantiopure 1-phenyl-2-propyn-1-ol (-)-(R)-58a
with 2-iodophenol in presence of a Pd catalyst.
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1-Phenyl-2-propyl-1-ol (±)-58a was one of the substrates that
Kundu2 has used in his paper. The experimental conditions were: 1-
phenyl-2-propyn-1-ol (±)-58a, o-iodophenol, PdCl2[P(Ph)3]2, CuI, TEA
in the ratio of 2:1:0.035:0.13:2 at 80°C for 24 h: the chemical yield of
phenylbenzo[b]furane carbinol (±)-27g was calculated to be 66% based
on 2-iodophenol (Scheme 6.3).
OH
H
OH
O
TEA, Ar, 80°
(±)58a (±)27g
2-Iodophenol, CuI
PdCl2[P(Ph)3]2
Scheme 6.3: Synthesis of phenylbenzo[b]furanecarbinol (±)-27g using Kundu's
procedure.
Unfortunately, the procedure proved to be not completely
reproducible and the best result obtained in our hands was 50% chemical
yield based on 2-iodophenol corresponding to 25% yield starting from the
propargylic alcohol. The method was therefore unacceptable because of
the low chemical yield and expecially since an excess of arylpropargylic
alcohols 58 was required. These are not commercially available neither
in racemic nor enantiopure forms, and are therefore synthetically most
demanding as described in chapter 5. Nevertheless the reaction was
carried out also with the chiral substrate (-)-(R)-58a in order to study
the stereochemical outcome. Indeed no racemization occurred when chiral
1-phenyl-2-propyn-1-ole (-)-(R)-58a was used as a substrate. This
discovery was considered a real breakthrough for the synthesis of
enantiopure aryl benzofurane carbinoles. Therefore, considerable time
was dedicated to the modification of the reaction conditions in order to
achieve our requirements. Several parameters were changed:
1) the base
2) the ratio of reactants
3) the temperature
4) the molar percentage of the Pd catalyst and CuI
It was the strategy for the optimization of Kundu's procedure to
change only one parameter at a time and mantaining all other parameters
constant.
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6.2.1  Heteroannullation of Phenyl-2-propyn-1-ol (±)-58a: 
          variation of bases.
Four different bases were tested in order to improve the chemical
yield of the product . Only one arylpropynol was used in the study,
racemic 1-aryl-2-propyn-1-ol (±)-58a (scheme 6.4).
OH
H
OH
O
TEA, Ar, 80°
(±)-58a (±)-27g
2-Iodophenol, CuI
PdCl2[P(Ph)3]2
Scheme: 6.4: Effects of different bases on the heteroannulation process of aryl propynol
(±)-58a mediated by Pd catalyst.
The molar ratio between the reagents was kept as documented in the
original paper 2.0 : 1.0 : 0.035 : 0.13 : 2.0 corresponding to
arylpropynols : iodophenole : PdCl2[P(Ph)3]2 : CuI. The results are shown
in table 6.1.
Entry Substrate Base n.Eq. T°C Product Yield
1 (±)-58a TEA 2 80 (±)-27g 55
2 (±)-58a Py 2 80 (±)-27g 35
3 (±)-58a Py 4 80 (±)-27g 40
4 (±)-58a TBuA 2 80 (±)-27g 60
5 (±)-58a TBuA 4 80 (±)-27g 63
6 (±)-58a TMG 2 80 (±)-27g 83
7 (±)-58a TMG 3 80 (±)-27g 91
8 (±)-58a TMG 4 80 (±)-27g 92
Table 6.1: effect of the bases and no. of equivalents in the synthesis of (±)-27g.
The temperature was always mainteined at 80°C and the solvent used
was DMF. Chemical yields were calculated based on 2-iodophenol after
purification by flash chromatography. Pyridine (Py) was the worst base in
terms of chemical yield, difficulties in work up and purification (entries
2,3; Table 6.1). Triethylamine (TEA) gave a low chemical yield (entry1;
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Table 6.1), tributylamine (TBuA) was somewhat better (entries 4,5; Table
6.1). Clearly the best base was tetramethyl guanidine (TMG) which
increased the chemical yield by more than 35% in comparison to TEA
which was the base used in Kundu's paper. The result was considered very
satisfactory since almost all of the 2-iodophenole was converted to the
corresponding aryl-benzo [b] furanyl carbinol (±)-27g.
6.2.2 Optimization of molar ratio between Phenyl-2-propyn-1-
         ol (±)-58a and 2-iodophenol.
Further optimization was achieved by decreasing the molar ratio of
1-phenyl-2-propyn-1-ole (±)-58a and iodophenol from 2:1 to 1:1 with
additional ratios of 1.5:1 and 1.1:1. (Scheme 6.5).
OH
H
OH
O
TMG, Ar, 80°
2-Iodophenol, CuI
(±)-58a (±)-27g
PdCl 2[P(Ph) 3]2
Scheme: 6.3: Effects of different ratios between 2-iodophenol and aryl propynol (±)-58a
on the heteroannulation process mediated by Pd catalyst.
Three equivalents of TMG were used in all of the experiments; Pd
catalyst and CuI were also maintained at the original ratio of 0.035 and
0.13 per cent. The results are shown in table  6-2.
With great surprise and enthusiasm it was discovered that excess of
1-phenyl-2-propyn-1-ol (±)-58a was indeed not necessary. Almost
quantitative yields were obtained with all molar ratios.
Entry Substrate molar ratio Product Yield
1 (±)-58a 2.0:1.0 (±)-27g 95.0
2 (±)-58a 1.5:1.0 (±)-27g 94.6
3 (±)-58a 1.1:1.0 (±)-27g 93.4
4 (±)-58a 1.0:1.0 (±)-27g 90.0
Table 6.2: Optimization of the molar ratio between propynol (±)-58a and 2-iodophenol.
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 This discovery allowed the use of the enantiopure aryl propynols
(+)-(S)-58 and (-)-(R)-58 obtained from the enzymatic resolution
(chapter 5) in an equimolar ratio with 2-iodophenol.
6.2.3: Optimization of temperature and time.
Temperature and time were optimized together. Four experiments
were carried out at different temperatures, the lower temperatures
corresponding to longer reaction times (Scheme 6.6).The molecular ratios
of the reagents were maintained constant at the optimal value (Paragraphs
6.2.2 and 6.2.1).
OH
H
OH
O
TMG, Ar, T,t
(±)-58a (±)-27g
2-Iodophenol, CuI
PdCl2[P(Ph)3]2
Scheme 6.6: Effect of temperature and reaction time on the Pd catalyzed
heteroannulation of (±)-58a
In table 6.3 the experimental conditions and the results of this study
are reported.
The best compromise between temperature and time was found to be
40°C (entry 3;Table 6.3), corresponding to a reaction time shorter than
four hours. Furthermore the crude reaction product was cleaner than that
obtained at higher temperature. No reaction occurred at room
temperature (entry 4; Table 6.3).
Entry Substrate T°C Time h Product yield
1 (±)-58a 80 0.5 (±)-27g 90.0
2 (±)-58a 60 2< (±)-27g 89.4
3 (±)-58a 40 4< (±)-27g 90.0
4 (±)-58a 25 24 (±)-27g -
Table 6.3: Studies of temperature and reaction time on the Pd catalyzed
heteroannulation of (±)-58a.
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6.2.4.  Optimization of catalyst (Pd) amount and CuI.
The last attempt of optimization was aimed at the reduction of the
amount of Pd catalyst and copper iodide. Five experiments were carried
out to find the best molar ratio (Table 6.4; scheme 6.7).
OH
H
OH
O
TMG, Ar, 40°
 PdCl2[P(Ph)3]2/CuI
(±)-58a (±)-27g
2-Iodophenol
Scheme 6.7: Optimization of Pd catalyst/ CuI ratio.
In the first experiment the ratio reported in the original publication was
used where Pd catalyst and CuI were present in 0.035 and 0.13 Mol% in
respect to the 2-iodophenole. The chemical yield was very high (table 6.4;
entry 1). In the second experiment the amount of CuI was reduced in
order to have an equimolar ratio betweeen Pd catalyst and CuI (entry 2,
Table 6.7).
Entry Substrate Molar ratio Pd/CuI Time h Product Yield
1 (±)-58a 0.035:0.13 4< (±)-27g 90.0
2 (±)-58a 0.035:0.035 4< (±)-27g 90.0
3 (±)-58a 0.025:0.025 4< (±)-27g 90.0
4 (±)-58a 0.010:0.025 40 (±)-27g 40.3
Table 6.4: Optimization of catalyst (Pd) amount and CuI.
Again the chemical yield was identical to the previous experiment
and proved that an excess of CuI is unnecessary.In the third experiment
the amounts of Pd and CuI were reduced to 2.5 Mol% (entry 3, table 6.4).
Again an identical result was obtained. In the last experiment only 1% of
Pd catalyst and CuI were used (entry 4, Table 6.4), leading to (±)-27g in
40% yield. The observation that both 2-iodophenol and the starting
material (±)-58a were completely consumed during the reaction led to
the discovery of a very polar side product which, after isolation and
characterization, was identified to be the uncyclized product (±)-62.
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OH
OH
(±)-62
Figure 6.1 : Side product (±)-62.
From these result it can be concluded that under these reaction
conditions the coupling process is complete while the cyclization was
incomplete. For this reason (±)-62 is recovered as an intermediate of the
reaction. (±)-62 was a very important intermediate for the understanding
of the catalytic Pd cycle.
In summary, the optimal reaction conditions after all optimizations
were: molecular ratios 1 : 1 : 0.025 : 0.025 : 3 between 2-iodophenol, 1-
phenyl-2-propyn-1-ol (±)-58a, PdCl2[P(Ph)3]2, CuI, TMG. The reaction
was carried out in DMF at 40°C and Ar was bubbled through the reaction
mixture at all times.
Also the sequence of addition of the reagents was found to be
important. In fact the reaction can be devided into three steps:
1) The mixture of DMF and TMG was heated to 40° and an Argon
stream led to the solution for 15' before the addition of the other
reagents. The argon stream was maintained during the whole reaction.
This was necessary in order to exclude oxygen from the reaction mixture
and thus to avoid the crosscoupling of the Copper (I) acetylide.
2) 2-Iodophenol, CuI, PdCl2[P(Ph3)]2, was added in one portion. The
mixture was stirred for 15' before the additon of (+)-58a.
3) Addition of 1-Phenyl-2-propyn-1-ol (±)-58a. The solution
changed colour from pale yellow to red brown.
In the same manner, the enantiopure (-)-(R)-1-phenyl-2-propyn-1-ol
(-)-(R)-58a was cyclized to (-)-(S)-phenyl benzo[b]furanil carbinol (-)-
(S)-27g in 91% of chemical yield and with 97.5% enantiomeric excess.
Reactions were scaled up to 2.5 g. both with the racemic and
enantiopure propargylic alcohols. Identical chemical yields and
enantiomeric excess were found.
The results of this study were so encouraging that the procedure was
applied to all racemic and enantiopure arylpropynols 58.
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6.3 Cyclization of racemic and enantiopure 1-Aryl-2-propyn-1-
ols 58-a-c,e,h-l to Aryl-benzo[b]furane methanols 27-g,l,h
and 63-a-d.
The optimal reaction conditions described in paragraph 6.2.3 were
applied to racemic and enantiopure 1-Aryl-2-propyn-1-ols 58-a-c,e,h-l
in order to explore the application of this reaction for the synthesis of
enantiopure Aryl-benzo[b]furane methanols 27-g,l,h and 63-a-d. The
reaction was always applied first to the racemic compound and then to the
enantiopure substrate (scheme 6.8).
OH
H
OH
O
R R
 PdCl2[P(Ph)3]2; CuI
TMG, Ar, 40°
58-a-c,e,h-l
2-Iodophenol
27-g,l,h,63-a-d
Scheme 6.8: Cyclization of racemic and enantiopure 1-Aryl-2-propyn-1-ols 58-a-c,e,h-
l to Aryl-benzo[b]furane methanols 27 g,l,h and 63a-d.
The results were very satisfactory indeed as reported in table 6.5.
Yields were calculated following flash chromatography. This purification
can be considered a mere filtration through silica since after work up the
products were always quite pure as judged by NMR and TLC. They were,
however, still colored yellow/brown. The enantiomeric excess was
determined by chiral HPLC of the crude materials (after the reaction
work up) prior to purification. It is interesting to note that the e.e. did not
change from the chiral starting material to the product before and after
purification.
This method gave very reproducible results both in terms of
chemical yields and enantiomeric excess. From the results shown in table
6.5 it is clear that different substituents on the aromatic ring did not lead
to any modification of the results.
They were also not influenced by the position of the substituent on
the aromatic ring (see entries 3,4,8,9,12,13; table 5.6) nor by
stereoelectronic effects (see entries 1,2,3,4,5,6; table 5.6).
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Entry Substrate R Time h Product Yield e.e.%
1 (±)-58a H 4.0 (±)-27g 91.0 -
2 (-)-(R)-58a H 4.0 (+)-(S)-27g 90.0 97.5
3 (±)-58b 4Me 4.0 (±)-63a 89.5 -
4 (+)-(S)-58b 4Me 4.0 (-)-(R)-63a 89.9 99.0
5 (±)-58c 4F 2.5 (±)27l 78.0 -
6 (+)-(S)-58c 4F 2.5 (-)-(R)-27l 79.7 97.7
7 (±)-58e 4CN 8.0 (±)-27h 0.0 -
8 (±)-58h 3Me 3.0 (±)-63b 92.0 -
9 (+)-(S)-58h 3Me 3.0 (-)-(R)-63b 93.0 98.1
10 (±)-58i 3F 5.0 (±)-63c 85.0 -
11 (+)-(S)-58i 3F 5.0 (-)-(R)-63c 82.8 98.5
12 (±)-58l 2Me 8.0 (±)-63d 89.5 -
13 (+)-(S)-58l 2Me 8.0 (-)-(R)-63d 82.8 93.3
Table 6.5: Times, yields and e.e. of Aryl-benzo[b]furane methanols 27-g,l,h and 63a-
d.obtained by heteroannulation of 1-Aryl-2-propyn-1-ols 58-a-c,e,h-l.
Unfortunately, there was one exception (entry 7; Table 6.5). All
attempts to cyclize racemic 1-[4cyanophenyl]-2-propyn-1-ole (±)-58e to
the corresponding benzo[b]furane, the most active Menarini anticancer
drug, failed. The reaction gave a large number of products among which
the desired product was not detectable.
The present work, to our knowledge, is the first application of
palladium catalysis for the synthesis of enantiopure aryl-benzo[b]furane
methanols 27-g,l,h and 63-a-d, derived from enantiopure
arylpropynols. Attempts to synthesize the same products by asymmetric
reduction of the corresponding prochiral ketones failed (chapter 2), and
up to now no chemical chiral synthesis or enzymatic resolution of the
racemic alcohols is reported.
6.4 Cyclization of racemic and enantiopure 1-aryl-2-propyn-1-
ols 58-a-c,e,h-l to racemic and enantiopure aryl-2-(N-
mesyl)indolyl methanols 64-a-g.
An obvious expansion of the procedure for the synthesis of
enantiopure arylbenzo[b]furan methanols 27-g,l,h and 63-a-d described
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in the previous paragraph was the application of the methodology to the
synthesis of aryl-2-indolyl methanols 64-a-g. Palladium catalysis is well
known for the synthesis of indols as described in chapter 2, and
benzo[b]furanes and indoles are structurally related. In order to obtain the
indoles it was formally sufficient to use the ortho iodoaniline instead of
ortho iodophenole.
However ortho iodoaniline under the reaction conditions used for the
synthesis of benzofuranes did not lead to the indole. The uncyclized
product (±)-65 was found to be the only reaction product (scheme 6.9).
This result was expected because it is described in literature that the free
amino group of the iodoaniline must have a strong electronwithdrawing
protection group in order to cyclize to indoles.
OH
H
OH
 PdCl2[P(Ph)3]2; CuI
(±)-58a
TMG, Ar, 40°
(±)-65
2-Iodoaniline
NH2
Scheme 6.9: Attempt for the direct cyclization of aryl propargylic alcohol (±)-58a to
aryl-2-indolylcarbinole.
Thus 2-iodoaniline was first mesylated using mesyl chloride and
pyridine (Scheme 6.10). A stoichiometric amount of mesyl chloride was
used because an excess led to the dimesylated product.
I
NH2
I
NHMs
MsCl ; Py; 0°
66
Scheme 6.10: Mesylation of 2-iodoaniline.
With this material identical reaction conditions were used for the
production of the indols 64-a-g as for the synthesis of benzofuranes 27
and 63 (Scheme 6.11).
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OH
H
OH
N
Ms
R R PdCl2[P(Ph)3]2; CuI
TMG, Ar, 40°
58-a-c,e,h-l 64-a-g
2-Iodomesylaniline 66
Scheme 6.11: Cyclization of racemic and enantiopure arylpropynols 58a-c,e,h-l to
racemic and enantiopure aryl-2-(N-mesyl)indolyl methanols 64a-g.
Entry Substrate R Time h Product Yield e.e %
1 (±)-58a H 1.0 (±)-64a 87.4 -
2 (-)-(R)-58a H 1.0 (+)-(S)-64a 87.0 99.1
3 (±)-58b 4Me 4.0 (±)-64b 83.3 -
4 (+)-(S)-58b 4Me 4.0 (-)-(R)-64b 84.3 95.97
5 (±)-58c 4F 1.5 (±)-64c 79.3 -
6 (+)-(S)-58c 4F 1.5 (-)-(R)-64c 78.0 98.1
7 (±)-58e 4CN 8.0 (±)-64d 0 -
8 (±)-58h 3Me 3.5 (±)-64e 93.0 -
9 (+)-(S)-58h 3Me 3.5 (-)-(R)-64e 93.2 99.1
10 (±)-58i 3F 3.0 (±)-64f 91.1 -
11 (+)-(S)-58i 3F 3.0 (-)-(R)-64f 92.0 99.55
12 (±)-58l 2Me 5.0 (±)-64g 83.4 -
13 (+)-(S)-58l 2Me 5.0 (-)-(R)-64g 85.0 93.2
Table 6.7: Times, yields and e.e.of aryl-2-(N-mesyl)indolyl methanols 64a-g obtained
by heteroannulation of 1-Aryl-2-propyn-1-ols 58-a-c,e,h-l.
Also in this case the results were very satisfactory as shown in table
6.7.
The reaction times were shorter than those with the corresponding
benzofurans 27 and 63. Both chemical yields and enantiomeric excess are
very high. No racemization occurred during the process of
heteroannulation. Also in this case the 1(4-cyanophenyl)-2-propyn-1ol
(±)-58e did not cyclize to the corresponding indol. All starting material
was decomposed during the reaction.
As in the case of benzofuranes this is the first application of palladium
catalysis to the synthesis of enatiopure aryl-2-indolyl carbinols 64-a-g.
These compounds are not obtainable by asymmetric reduction of the
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corresponding prochiral ketones or by enzymatic resolution of the
racemic alcohols.
6.4.1 Deprotection of Phenyl-2-(N-mesyl)Indonyl methanole 
(±)-64a.
In order to obtain the free amino compounds from the Aryl-2-(N-
mesyl)-Indolyl carbinols 64-a-g it was necessary to remove the mesyl
group from the nitrogen. Due to the high stability of this protecting group
drastic basic reaction conditions were required. The first attempt  using
K2CO3/methanol under reflux was unsuccessful; after eighteen hours no
conversion of the starting material was observed. With NaOH in methanol
under reflux, after twentyfour hours all starting material was converted
to the product aryl-2-indolyl carbinole (±)67 in 85% yield (Scheme
6.13).
OH
N
Ms OH
N
H
(±)-64a (±)-67
NaOH/ MeOH
reflux
Schem 6.13: Deprotection of phenyl-2-(N-mesyl)-indolyl methanol (±)-64a.
6.5. Cyclization of propargyl alcohol and propargyl amine to 
Benzo[b]furane-2-methanole 68 and Benzo[b]furane-2-
methyl amine 69.
2-iodophenol was used as a substrate for the cyclization with
propargylic alcohol and propargylic amine to the corresponding
benzofurane derivatives. Identical reaction conditions were used as for the
synthesis of aryl-benzo[b]furane carbinols 27 and 63 (see paragraph
6.2.3). In the literature it is reported that the use of these unprotected
propargylic derivatives gives poor results and the cyclization process is
quite inefficient. With the optimized procedure developed for the aryl-
benzo[b]carbinols 27 and 63 the coupling and cyclization of the
 propargylic alcohol and amine proved to be in fact quite efficient and
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afforded the benzo[b]furane-2-methanole 68 and benzo[b]furane-2-
methylamine 69 in 97 and 86 % yield, respectively (Scheme 6.14).
I
OH
H
X
O X
TMG, Ar, DMF, 40°
 PdCl2[P(Ph)3]2; CuI
68 X=OH 
69 X=NH2
X= OH, NH2
Scheme 6.14: Cyclization of unprotected propargylic alcohol and amine to
benzo[b]furane derivatives 68 and 69.
For a full characterization 69 was acetylated in dichloromethane in
presence of acetyl chloride and triethylamine in 95 % yield to obtain 70
(Scheme 6.15).
O NH2 O N
H
69
O
70
AcCl TEA 2Cl2 CH
Scheme: 6.15: Acetylation of 69.
6.6. Studies of the Pd catalyzed reaction mechanism.
Several mechanisms were proposed in the literature for the coupling
and cyclization of alkynes under palladium catalysis. The mechanism of
coupling between alkynes and aryliodide is well established. On the
contrary, for the cyclizations of alkynes to benzofuranes or indoles
several hypotheses are existing. One of the most complete descriptions of
the coupling reaction was reported by J.Burton3 and coworkers in 1993
(Scheme 6.16).
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[P(Ph) 3PdCl 2]
RCu RH
CuI; DIPEA
DIPEA.HCl
R[Pd(Ph 3)P]
2
RR
[P(Ph) 3]Pd°
R'
X
Pd
Ph3P
Ph3P
X
Pd
Ph3P
Ph3P RCu
CuX
R
2+
2+
R
R'
Scheme 6.16: Crosscoupling  mediated by Pd0.
The coupling reaction appears to involve Pd° catalysis, the species
being generated by reduction of palladium II in the organopalladium
halide by attack of the copper acetylide anion. The thus formed bis
(triphenylphophine)dialkynyl palladium undergoes reductive elimination
of disubstituted acetylene to form bis(triphenylphosphine) Palladium(0).
The thus resulting Palladium(0) species enters the catalytic cycle (scheme
6.16) by oxidative addition of para substituted aryliodide, followed by
alkylation to generate again a palladium II species. Finally, reductive
elimination leads to a coupling product and the palladium(0) catalyst is
regenerated. This mechanism is the most accepted one for the coupling
between the aryliodide and acetylenic compounds. It seems reliable also
for the coupling between arylpropynols 58 and 2-iodophenol. The second
step of the synthesis of benzofurans or indols might involve more than
one mechanism. In fact, in the literature4 it is reported that Pd° can
catalyze the annulation step (Scheme 6.17).
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Pd
Ph3P
Ph3P
Pd
Ph3P
Ph3P H
[P(Ph)3]Pd°
2+
OH
R
O
R
O
R OH
R
Scheme 6.17: Pd° catalysis in the heteroannulation step.
An easier explanation could involve a simple base catalyzed 5-
endotrig cyclization favoured by the Baldwin rules (scheme 6.18).
R
OH
+BASE
R
O-
+H+B-
O
R
Scheme 6.18: base catalyzed cyclization to benzofuran.
The first hypothesis involving the coordination of the triple bond
from Pd° would implicate a double palladium catalytic cycle, whereas the
second hypothesis implicates a single Pd° catalytic cycle and a basic
cyclization to the final product. In order to shine more light on the
mechanism in the next paragraphs studies to elucidate further the
 mechanism are described.
6.6.1. Cyclization studies.
For this 2-iodophenol was first acetylated with acetyl chloride in
dichloromethane and then coupled under palladium catalysis with racemic
Chapter 6 148
1-phenyl-2-propyn-1-ol (±)-58a to form the compound (±)-71(Scheme
6.19)
I
OH
I
OAc
AcCl; TEA; PdCl 2[P(Ph 3)2];CuI
TMG; 40°; ArCH 2Cl2
OAc
OH
(±)-71
Schem 6.19: Synthesis of (±)-71.
In an attempt to deprotect the acetyl group in (±)-71 using a
saturated solution of K2CO3 in absolute methanol at 0°C led to the
racemic aryl-benzo[b]furan carbinol (±)-27g (Scheme 6.20).
OAc
OH
OH
O
(±)-71 (±)-27g
 K2CO3, MeOH
Scheme 6.20: synthesis of (±)-27g by 5-endotrig base catalized cyclization.
The formation of (±)-27g under these reaction condition proved
that the 5-endo trig cyclization can occur in these substrates.
The unprotected analogue of (±)-71, e.i.(±)-62 had already been
obtained in 60 % yield as side product of the Pd catalyzed cyclization
when only 1% of catalyst was used (entry 4, Table 6.4). In order to
improve the chemical yield it was enough to use only one equivalent of
base. This way (±)-62 was obtained in 89.5% chemical yield (scheme
6.21).
(±)-62 can be considered a key intermediate for studying the
mechanism involved in the second part of the reaction, e.i. for the
synthesis of benzofuranes or indoles.
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OH
H
2-Iodophenol
TMGA; PdCl 2[P(Ph) 3]2; CuI
(±)-62(±)-58a OH
OH
Scheme 6.21: Synthesis of (±)-62 by Pd catalyses.
The first experiment was carried out to show that the base indeed
catalyzes a 5-endotrig cyclization under the reaction conditions used for
the synthesis of benzofuranes or indols. Two equivalents of tetramethyl
guanidine were added to a solution of (±)-62 in DMF at 40°C to try the
5-endotrig cyclization leading to the benzofuran (±)-27. Surprisingly the
cyclization did not occur at all (Scheme 6.22). This result clearly excluded
the use of a simple base 5-endotrig catalyzed cyclization which was
observed with (±)-71 using K2CO3/MeOH (Scheme 6.20).
OH
OH
OH
O
(±)-62 (±)-27g
TMG 40°C
DMF
Scheme 6.22: Attempt to cyclize (±)-62 with TMG.
A second attempt of cyclization was carried out by adding
PdCl2[P(Ph)3]2 and TMG to a solution of (±)-62 in DMF at 40° (Scheme
6.23).
OH
OH
OH
O
(±)-62 (±)-27g
PdCl2[P(Ph)3]2, TMG
40°C DMF
Scheme 6.23: Attempt to cyclize (±)-62 with PdCl2[P(Ph)3]2 and TMG.
Again no cyclization occured after four hours of reaction time. This
result proved that the palladium is involved only in the crosscoupling step
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between aryliodide and copper acetylide and not in the final cyclization
step. A third attempt was made by using the normal cyclization conditions
for the synthesis of benzofurans (±)-27g using palladium catalysis. (±)-
62 as expected cyclized in less than three hours to the benzofuranes (±)-
27g in 89% yield (Scheme 6.24)
OH
OH
OH
O
(±)-62 (±)-27g
CuI, 40°C,DMF
PdCl2[P(Ph)3]2, TMG
Scheme 6.24: Cyclization of (±)-62 under the optimized conditions for the synthesis of
aryl benzofuran carbinols.
A final attempt was made by adding CuI and TMG to a solution of
(±)-62 in DMF at 40°C under argon. Here in less than one hour (±)-62
was converted completely to the benzofurane (±)-27g. The result proved
again that cyclization takes place only in presence of CuI in basic media.
OH
OH
OH
O
(±)-62 (±)-27g 40°C,DMF
CuI, TMG
Scheme 6.25: Cyclization of (±)-62 to aryl benzofuran carbinol (±)-27g by copper-
iodide.
The process is clearly copper mediated as hypothesized in Castro's
publications (Scheme 6.25).
The four different experiments decribed above clearly indicate that
the palladium catalyst is involved only in the crosscoupling between aryl
iodide and the acetylenic compound to form compounds such as (±)-62
but not in the final cyclization step to benzo[b]furane. The
heteroannulation is not working by simple organic base catalysis as
proven in the first experiment where tetramethyl guanidine was used as
base to cyclize (±)-62. In reality it is mediated by the copper iodide in
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presence of base as decribed in the last experiment and as tentatively
described in figure 6.2.
O
OH
Cu
I
L
Figure 6.2: possible Copper coordination.
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7 Summary:
Numerous drugs are chiral, generally only one enantiomer is
therapeutically active while the other antipode is completely inactive or
shows often undesired and/or toxic side effects. For this reason, all new
chiral drugs are now formulated in enantiopure form, and consequently
the synthesis of enantiomerically pure compounds is becoming one of the
most important areas in the organic chemistry.
Non-steroidal anticancer and antifungal drugs are particularly
interesting as therapeutic agents. Several classes of these two different
families of drugs contain the same chemical structure e.g. Bifonazole 6a
and non-steroidal aromatase inhibitors such as the Menarini anticancer
drug 18 (Fig.7.1).
N
N
O
N
N
Bifonazole 6a Menarini anticancer Drug 18
R
Fig 7.1: Bifonazole 6a and the Menarini anticancer drug 18.
They are characterized by the presence of an N-imidazole group in a
benzhydrilic position. The carbon atom link to the three aromatic moieties
is the only chiral centre of the molecule. The present work was aimed at
new procedures for the synthesis of both Bifonazole 6a and the Menarini
aromatase inhibitors 18 in enantiomeric form as well as structural
analogues.
In order to prepare enantiopure synthons and final products several
synthetic methods were developed.
A special attention was dedicated to the synthesis of enantiopure
benzhydrols 27a-f and aryl-2-benzo[b]furancarbinols 27g-i and 63a-d.
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A chiral lithium aluminiumhydride complex with (R)-(-)-2-
isoindolinyl-butan-1-ol (R)-(-)-24 as auxiliary was used for the
asymmetric reduction of ketones 25a-d and 26a,c in order to obtain the
corresponding enantiopure alcohols. Using this method with the
benzophenones 25b-d high enantiomeric excesses and chemical yields
were obtained, whereas in the case of the aryl-2-benzo[b]furan ketones
25a,c only low enantiomeric excesses yet high chemical yields were
achieved (Scheme 7.1).
X
O
N
OH
X
OH
R
(±)-27a  X=H                         R=4-Ph 
(+)-27b  X=Br                        R=H 
(+)-27c  X=2-BrPh                 R=4-Ph 
(+)-27d   X=2-FPh                  R=H 
(±)-27g  X=2-Benzo[b]furan  R=H 
(+)-27i    X=2-Benzo[b]furan  R=2,4Cl
25a  X=Ph                        R=4-Ph 
25b  X=2-BrPh                 R=H 
25c  X=2-BrPh                 R=4-Ph 
25d  X=2F-Ph                  R=4-Ph 
26a  X=2-Benzo[b]furan  R=H 
26c  X=2-Benzo[b]furan  R=2,4Cl
Dry ether
(-)-24
LiAlH4
R
Scheme 7.1: Synthesis of enantiopure alcohols (+)-27b-d,i by reduction with chiral
lithium aluminium complex
Racemic and enantiopure alcohols 27a-c,g,m and 31a-1 were used
as starting materials in multi-step syntheses for the corresponding N-
imidazole derivatives in racemic and enantiopure forms. Involved are
three reaction steps (Scheme 7.2): (a) Mitsunobu reaction with 4,5-
dicyano imidazole to obtain the N-4,5-dicyanoimidazole derivatives 33a-
m; (b) hydrolyses of the N-imidazole-4,5-dicarbonitrile derivatives 33a-
m to the corresponding diacids 34a-m, (c) thermic decarboxylation of
the diacids  34a-m to the final N-imidazole derivatives 35a-d.
This synthetic procedure was exceptionally well suited for the
production of enantiopure N-alkyl imidazole derivatives 34a,b.
Complete inversion of the stereochemistry of the starting alcohol was
observed during the Mitsunobu reaction, high enantiomeric excesses were
achieved with generally moderate chemical yields.
Benzhydrilic alcohols 31d showed partial racemization during the
synthesis of 1-(1-Phenyl-1-propyl)-imidazole-4,5-dicarbonitrile 33e in
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the Mitsunobu reaction. No evidence for further racemization was found
during the hydrolysis to the 1-(1-Phenyl-1-propyl) imidazole-4,5-
dicarboxylic acid 34c, but a complete racemization was observed in the
thermic decarboxylation to the final (1-phenyl-1-propyl) imidazole 35c.
OH
R1 R2
N
R1 R2
N
CN
CN
N 
H
N
CN
CN
N
R1 R2
N
CO2H
CO2HN
R1 R2
N
DEAD PPh3
31a-i,27a-c,g,m 33a-m
32
Hydrolysis
Decarboxylation
34a-m35a-d; 6a
Scheme 7.2: Mitsunobu-Hydrolyses-Decarboxylation for the synthesis of
enantiomeric and racemic N-Alkyl imidazole derivatives.
 The application of the Mitsunobu reaction to the enantiopure
benzhydroles 27a-c led to a completely racemic N-4,5-dicyano imidazole
derivatives 33g-i in high chemical yields. The syntheses proceeded
through the next two steps with high chemical yields to produce the
imidazole derivative 35d and bifonazole 6a in racemic form. All
synthetic pathways were completely unsatisfactory in the case of the aryl-
2-benzo[b]furan methanols 27g,m. An identical procedure was applied to
4(5)-ethylimidazole carboxylate 37 in order to avoid the drastic
conditions during the hydrolyses of the cyano groups of the 4,5-
dicyanoimidazole derivatives 33a-m. Overall no advantages in using this
substrate were found.
To demonstrate the complete inversion of the stereocenter during the
Mitsunobu reaction, several alternative synthetic methods of N-imidazole
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derivatives were tried. Using a modified Marckwald procedure starting
from chiral amines (S)-(+)-44 and (S)-(+)-51 it was possible to
synthesize the imidazole ring and to obtain the corresponding enantiopure
(S)-(+)-1-(2-octyl) imidazole (S)-(+)-35a and (S)-(+)-1-phenyl-1-ethyl
imidazole (S)-(+)-54 (Scheme 7.3). (S)-(+)-35a presented an identical
specific rotation as the corresponding compound obtained from the three
step synthesis discussed above.
R
NH2
R
H 
N
OMe
MeO
Br
OMe
OMe
R
N
N
HS
R
N
N
R = n-Hexyl (S)- (+)-44; (±)-44 
R = Ph          (S)-(+)-51; (±)-51 
K2CO3 / CH3CN
R = n-Hexyl(S)-(+)-52a; (±)-52a 
R = Ph          (S)-(+)-52b; (±)-52b 
KCNS / 
HCl THF
Raney Nickel
MeOH
R = n-Hexyl (S)-(+)-53a; (±)-53a 
R = Ph          (S)-(+)-53b; (±)-53b 
R = n-Hexyl (S)-(+)-35a; (±)-35a 
R = Ph         (S)-(+)-54; (±)-54 
Scheme 7.3: Synthesis of the enantiomeric N-alkylimidazole (S)-(+)-35a and (S)-(+)-
54
This clearly demonstrated that complete inversion of the
stereochemistry occurred in the Mitsunobu reaction. Futhermore the
modified Marckwald procedure is a good method for the synthesis of
enantiopure benzyl imidazol derivatives. A natural extention was the
application of this methodology to enantiopure benzhydrilic amines.
Syntheses of chiral benzhydrilic amines 56a,b and aryl-2-benzo[b]furan
methylamines 56c,d were performed starting from the corresponding
chiral alcohols; unfortunally no good results were achieved with this
approach.
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In order to obtain the enantiopure aryl-2-benzo[b]furan methanols
27 a new synthetic method was considered instead of the asymmetric
reduction of the corresponding ketones. The use of the lipase SAMII
allowed the synthesis of enantiopure 1-aryl-2-propyn-1-ols (R)-(-)-58a-
c,e,h-l in high enantiomeric excesses and good chemical yields via
hydrolysis of corresponding racemic acetates 60a-c and chloroacetates
61a-l (Scheme 7.4).
O
H H H
O HH HO
R R R
O
X
O
X
X=Cl (±)-61b,c,e,h-l 
X=H (±)-60a-c
PH=7; R.T.
SAM II
(S)-(-)-61b,c,e,h-l 
(S)-(-)-60a-c
(R)-(-)- 58a-c,e,h-l
+
Scheme 7.4: Enzymatic hydrolyses of acetates and chloroacetates
The racemic and enantiopure 1-aryl-2-propyn-1-ols 58 a-l were
cyclized with 2-iodophenol to the corresponding aryl-2-benzo[b]furan
carbinols 27g-h and 63a-d and with 2-N-Mesyl iodoaniline to aryl-2-(N-
mesyl)indol carbinols 64a-g using Pd(0) as catalyst (Scheme 7.5). Both
products were obtained in high e.e. and chemical yield. These constitute the
first applications of Pd catalyses with enantiopure arylpropynols.
PdCl
2
{P(Ph
 3
)]
2
; CuII
X
X = O; M=N-Ms
H
OH OH
`
X
H+
TMG, AR, 400 C
( R )-58 X=O  (S )-2 7 or (S)-63
X= N -Ms ( S)-64
Scheme 7.5:Cyclization of racemic and enantiomeric 1-aryl-2-propyn-1-ols to aryl-
benzo[b]furancarbinols 27 and 63or Aryl-N-Ms indolylcarbinols 64
The reaction conditions were optimized in order to maximize
chemical yields and enantiomeric excesses. The reaction was also applied
to propargylic amines to synthesize the 2-benzo[b]furanemethylamines 69.
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Finally an hypothesis for the mechanism of cyclization was
formulated. The first step is the Pd0 catalyzed addition of the acetylenic
compound to the 2-iodophenol leading to 62; the second step is the CuI
catalyzed cyclization to benzo[b]furane derivatives 27 or to N-Ms-indol
derivatives 64.
In conclusion the present work led to advances in the stereoselective
synthesis of antifungal agents such as bifonazole 6a and the aromatase
inhibitors 18; in fact the application of the described methodology to an
enantiopure amine may probably lead to the target molecule in
enantiopure form.
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8. Synthetic Procedures and Analytical Data
General Methods. Melting points were taken on a Gallenkamp
apparatus and are uncorrected. Optical rotations were measured on a
Perkin-Elmer 241 polarimeter. IR spectra (CHCl3 solutions unless
otherwise stated) were recorded on a Perkin-Elmer 398
spectrophotometer. NMR spectra were run on Bruker AC 200 (200
MHz), Bruker AV 250 (250 MHz) or Varian XL 300 (300 MHz)
spectrometers. 1H NMR chemical shifts are reported relative to CDCl3 at
 _ 7.24 ppm and tetramethylsilane at  0.00 ppm. EI low-resolution mass
spectra were recorded on a Kratos MS 80 spectrometer with an electron
beam of 70 eV. Elemental analyses (C, H, N) were performed in house on
a Perkin-Elmer 240C Analyzer.
Anhydrous DMF was purchased from Aldrich Chemical Co. THF
was distilled from potassium benzophenone ketyl. CH3CN was distilled
from P2O5. Reagents were from commercial suppliers and used without
further purification. Extracts were dried over Na2SO4 and evaporated
under reduced pressure using a rotary evaporator. Merck silica gel 60
was used for chromatography (70-230 mesh) and flash chromatography
(230-400 mesh) columns. The plates used for analytical and preparative
TLC were Merck silica gel 60 F254 (0.2 mm and 2 mm thickness,
respectively). Yields of the reactions refer to the purified products and
are not optimized.
8.1 Synthesis of prochiral benzophenones 25-a-f:
8.1.1 General synthetic procedure:
Benzoyl chloride (20 mmoles) was added dropwise within 20 min. to
a suspension of AlCl3 (28 mmoles) in dry 1,2-dichloroethane cooled to
0°C with an ice bath. A solution of biphenyl (20 mmoles) in dry 1,2-
dichloroethane was added to the reaction mixture 10 min. after the first
addition. The reaction mixture was heated to reflux for 28 hours, then
cooled to R.T. and poured into a 6N HCl solution. The mixture was
stirred for 15 min. The organic phase was separated, the water phase was
washed with  (2 x 100 ml) CHCl3 , the organic phases were collected and
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were washed with a saturated solution of NaCl until neutral pH and finally
dried over anhydrous Na2SO4. The organic phase was evaporated on the
rotavapor and the resulting crude product was triturated with petroleum
ether. 19.4 mmoles of 25a (97% yield) were recovered as white solid.
Identical procedures were used for compounds 25a-f. Only for 25b
benzene was used as solvent instead of 1,2-dichloroethane. See table 3.1,
chapter 3 for chemical yields, temperatures and reaction times.
8.2 Synthesis of Aryl-2-benzo[b]furanones 26a-e by the
Rapp Stormer procedure:
8.2.1 General procedure:
Salicyl aldehyde (469 mmoles, 50 ml) was added to an ethanolic
solution of NaOH (469 mmoles in 400 ml of abs. EtOH). Some solid was
formed during the addition. The reaction mixture was warmed to 50°C,
and 2,4-trichloroacetophenone in 300 ml of abs. EtOH was added
dropwise during 30 min. The mixture was refluxed for 24h, than was
cooled to R.T. and a white solid precipitated. It was filtered off on a
gooch funnel and washed with water and abs. EtOH. Finally it was kept
under high vacuum overnight. 118 gr of a white product 26c were
recovered (88% yield).
Identical procedures were used to obtain 26a-e, see chapter 3, table
3.2 for chemical yields and reaction times.
8.3 Synthesis of racemic alcohols (±)-27a-m by NaBH4
reduction:
8.3.1 General procedure:
The prochiral ketone 25c (14.8 mmoles) was dissolved in a 1:1
mixture of THF and EtOH. NaBH4 (44,5 mmoles) was added to the
Chapter 8 160
mixture as solid in small portions. The reaction was completed after the
last addition. The mixture was diluted with water, and the product was
extracted with CHCl3, the organic phase was washed with (50ml) 1N HCl,
saturated NaHCO3, saturated NaCl and the organic phase finally dried
using anhydrous Na2SO4. The organic phase was evaporated on a
rotavapor, the resulting crude solid was triturated with n-hexane. The
alcohol (±)-27c (14.6 mmoles, 95% yield) was recovered as white solid.
Identical procedures were used for the syntheses of 27a-m; see table
3.3, chapter 3 for chemical yields and reaction temperatures.
8.4 Synthesis of (R)-(-)-2-(isoindonylinyl)-butane-1-ol (R)-
            (-)-24
R-2-amino-1-butanole (0.84 mole; 79,64 ml) and 1,2-dichloroxylene
(0.84 mole; 465.1 g) were added to a suspension of K2CO3 (3.36 mol) in
1 L of acetonitrile. The mixture was stirred using a mechanical stirrer
under reflux for 24h. The mixture was cooled to room temperature and
the K2CO3 was filtered off. The solvent was evaporated and the resulting
crude oil was dissolved in EtOAc (750 ml). The organic solution was
washed with saturated NaHCO3 (2 x 200 ml), then the product was
extracted with 2N HCl solution (400 ml). 3N NaOH solution was added to
the acid solution until pH 12 was reached. The product was extracted with
EtOAc (800 ml) and after solvent evaporation the crude product was
purified by two high vacuum distillations. 134 g (84% yield) of product
(R)-(-)-24 were recovered.
8.5 Synthesis of chiral alcohols 27a-d,g,i by asymmetric 
reduction:
8.5.1.General synthetic procedure:
To a 1 M solution of LiAlH4 in Et2O (30 ml, 30 mmol) a solution of
(R)-(-)-2-(2-isoindolinyl)butan-1-ol (R)-(-)-24 (14.32 g, 75 mmol) in
200 ml of Et2O was added dropwise over 3 h at room temperature. After
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45 min, the mixture was cooled to -15 °C and a solution of 2-bromo-4'-
phenylbenzophenone 25c (8.43 g, 25 mmol) in 30 ml of Et2O was slowly
added during 2 h under stirring. After a further 15 min, the reaction
mixture was quenched with 1 N NaOH (20 ml). The organic phase was
successively washed with 1 N HCl (2 x 100 ml) and 1 N NaOH (2 x 100
ml), then with water to neutral pH. Concentration of the dried extracts
afforded a crude oil, which was purified by flash chromatography
(CHCl3/hexane 8:2) to give the title compound.
Identical synthetic procedures were used to reduce ketones 25a-d
and 26a,c. See chapter 3, table 3.4 for chemical yields and optical
purities (% e.e.) for 25a-d and chapter 3, table 3.5 for 26a,c.
8.6 Dehalogenation of (±)-27c, (+)-27c and (±)-27i:
8.6.1 Dehalogenation with Raney Nickel: general procedure.
Excess Ra-Ni (50% slurry in water) was added to a solution of
alcohol 27 (2.0 mmol) in 10 ml of MeOH. The mixture was heated to
reflux for 30 min. After cooling the reaction mixture was filtered
through celite and the filtrate was diluted with CHCl3, washed with brine
and dried. Evaporation of the solvent afforded a residue which was
purified by column chromatography .
4-phenyl benzhydrole (±)-27a was recovered in 35% yield and 28
n 35%yield.
(±)-27i decomposed under identical reaction conditions.
8.6.2 Dehalogenation with LiAlH4: general procedure.
LiAlH4 (1M THF solution, 2 mmol) was added to a solution of (±)-
27c (1 mmol) in dry THF. The reaction mixture was refluxed for 6 h,
then cooled to RT and the 1N HCl solution was added to quench the
reaction. The product was extracted with CHCl3 (2x50 ml), the organic
phase was dried over anhydrous Na2SO4. The crude product was purified
by flash chromatography. 4-Phenyl benzhydrole (±)-27a was recovered
in 89% yield. Identical reactions were carried out with the enantiopure
(+)-27c leading to enantiopure (+)-27a in 85 % yield.
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(±)-27i was almost unreactive under identical reaction conditions.
8.7 Mitsunobu Reaction with 4,5-dicyanoimidazole.
8.7.1 General synthetic method a:
Diethylazodicarboxylate (DEAD) (1 ml, 6.0 mmol) was added
dropwise to a cooled (0 °C) solution of alcohol 27 or 31 (6.0 mmol),
Ph3P (1.57 g, 6.0 mmol) and 4,5-dicyanoimidazole DCI (0.71 g, 6.0
mmol) in 60 ml of dry THF. The mixture was stirred for 0.5 h at room
temperature. Then the solvent was removed and the residue treated with a
1:1 mixture of hexane/Et2O. The solution was filtered, and the precipitate
was washed with hexane. Evaporation of the combined filtrates afforded a
crude product 33 which was purified as described below.
8.7.2 General synthetic method b:
The reaction was carried out by adding 1 equivalent of all the
reagents to alcohol 27 or 31 at 45 min intervals. After four additions of
reagents, the reaction mixture was allowed to stir at room temperature
for 24 h and was then treated as above.
For yields, absolute configurations and optical purities (% ee) see
Table 4.1 chapter 4.
8.8 Synthesis of the diacids 34.
8.8.1 General Procedure for the Hydrolysis of dicyanoimidazol
derivatives 33 to the Diacids 34.
A solution of 33 (10 mmol) in 30 ml of EtOH was refluxed for 24 h
in the presence of 10 M NaOH (30 ml, 0.30 mol). The hot solution was
poured into 150 ml of cold water, filtered, and brought to pH 2 with 37%
HCl. After cooling, the precipitate was filtered, washed with EtOH, then
with Et2O, and dried. For yields, absolute configuration and optical
purities (% ee) of the products, see Table 4.3; chapter 4.
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8.9 Decarboxylation of the diacids 34 to 1-Alkylimidazoles 35 
and Bifonazole 6a.
8.9.1 Decarboxylation: general procedure.
A solution of 34 (10 mmol) in 20 ml of diphenyl ether was heated at
reflux for 0.5 h and, after cooling, applied to a silica gel column. Elution
with Et2O eliminated the excess diphenyl ether and further elution with
AcOEt led to the products, which were further purified by preparative
TLC (AcOEt for 35a and 35b, CHCl3/MeOH 98:2 for 35c) or
recrystallization (for 35d and 6a). For yields, absolute configurations and
optical purities (% ee) of the products, see Table 4.4, chapter 4.
8.10 Synthesis of 4-(5)-ethyl imidazole carboxylate 37:
8.10.1 Synthesis of acetylglycine ethyl ester 38:
To a suspension of acetyl glycine hydrochloride(100 mmol) in
dichloromethane (400 ml) at 0° C triethylamine (TEA; 220 mmol) and
acetyl chloride (100 mmol) were added. After two hours the reaction
mixture was diluted with dichloromethane and water, the organic phase
was separated and washed with 1 N HCl solution,  saturated NaCl solution,
and then dried over anhydrous Na2SO4. The solid 38 was recovered after
evaporation (98 mmol, 98 % yield).
8.10.2 Synthesis of ethyl 4(5)-(2-thiol)-imidazole carboxylate
40:
Sodium methoxide (95 mmol) was added to a solution of acetyl
glycine ethyl ester 38 (86 mmol) in benzene at 0°C in 10 small solid
portions. Ethyl formiate (258 mmol) was then added dropwise. The
reaction was carried out for 24 h at 0°C. An orange solid precipitated in
the reaction mixture and cold water (55ml) was added to the mixture
which then became clear. The benzene solution was separated from the
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aqueous phase which was cooled again to 0°C and then acidified with 12N
HCl (15.6 ml). KCNS (99 mmol) were added, the mixture was heated to
70°C for two hours and was then left to stand in the refrigerator for 48 h.
A precipitate was formed during this time , which was filtered off and
washed with cold water, and then dried under high vacuum over P2O5
overnight. 55 mmol of 40 were recovered (68 % overall yield).
8.10.3 Synthesis of ethyl 4(5)-imidazole carboxylate 37:
1.65 ml of conc. HNO3 were diluted with 4.75 ml of water and the
resulting solution was cooled to 0°C. NaNO2 (100mg) was added after 10
min.in a single portion and 4(5)-(2-thiol)-imidazole carboxylate 40 1.5 g
(8.7 mmol) was added in small solid portions. During the last addition the
temperature must be kept below 25 °C. After 30 min solid Na2CO3 was
added to the reaction mixture to neutralize the pH. The product was
extracted in CHCl3 (200 ml), the organic phase was washed with saturated
NaCl solution (2x 150 ml) and then dried over anhydrous Na2SO4. 840
mg of product 37 were recovered (69% yield).
8.11 Synthesis of ethyl 1-[-(4-Biphenylyl)benzyl]imidazole-5-
carboxylate 41a and ethyl 1-[-(4-biphenylyl)benzyl] 
imidazole-4-carboxylate 41b.
8.11.1 Synthesis 1:
Prepared by Mitsunobu coupling of alcohol 27a and ethyl 4(5)-
imidazole carboxylate 37 as the acidic reagent, following the same
procedure ( synthetic method 7.7.2 b) as described for the synthesis of
(±)-33g. After preliminary purification by flash chromatography (n-
hexane/AcOEt 3:1), the isomeric mixture was separated by another
chromatography using the same eluent affording the less polar compound
(Rf 0.66), which was assigned to have  the structure (±)-41a. The second
eluted isomer (±)-41b (Rf 0.22) was further purified by flash
chromatography using gradient elution with n-hexane/AcOEt 3:1 to 1:1.
8.11.2 Synthesis 2:
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Alcohol 27a (0.2 mmol) was dissolved in 5 ml of acetonitrile, the
solution was cooled to 0°C and bromo triphenyl phosphine (1.4 mmol)
was added to the solution. The reaction was stirred for three hours. TLC
showed that all of the starting material was consumed and was converted
into 42. Diisopropylethyl amine DIPEA and ethyl 4(5)-imidazole
carboxylate 37 were added and the temperature was allowed to rise to
RT. Stirring was continued over night, the solvent was evaporated, the
crude oil dissolved in CHCl3 and washed consecutively with 1 N HCl,
saturated solution of NaHCO3 and saturated  NaCl solution. The crude
product was purified by flash chromatography (n-hexane:EtOAc 1:1).
Products (±)-41a and (±)-41b were recovered in a 1 to 1 ratio with
32.5 % overall yield.
8.12 Synthesis of 1-[a-(4-Biphenylyl)benzyl]imidazole-5-
carboxylic Acid (±)-43.
10% aqueous LiOH (1 ml, 4.2 mmol) was added to a solution of 41a
(0.110 g, 0.29 mmol) in 4 ml of EtOH. After being stirred for 2 h, the
reaction mixture was cooled to 0 °C and acidified by addition of 1 N HCl.
The white precipitate was stirred at 0 °C for another 30 min, and then
filtered to give pure (±)-43 (0.098 g, 96%) as white crystals.
8.13 Synthesis of 5-amino-1-(2-octyl)imidazole-4-carbonitrile
(±)-46:
Dry NH3 was bubbled for 30 min through a stirred suspension of
aminomalonitrile p-toluensulfonate (3.9 g, 15.5 mmol) in dry CH3CN
(200 ml). After the separated solid was filtered off, the solution was
concentrated to 100 ml and then added to triethyl orthoformiate (2.6 ml,
15.5 mmol). The solution was heated under reflux for 15 min. To the
cooled mixture 2-octylamine (44) (2.6 ml, 15.5 mmol) was added and the
solution stirred at room temperature overnight. The solvent was
evaporated and the residue was purified by flash chromatography
(AcOEt/n-hexane 3:2) to give a yellow semisolid product, that after
trituration with Et2O/hexane afforded 5-amino-1-(2-octyl)imidazole-4-
carbonitrile (46) (1.8 g, 53%) as a white crystalline compound.
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8.14 Synthesis of 5-amino-1-(2-octyl)imidazole-4-carboxylic
acid (±)-47:
A mixture of 5-amino-1-(2-octyl)imidazole-4-carbonitrile 46 (0.30
g, 1.36 mmol), EtOH (3 ml) and aqueous 10 N NaOH (3 ml) was heated
under reflux for 24 h. The solution was cooled to room temperature,
diluted with water (2 ml) and neutralized by slow addition of 2 N HCl.
After 2 h in a cool place, the precipitate was filtered off and washed with
water to give 5-amino-1-(2-octyl)imidazole-4-carboxylic acid (47) (0.32
g, 115%) as a chromatographically pure (5% AcOH in AcOEt, Rf 0.58),
white crystalline solid with no defined melting point, containing some
crystal water.
8.15 Synthesis of 5-amino-1-(2-octyl)imidazole 48
The 5-amino-1-(2-octyl)imidazole-4-carboxylic acid 47 was
decarboxylated following the same procedure 7.9 as described for acids
34 affording 5-amino-1-(2-octyl)imidazole 48 in 15% yield.
8.16 Synthesis of 1-(2-Octyl)imidazole-4-carboxamide 49:
A solution of 5-amino-1-(2-octyl)imidazole-4-carbonitrile 46 (0.33
g, 1.5 mmol) in 10 ml of THF was added during 1 h to a refluxing
solution of isoamyl nitrite (0.63 ml, 4.5 mmol) in 5 ml of THF. After
being heated under reflux for 1 h, the reaction mixture was cooled,
concentrated and purified by flash chromatography (2.5% Et3N in
AcOEt, Rf 0.45) to provide 49 (0.19 g, 45%) as a white amorphous
powder with no defined melting point.
8.17 General procedure for the synthesis of N-[2,2-
(Dimethoxy)ethyl]amines 52a and 52b.
To a solution of (S)-(+)-2-octylamine (+)-44  and (S)-(-)-_-
methylbenzylamine (-)-51 (4.0 mmol) in 30 ml of CH3CN were added
anhydrous K2CO3 (0.83 g, 6.0 mmol) and bromoacetaldehyde dimethyl
acetal (0.68 g, 4.0 mmol). The reaction mixture was heated under reflux
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for 48 h. After cooling, the inorganic salts were removed by filtration
and the solution was evaporated under reduced pressure. The residue was
purified by column chromatography (AcOEt) to give 52a and 52b as
yellow oils which were used without further purification.
8.18 General procedure for the synthesis of 53a and 53b:
To a solution of 52a or 52b (2.0 mmol) in 50 ml of THF were
added 3 N HCl (0.8 ml, 2.4 mmol) and KSCN (0.23 g, 2.4 mmol). After
stirring at 70 °C for 8 h, the cooled solution was made basic by addition
of 1 N NaOH and extracted with CH2Cl2. The organic layer was washed
with brine, then dried and evaporated. The residue was purified by
column chromatography (AcOEt) to give pure 53a and 53b both in 84%
yield.
8.19 General procedure for the hydrogenolysis of 53a and 53b.
Ra-Ni (50% slurry in water; 500 mg) was added to a solution of 53a
or 53b (2.0 mmol) in 10 ml of MeOH. The flask was immersed in an oil
bath preheated to 100 °C and after 5 min cooled to room temperature.
The reaction mixture was filtered through celite and the filtrate was
diluted with CHCl3, washed with brine and dried. Evaporation of the
solvent afforded a residue which was purified by column chromatography
(5% MeOH in AcOEt) to give (S)-(+)-35a (85% yield) [identical in all the
respects to that obtained by decarboxylation of (S)-(+)-34a)] and (S)-(+)-
54 (quantitative yield).
8.20 Synthesis of Azides 55 a-d:
8.20.1General azide synthesis by diphenylphosphorylazide 
DPPA under Mitsunobu conditions:
To a solution of alcohol 27 (1 mmol), triphenyl phosphine (1 mmol)
and diethyldiazodicarboxylate (1 mmol) in dry THF, a solution of
diphenylphosphorylazide  (1 mmol) was added over a period of 15 min
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and the stirring was continued for about 24 h. The solvent was removed
by evaporation on a rotavapor, the crude oil dissolved in CH2Cl2, filtered
through a Florosil pad and then purified by flash chromatography
(CH2Cl2) on silica gel.
See chapter 4 and table 4.6 for chemical yields and enantiomeric
eccesses.
8.20.2 General azide synthesis by diazabicycloundecene 
(DBU) and diphenylphosphorylazide (DPPA):
Alcohol 27 (1 mmol) and DPPA (1.2 mmol) were dissolved in dry
toluene so that the final concentration of the alcohol was ca. 0.5-1 M. To
the mixture was added a slight excess of DBU (1.1-1.5 mmol). The
reaction mixture was stirred 12-24 h at RT, was then diluted with toluene
and washed consecutively with 1 N HCl, saturated NaCl solution and dried
over anhydrous Na2SO4. After solvent evaporation the crude oil was
purified by flash chromatography (CH2Cl2) on silica gel .
See chapter 4, table 4.7 for chemical yields and enantiomeric
purities.
8.21 General procedures for the synthesis of amines 56a-d:
8.21.1 Reduction of azides 55 by Ph3P/H2O:
To a solution of azide 55 (1 mmol) in THF/water 10:1 a solution of
Ph3P in THF was added. The mixture was stirred for 3 h. The solvent was
evaporated and the crude oil was purified by flash chromatography over
silica gel.
See chapter 4, table 4.8, method A for the chemical yields.
8.21.2 Reduction of Azides 55 by SnCl2:
To a stirred suspension of stannous chloride (2mmol) in methanol, a
solution of azide 55 (1mmol) in methanol was added dropwise. The
reaction was exothermic and N2 gas evolved. The mixture was stirred at
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room temperature for two hours. Methanol was evaporated , the resulting
oil was dissolved in ethylacetate and washed with 0.5 N NaOH solution.
The organic phase was washed with saturated solution NaCl and dried
over anhydrous Na2SO4. The crude oil was purified by flash
chromatography on silica gel.
See chapter 4, table 4.8 for the chemical yields.
8.22 Synthesis of diamides 57: general procedure
Diacid (±)-34e (1.25 mmol) was dissolved in dry dioxane (20ml)
containing carbonyl diimidazole (CDI; 2.89 mmol) and chiral amine (2.55
mmol). The mixture was refluxed for 8 h and after cooling, the solvent
was evaporated. The crude reaction mixture was dissolved in CHCl3, and
the solution washed consecutively with 1N HCl, saturated NaHCO3
solution and saturated solution of NaCl. The crude product was purified
by preparative TLC (eluent CH2Cl2-MeOH- AcOH 98:1:1). The two
diasteroisomers were completely separated in 1:1 ratio. Overall yield was
90%.
8.23 Synthesis of Aryl propynoles
8.23.1 Synthesis of 1-phenyl-2-propyn-1-ol (±)-58a by 
          addition of lithium acetylide to benzaldeyde:
Benzaldehyde (3.5 mmol) was dissolved in 10 ml of dry THF, the
solution was cooled to -78°C, and a 1N solution of lithium acetylide in
THF (3.7 mmol) was added dropwised over 30 min. After the addition the
temperature was raised to 0°C. The mixture was quenched with a
saturated solution of NH4Cl and was diluted with CH2Cl2 and water. The
organic phase was separated and washed with a saturated solution of NaCl,
and then dried over anhydrous Na2SO4. The product was purified by
flash chromatography on silica gel. The 1-phenyl-2-propyn-1-ol (±)-58a
 was recovered as colorless oil in 45 %yield.
Following the same procedure but with the addition of ethylen
diamine to the benzaldehyde solution the yield of (±)-58a was 42%.
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8.23.2      Synthesis of 1-aryl-(2-propyn-3-trimethylsilyl)-1-
       ols 59a-g: general procedure.
To a solution of trimethylsilyl acetylene (10 mmol) in dry THF at -
78°C n-butyl lithium (10.5 mmol) was added dropwise over 15 min. This
mixture was transferred via a needle to a solution of arylaldehyde in dry
THF at -78°C. The mixture was stirred without further cooling and the
temperature was allowed to raise to 0°C. The reaction was quenched with
a saturated solution of NH4Cl and diluted with CH2Cl2 and water. The
organic phase was separated and washed consecutively with saturated
NaCl solution and dried over anhydrous Na2SO4. The product was
purified by flash chromatography on silica gel.
See chapter 5, table 5-1 for products (±)-59a-g and chemical yields.
8.23.3 Desilylation of 1-aryl-(2-propyn-3-trimethylsilyl)-1-ols
     59a-g:
8.23.3.1 Desilylation using KF:
The (±)-1-aryl-(2-propyn-3-trimethylsilyl)-1-ol (±)-59(10 mmol)
was dissolved in 3 ml of DMF, KF (11 mmol) was added, and the mixture
was heated to 60°C for 3 h. It was then cooled to rt and diluted with
CH2Cl2 and 1N HCl. The organic phase was separated and washed
consecutively with 1N HCl, water and saturated NaCl solution. It was
finally dried over anhydrous Na2SO4. The crude oil was purified by flash
chromatography on a silica gel column.
See Table 5-2, chapter 5 for products (±)-58a-g and chemical
 yields.
8.23.3.2 Desilylation using TBAF in dry THF:
1-aryl-(2-propyn-3-trimethylsilyl)-1-ol ( 59 ) (10 mmol) was
dissolved in 5 ml of dry THF, the solution was cooled to -20°C and a 1 N
solution of TBAF in dry THF (11 mmol) was added. The cooling bath
was removed after 1 h and the reaction mixture was stirred at room
temperature for 4 h. The solvent was evaporated, the crude oil dissolved
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in CH2Cl2 and washed several times with water, then with a saturated
solution of NaCl, and finally dried over anhydrous Na2SO4. The crude oil
was purified by flash chromatography on silica gel.
See Table 5.3 chapter 5 for products (±)-58 and chemical yields.
7.23.3.3 Desilylation using K2CO3 in MeOH:
1-(3,4 dimethoxyphenyl)-(2-propyne-3-trimethylsilyl)-1-ol (±)-59g
(10 mmol) was dissolved in 25 ml of saturated K2CO3 solution in MeOH.
The mixture was stirred for five days at room temperature. The solvent
was evaporated and the crude product was dissolved in EtOAc. The
solution was washed with water, 1 N HCl and saturated NaCl solution.
The crude oil was purified by flash chromatography on silica gel. 1-(3,4
dimethoyphenyl)-2-propyne-1-ol (±)-58g was recovered in 43 % yield as
oil.
8.23.4 Synthesis of (±)-58a by addition of magnesium
methynyl   halide  to  benzaldehyde:
The aromatic aldehyde (15 mmol) was dissolved in dry (100ml)
THF, and the solution was cooled to low temperature. A THF solution of
magnesium methynyl halide (16 mmol) was added dropwise to the
solution within 30 min. The reaction mixture was stirred 1 h and then
quenched with 1 N HCl solution. The product was extracted with ethyl
acetate, and the organic phase washed with saturated NaCl solution. The
crude oil was purified by flash chromatography on silica gel, or by
distillation under high vacuum. In both cases further purifications were
not necessary.
See Table 5.4, chapter 5 for product (±)-58, chemical yield and
temperature.
8.24 Screening of lipases for the esterification of arylpropynols.
8.24.1 General screening procedure:
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In 10 ml of MTBE 100 mg of 1-(4-cyanophenyl)-2-propyn-1ol (±)-
58e were suspended, 50 mg of lipase and 150 mg of vinylacetate were
added. The reaction mixtures were stirred at room temperature for 7
days, and monitored every 24h by chiral GC. The analysis was
quantitative and allowed the determination of the conversion and the
enantiomeric excess of both product and starting material. Using this
method ten different lipases were tested, see chapter 5, table 5.5 for
qualitative results and enzymes tested. Only the lipases SAM I and SAMII
were considered for futher applications.
8.25 Synthesis of 1-aryl-2-propyn-1-ol acetate :
8.25.1 General method a:
To a solution of 1-phenyl-2-propyn-1ol (±)-58a (10 mmol) and
pyridine (10 ml) at 0°C, acetanhydride (10 mmol) was added dropwise
over 30 min. Reactions were carried out under stirring at rt for 12 h. The
reaction mixture was poured into 1 N HCl solution and the product
extracted with ethyl acetate. The organic phase was washed with 1 N HCl
solution and saturated NaCl solution and finally dried over anhydrous
Na2SO4. The crude oil was purified by flash chromatography on silica
gel. 1-phenyl-2-propyn-1ol acetate (±)-60a was recovered in 95.5 %
yield.
See chapter 5, table 5.6 for substrates, products and chemical yields.
8.25.2 General method b:
To a solution of aryl propynol (±)-58 (10 mmol) and triethylamine
(11 mmol) in dichloromethane (40 ml) at 0°C, acetyl chloride (10.5
mmol) was added dropwise over 30 min. The reaction mixture was
stirred for 1 h at room temperature, it was then diluted with CH2Cl2 and
washed consecutively with 1 N HCl solution, saturated NaCl solution and
then dried over anhydrous Na2SO4. The crude product was so clean that
further purification was unnecessary.
See chapter 5, table 5.6 for substrates, products and chemical yields.
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8.26 Screening of lipases and reaction conditions for the
hydrolysis of arylpropynol acetates (±)-60.
8.26.1 General procedure for the screening of lipases:
In 10 ml of 0.1 N phosphate buffer pH=7.0, 100 mg of 1-(4-
cyanophenyl)-2-propyn-1ol (±)-60e and 100 mg of lipase were
suspended. The reaction mixture was stirred at room temperature for 7
days and the reaction progress was monitored every 24h by chiral GC.
The analysis was quantitative and allowed to determine the conversion and
the enantiomeric excess of both product and starting material. Under
identical reaction conditions ten different lipases were tested, see chapter
5, table 5.8 for qualitative results and screened enzymes. Only the lipases
SAM I and SAMII were considered for further applications.
8.26.2 Cosolvent effect on the hydrolysis of arylpropynols
acetates (±)-60 by SAMII lipase:
In 10 ml of 0.1 N phosphate buffer pH=7.0 100 mg of 1-aryl-2-
propyn-1-ol acetate (±)-60, and 10 mg of crude lipase SAMII were
suspended. 0.1N NaOH was used as titrating reagent. The cosolvent of
choice was added as last component of the mixture. The reaction mixtures
were stirred at room temperature and reaction progress was monitored by
chiral GC. The analysis was quantitative and allowed the determination of
the conversion and the enantiomeric excess of both product and starting
material from the single chromatogram.
See chapter 5, table 5.8 for substrates and products, chemical yields,
conversions, E values and % of cosolvent used.
8.26.3 Temperature effect on the hydrolysis of arylpropynol
acetates (±)-60 in presence of SAMII lipase:
In 10 ml of 0.1 N phosphate buffer pH=7.0 100 mg of 1-aryl-2-
propyn-1-ol acetate (±)-60 and 10 mg of crude lipase SAMII were
suspended. 0.1N NaOH was used as titrating reagent. The reaction was
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carried out in a thermostated reactor. The reaction mixtures were stirred
at the desired temperature and monitored by chiral GC. The analysis was
quantitative and allowed the determination of conversion and the
enantiomeric excess of both product and starting material from the single
chromatogram.
See chapter 5, table 5.10 for substrates and products, chemical yields,
conversions and E-values and temperatures.
8.27 Synthesis of 1-aryl-2-propyn-1-ol chloroacetate (±)-61:
To a solution of aryl propynol (±)58 (10 mmol) and triethylamine
(11 mmol) in dichloromethane (40 ml) at 0°C, chloroacetic anhydride
(10.5 mmol) was added dropwise over 30 min. The mixture was stirred
 for 1 h at room temperature, then diluted with CH2Cl2 and washed
consecutively with 1 N HCl solution, saturated NaCl solution and finally
dried over anhydrous Na2SO4. The crude product was so clean that
another purification was unnecessary.
See chapter 5, table 5.11 for substrates, products and chemical yields.
8.28 Enzymatic resolution of chloroacetates (±)-61 b-c,e,h-l:
8.28.1 General procedure:
Chloroacetate (±)-61 (10 mmol)was suspended in 0.1 N phosphate
buffer (10 ml, pH=7.0) and the mixture was stirred 10 min.on the
autotitrator in order to test for non-catalyzed hydrolysis. Then the crude
lipase preparation of Pseudomonas species (SAMII) was added (10% by
weight of the ester). The reaction mixture was stirred at room
temperature, while the pH of the reaction was kept at pH 7.0 by
continuous addition of 1 N NaOH from an autoburette. The reaction
progress was monitored by chiral GC allowing simultaneous
determination of conversion and enantiomeric purities of both educt and
product. After the desired or required conversion was achieved the
reaction mixture was diluted with water and diethyl ether and the
resulting phases were separated. The organic phase was washed with
water and saturated NaCl solution and finally was dried over anhydrous
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Na2SO4. After removal of the solvent the resulting products were
separated and purified by flash chromatography on silica gel. The
enantiomeric purities of the products were determinated by chiral GC.
The enantiomeric excess of both the purified alcohol and the chloroacetate
were identical to those obtained directly from the reaction mixture.
In no case indications for a racemization during the work up or
purification were found.
See chapter 5, table 5.12 for products, starting materials, reaction
times, E-values, % e.e. and chemical yields.
8.29 Hydrolysis of enantiopure acetate (S)-60 and chloroacetate
(S)-61:
In 10 ml of satured K2CO3  the acetate (S)-60 or the chloroacetate
(S)-61 ( 2 mmol) were dissolved at 0°C. The raction mixture was stirred
for 30 min until the complete consumption of the starting material was
observed on TLC.The mixture was diluted with ethylacetate and water,
the organic phase was separated and washed with saturated NaCl and dried
over anhydrous Na2SO4 to afford the clean product (S)-(+)-58 which was
recovered in high yield.
See chapter 5, table 5.13 for substrates, products, % e.e  and
chemical yields.
8.30 Synthesis of Aryl-2-benzo[b]furanyl carbinoles 27g,l and
63a-d in racemic and enantiopure form via palladium-
catalyzed heteroannulation (general procedure).
Argon was bubbled into a solution of tetramethylguanidine (TMG,
376 ml, 3 mmol) in 2.5 ml of DMF for 15 min at 40°C before the addition
of 2-iodophenol (220.01 mg, 1 mmol), bis-triphenylphosphine palladium
(II) dichloride ( 17.5 mg, 0.025 mmol), CuI (4.5mg, 0.025 mmol) and 1-
Phenyl-2-propyn-1-ol (±)-39a ( 123.9 ml, 1mmol). The mixture was
stirred under argon at 40°C for four hours, whereby the color changed
from pale yellow to red/brown. After cooling, the reaction mixture was
diluted with 1N HCl (100ml) solution and ethyl acetate (200ml). The
organic layer was separated and washed with water, saturated NaCl
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solution and finally dried over anhydrous Na2SO4. After solvent
evaporation the crude oil was purified by flash chromatography on silica
gel to afford (±)-27g in 91% chemical yield.
The experimental procedure described above was applied also to the
racemic and enantiopure aryl propynols 58a-c,e,h-l. See chapter 6, table
6.5.for reaction times, chemical yields and enantiomeric purities.
8.31 Synthesis of aryl benzo[b]furan carbinol by base 
catalyzed 5-endotrig cyclization
8.31.1 Synthesis of phenyl-2benzo[b]furanyl carbinol (±)-27g
by base catalyzed 5-endotrig cyclization:
(2'-Hydroxyphenyl)-2-propyne-1-phenyl-1-ol (±)-62 (224 mg, 1
mmol) was dissolved in 2 ml of saturated K2CO3 solution in methanol.
After two hours the reaction was completed. Methanol was evaporated
and the crude product dissolved in ethylacetate. The solution was washed
with water and saturated solution of sodium chloride and finally dried
over anhydrous Na2SO4. The solvent was evaporated and the crude
product was filtered through a silica gel pad to afford phenyl-
2benzo[b]furanyl carbinol (±)-27g in 92% yield. All spectroscopic data
were identical with those obtained via other routes.
8.31.2  Cyclization of 1-phenyl-3-(2'acetoxyphenyl)-2-propyn-
          1-ol (±)71 to phenyl-2benzo[b]furanyl carbinol (±)-2 by 
          basic catalyzed 5-endotrig cyclization.
1-phenyl-3-(2'-acetoxyphenyl)-2-propyn-1-ol (±)-71 (265 mg,
1mmol) was dissolved in 5 ml of a saturated solution of K2CO3 in
methanol at 0°C. After one hour the TLC showed complete consumption
of the starting material. The methanol was evaporated, and the resulting
oil dissolved in ethylacetate and water. The organic phase was separated
and washed with saturated NaCl solution, and was finally dried over
anhydrous Na2SO4. After evaporation of the solvent (±)-27g was
obtained in 95.0% chemical yield.
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NMR and MS analysis were identical to that of (±)-27g synthesized
by Pd mediated cyclization.
8.32 Synthesis of racemic 1-phenyl-3-(2'aminophenyl)-2-
propyn-1-ol (±)-65.
Argon was bubbled trough a solution of tetramethylguanidine (TMG,
2.02 ml, 16 mmol) in 2.5 ml of DMF for 15 min at 40°C before the
addition of 2-iodoaniline (883.4 mg, 4 mmol), bis-triphenylphosphine
palladium (II) dichloride ( 141 mg, 0.05 mmol), CuI (38mg, 0.050 mmol)
and 1-Phenyl-2-propyn-1-ol (±)-27g ( 500 ml, 4 mmol). The mixture
was stirred under argon at 40°C for four hours, whereby color changed
from pale yellow to red/brown. After cooling, the reaction mixture was
diluted with ethyl acetate and was then washed consecutively with water,
saturated NaCl solution and finally dried over anhydrous Na2SO4. After
evaporation of the solvent the crude oil was purified by flash
chromatography on silica gel to afford (±)-65 in 48.8% chemical yield.
8.33 Synthesis of N-Mesyl-2-iodoaniline 46.
To a solution of methanesulfonyl chloride ( 371.1 ml, 4.79 mmol) in
5 ml of pyridine 2-iodoaniline ( 1.0 g, 4.56 mmol) was added at 0°C.The
reaction was carried out at room temperature for four hours after which
the TLC showed complete consumption of the starting material. The
reaction mixture was poured into 300ml of ice and the product
precipitated out. The solid was separated by filtration and washed with
water, then dried in a desiccator under vacuum over P2O5. 1.31 g of N-
Mesyl-2-iodoaniline 46 were obtained corresponding to 95% chemical
yield. The reaction was scaled up to 69 mmoles with identical results.
8.34 Synthesis of Aryl 2-(N-mesyl)-indolyl carbinols 64a-g in 
racemic and enantiopure form via palladium-catalyzed 
heteroannulation of arylpropagylic alcohols 58 (general 
procedure).
Argon was bubbled into a solution of tetramethylguanidine (TMG,
376 l, 3 mmol) in 2.5 ml of DMF for 15 min at 40°C before the
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 addition of N-Mesyl-2-iodoaniline 46  (297.11 mg, 1 mmol), bis-
triphenylphosphine palladium (II) dichloride ( 17.5 mg, 0.025 mmol),
CuI (4.5mg, 0.025 mmol) and 1-phenyl-2-propyn-1-ol 58a ( 123.9 ml,
1mmol). The mixture was stirred under Argon at 40°C for 4 whereby the
color changed from pale yellow to red/brown. After cooling, the reaction
mixture was diluted with 1N HCl solution and ethyl acetate. The organic
layer was separated and washed consecutively with water and saturated
NaCl solution and was finally dried over anhydrous Na2SO4. After
evaporation of the solvent the crude resulting oil was purified by flash
chromatography on silica gel to afford (±)-64a in 87% chemical yield.
The same experimental procedure was applied to all of the racemic
and enantiopure aryl propynols 58a-c,e,h-l. See chapter 6, table 6.7 for
reaction times, chemical yields and enantiomeric excesses.
8.35 Synthesis of (2'-Hydroxyphenyl)-2-propyn-1-phenyl-1-ol
(±)-62.
(±)-62 can be obtained as side product in the synthesis of 1-phenyl-
2-benzo[b]furane carbinol (±)-27g using 1% of palladium catalyst and
CuI (see Chapter 6.2.4.) or by using one equivalent of base (TMG,
Chapter 6.3.1) The second procedure is described below.
Argon was bubbled thruogh a solution of tetramethylguanidine
(TMG, 125 ml, 1 mmol) in 2.5 ml of DMF for 15 min at 40°C before the
addition of 2-iodophenol (220.01 mg, 1 mmol), bis-triphenylphosphine
palladium (II) dichloride ( 7.5 mg, 0.010 mmol), CuI (1.8 mg, 0.010
mmol) and 1-Phenyl-2-propyn-1-ol (±)-58a ( 123.9 ml, 1mmol). The
mixture was stirred under argon at 40°C for 4 h, whereby the color
changed from pale yellow to red/brown. After cooling, the reaction
mixture was diluted with 1N HCl solution and ethyl acetate. The organic
layer was separated and washed with water, saturated NaCl solution and
was finally dried over anhydrous Na2SO4. After evaporation of the
solvent the resulting crude oil was purified by flash chromatography on
silica gel to afford (±)-62 in 90% chemical yield.
8.36 Synthesis of racemic 1-Phenyl-3-(2'acetoxyphenyl)-2-
propyn-1-ole (±)-71.
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Argon was bubbled thrugh a solution of tetramethylguanidine (TMG,
2263.3 ml, 2.1 mmol) in 2.0 ml of DMF for 15 min at 40°C before the
addition of 2-acetyliodophenol (500 mg, 1.91 mmol), bis-
triphenylphosphine palladium (II) dichloride ( 66.7 mg, 0.09 mmol), CuI
(18.1 mg, 0.09 mmol) and 1-Phenyl-2-propyn-1-ol 58a ( 1260.1 ml, 2.1
mmol). The mixture was stirred under argon at 40°C for 4 h, whereby
color changed from pale yellow to red/brown. After cooling, the reaction
mixture was diluted with ethyl acetate. The organic layer was washed with
water and saturated NaCl solution and was finally dried over anhydrous
Na2SO4. After evaporation of the solvent the resulting crude oil was
purified by flash chromatography on silica gel to afford (±)-71 in 78.9%
chemical yield.
8.37 Analytical data:
4-Phenylbenzophenone 25a:
Synthetic procedure 7.1.1
1H-NMR (300 MHz; CDCl3) d = 7.70-7.31 (m,14H)
IR (CHCl3): n (cm-1) = 3030, 1690, 1610, 1290.
GC-MS = 258 (M+ 70%).
M.P. =110-112°C.
4'-Phenyl-2-bromobenzophenone 25c:
Synthetic procedure 7.1.1
1H-NMR (300 MHz; CDCl3) d = 7.88 (d 2H,8.7 Hz), 7.70-7.59 (m
5H), 7.52-7.31 (m 6H).
IR (CHCl3): n (cm-1) = 1675, 1625, 1300.
GC-MS = 338 (M+ 72%), 181 (100%).
M.P. = 97-98 °C.
4'-Phenyl-2-fluorobenzophenone 25d:
Synthetic procedure 7.1.1
1H-NMR (300 MHz; CDCl3) d = 7.95 (d 2H,8.5 Hz), 7.75-7.35
(m8H), 7.30-7.10 (m 3H).
13C-NMR (CDCl3) d = 192.92, 162.51, 157.50, 146.12, 139.83,
136.04, 133.03, 132.87, 130.70, 130.65, 130.40, 128.93, 127.29,
127.11, 127.01, 124.32, 124.25, 116.46, 116.03.
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IR (CHCl3): n (cm-1) = 1680, 1600, 1295.
GC-MS = 278 (M+ 100%).
M.P. = 101-102 °C.
4'-Phenyl-4-nitrobenzophenone 25e:
Synthetic procedure 7.1.1
1H-NMR (300 MHz; CDCl3) d = 8.35 (d 2H,8.9Hz), 8.10-7.85 (m
3H), 7.80-7.55 (m 4H), 7.50-7.30 (m 3H).
IR (CHCl3): n (cm-1 )= 1660.
GC-MS = 304 (M+ 100%).
M.P. = 135-136 °C.
4'-Phenyl-3-nitrobenzophenone 25f:
Synthetic procedure 7.1.1
1H-NMR (300 MHz; CDCl3) d = 8.65 (s 1H), 8.46 (d 1H, 7.70 Hz),
8.18 (d 1H, 6.10 Hz), 7.81 (d 2H, 7.7 Hz), 7.73-7.62 (m 5H), 7.49-
7.35 (m 3H).
IR (CHCl3): n (cm-1= 1675.
GC-MS = 304 (M+ 100%).
M.P. = 154-155 °C.
Phenyl-2-benzo[b]furanone 26a:
Synthetic procedure 7.2.1.
1H-NMR (300 MHz; CDCl3) d = 8.07-8.02 (m 1H), 7.75-7.46 (m
8H), 7.46-7.25 (m 1H).
IR (CHCl3): n (cm-1= 1675,1605,1550.
GC-MS = 222 M+ (100%).
M.P.= 105-106 °C.
4'-Cyanophenyl-2-benzo[b]furanone 26b:
Synthetic procedure 7.2.1.
1H-NMR (300 MHz; CDCl3) d =8.16 (d 2H, 9.0Hz), 7.84 (d2H, 9.0
Hz), 7.71 (d 1H,7.8Hz), 7.62-7.41 (m3H), 7.30 (d 1H 7.8Hz).
IR (CHCl3): n cm-1= 2220,1680,1610,1550.
GC-MS = 247 M+ (100%).
M.P.= 205-206 °C.
2',4'-Dichlorophenyl-2-benzo[b]furanone 26c:
Synthetic procedure 7.2.1.
1H-NMR (300 MHz; CDCl3) d = 7.70 (d1H, 8.1 Hz), 7.59-7.51
(m3H), 7.47 (s1H), 7.40 (m 3H).
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IR (CHCl3): n cm-1= 1675,1600,1560.
GC-MS = 291 M+ (100%)
M.P.= 96-97 °C.
4'-Fluorophenyl-2-benzo[b]furanone 26d:
Synthetic procedure 7.2.1.
1H-NMR (300 MHz; CDCl3) d  =7.99-7.92 (m 2H), 7.56 (d 1H
8.5Hz) 7.50 (m3H), 7.20-7.00 (m 3H).
IR (CHCl3): n cm-1= 1685,1600,1550.
GC-MS = 240 M+ (100%)
M.P.= 145-147°C.
4'-Chlorophenyl-2-benzo[b]furanone 26e:
Synthetic procedure 7.2.1.
1H-NMR (300 MHz; CDCl3) d =8.03 (d 2H, 9.2 Hz), 7.75-7.61 (m
2H), 7.55-7.38 (m4H), 7.37-7.30 (m 1H).
IR (CHCl3): n cm-1= 1680,1595,1540.
GC-MS = 256 M+ (100%)
M.P.= 152-153°C.
(±)-4-Phenyl benzhydrol (±)-27a:
Synthetic procedure 7.3.1.or 7.6.1 or 7.6.2.
1H-NMR (300 MHz; CDCl3) d =7.64 (m;3H), 7.50 (m, 9H), 7.32
(m,2H), 5.85 (s,1H), 2.45 (s,1H).
IR (CHCl3): n cm-1= 3380, 1605, 1295.
GC-MS = 260 M+ (58%), 243 M-OH (100%).
M.P. = 115-117°C.
(±)-2-Bromobenzhydrol (±)-27b:
Synthetic procedure 7.3.1.
1H-NMR (200 MHz; CDCl3) d =7.59 (1H), 7.53 (1H), 7.40 (2H),7.33
(3H), 7.27 (1H), 7.15 (1H), 6.19 (1H, d 3.7 Hz), 2.41 (1H,d 3.7 Hz).
IR (CHCl3): n cm-1= 3375, 1580, 1325.
GC-MS: 262 M+(76%), 246 M-OH (100%)
M.P = 58-59 °C.
(+)-2-Bromo-benzhydrol (+)-27b:
Synthetic procedure 7.5.1
[a]20D +46.6 (c 1.30, acetone). e.e. >95 %.
Absolute stereochemistry not determinated.
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Physical and spectral data were identical with those described above
for the racemate (±)-27b.
(±)-2-Bromo-4'-phenyl benzhydrol (±)-27c:
Synthetic procedure 7.3.1.
1H-NMR (200 MHz; CDCl3) d =7.48 (m,13 H), 6.24 (s, 1H), 2.44 (s,
1 H).
IR (CHCl3): n cm-1= 3365,1530,1350.
GC-MS: 339 M+ (68%), 322 M-OH (100%).
M.P. = 101-103 °C.
Anal. Calcd for C19H15BrO: C, 67.27; H, 4.46. Found: C, 67.35; H,
4.40.
(+)-2-Bromo-4'-phenylbenzhydrol (+)-27c.
Synthetic procedure 7.5.1
[a]20D +65.4 (c 2.60, CHCl3).
e.e.>95 % HPLC: chiracel OD n-hexane/EtOH 90:20; 1 ml/min. rt=
9.92 min (+)-27c; 13.44 min (-)-27c.
Absolute stereochemistry not determinated.
Physical and spectral data were identical with those described above
for the racemate (±)-27c.
(±)-2-Fluoro-4'-phenyl benzhydrol (±)-27d:
Synthetic procedure 7.3.1.
1H-NMR (200 MHz; CDCl3) d = 7.85 (d 2H,8.5 Hz), 7.75-7.45 (m
8H), 7.35-7.10 (m 3H), 6.35 (s 1H), 2.48 (s 1H).
MP=oil
(+)-2-Fluoro-4'-phenylbenzhydrol (+)-27d:
Synthetic procedure 7.5.1
[a]20D +58.4 (c 2.35, CHCl3).
e.e.>95 % HPLC: chiracel OD n-hexane/EtOH 90:20; 1 ml/min. rt=
8.52(+)-27d; 12.44 (-)-27d.
Absolute stereochemistry not determinated.
Physical and spectral data were identical with those described above
for the racemate (±)-27d.
(±)-4-Nitro-4'-phenyl benzhydrole (±)-27e:
Synthetic procedure 7.3.1.
1H-NMR (200 MHz; CDCl3) d= 7.85 (d, 2H, 9.1Hz), 7.50 (m, 11 H),
5.95 (s1H), 2.60 (s, 1H).
IR (CHCl3): n cm-1= 3375, 1515, 1340.
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GC-MS: 305 M+ (68%), 288 M-0H (100%).
M.P. = 165-166 °C.
(±)-3-Nitro-4'-phenyl benzhydrol (±)-27f:
Synthetic procedure 7.3.1.
1H-NMR (200 MHz; CDCl3) d =8.32 (s, 1H), 8.07 (d 1H, 9.1Hz),
7.73 (d 1H, 7.6Hz), 7.42 (m, 10H), 5.95 (s 1H), 2.34 (s 1H).
IR (CHCl3): n cm-1= 3380,1525,1335.
GC-MS: 305 M+ (78%), 288 M-OH (100%).
M.P. = 143-144 °C.
(±)-Phenyl-2-benzo[b]furanyl carbinol (±)-27g:
Synthetic procedure 7.3.1. or 7.30
1H-NMR (200 MHz, CDCl3) d = 2.70 (d,1H), 5.92 (d,1H), 6.51(
s,1H), 7.55-7.16 (m, 9H);
13C-NMR (CDCl3) d = 70.514, 103.912, 111.241, 121.057, 122.735,
124.191, 126.727, 127.969, 128.220, 128.477, 140.237, 155.010;
158.484;
13C-J MOD-NMR (CDCl3) d =(+)70.514, (+)103.912, (+)111.241,
(+)121.057, (+)122.735, (+)124.191, (+)126.727, (-)127.969,
(+)128.220, (+)128.477, (-)140.237, (-)155.010; (-)158.484;
GC-MS = M+ 224 (100%), M+-OH 207.
IR (CHCl3): n cm-1= 3390,1640,1600.
M.P. = 53-54 °C.
(S)-(+)-Phenyl-2benzo[b]furanyl carbinol (S)-(+)-27g:
Synthetic method 7.30:
[a]20D +16.94, (c 1.18 CHCl3 )97.53% ee (Chiracel OD n-
hexane/isopropanol) (S)-(+)-2a  rt=10.00 min., (R)-(-)-2a
rt=11.62 min.
Physical and spectral data were identical to those described above for
the racemate (±)-27g.
(±)-4'-Cyanophenyl-2-benzo[b]furanyl carbinol (±)-27h:
Synthetic procedure 7.3.1.
1H-NMR (200 MHz, CDCl3) d = 7.69-7.59 (m 4H), 7.54-7.41 (m
2H), 7.28-7.18 (m 2H), 6.55 (s 1H), 6.00 (d 1H, 4.3 Hz), 2.71 (d 1H,
4.3 Hz).
IR (CHCl3): n cm-1= 3385,1620,1590.
GC-MS = M+ 249 (73%), M+-OH 232 (100%).
M.P. = 115-116 °C
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(±)-2',4'-Dichlorophenyl-2-benzo[b]furanyl carbinol (±)-
27i:
Synthetic procedure 7.3.1.
1H-NMR (200 MHz, CDCl3) d = 7.64 (d 1H,8.6 Hz), 7.51-7.16 (m
5H), 6.46 (s 1H), 6.28 (d 1H, 3.16 Hz), 2.76 (d 1H, 3.16 Hz).
IR (CHCl3): n cm-1= 3380,1630,1590.
GC-MS = M+ 293 (87%), M+-OH 276 (100%).
M.P. = 85-86 °C.
(+)-2',4'-Dichlorophenyl-2-benzo[b]furanyl carbinol (+)-
27i:
Synthetic procedure 7.5.1
[a]20D +38.5(c 2.98, CHCl3).
e.e. = 66 % HPLC: Chiracel OD n-hexane/propanole 99-1; 1 ml/min.
rt= 61.52 min (+)-27i; 53.46 min (-)-27i
1H-NMR (200 MHz, CDCl3) of the crude of (+)-27i camphanic
ester (significant signals) d= 6.62 (s) (+)-27i, 6.58 (s) (-)-27i
relative ratio 7.99 / 1.72; e.e. 66%.
Unknown absolute stereochemistry.
Physical and spectral data were identical to those described above for
the racemate (±)-27i.
(±)-4'-Fluorophenyl-2benzo[b]furanyl carbinol (±)-27 l:
Synthetic procedure 7.3.1. or 7.30
1H NMR (200 MHz, CDCl3) d = 3.97 (s,1H), 5.85 (s,1H), 6.48
(s,1H), 7.05 (t,10 Hz,2H), 7.55-7.21 (m, 6H).
13C NMR (CDCl3) d= 69.764, 103.937, 111.206, 115.070, 115.499,
121.101, 122.833, 124.331, 127.847, 128.453 d, 136.003 d, 154.975,
158.177, 160.042, 164.942.
13C J MOD NMR (CDCl3) d= (+)69.764, (+)103.937, (+)111.206,
(+)115.070, (+)115.499, (+)121.101, (+)122.833, (+)124.331, (-
)127.847, (-)128.453 d, (-)136.003 d, (-)154.975, (-)158.177, (-
)160.042, (-)164.942.
IR (CHCl3): n cm-1= 3370,1660,1600.
GC-MS M+ 242(100%), M+ -OH 225 (86%).
M.P.=58-59°C
(R)-(-)-4'-Fluorophenyl-2benzo[b]furanyl carbinol (R)-(-)
-27 l:
Synthetic method 7.31.
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[a]20D -5.7 (c 1.75, CHCl3), enantiomeric excess 97.66% (Chiracel
OD n-hexane/isopropanole), rt= (S)-(+)-27 l 72.90 min., (R)-(-)-
27 l 76.29 min.
Physical and spectral data were identical to those described above for
the racemate (±) 27 l.
(±)-4'-Chlorophenyl-2-benzo[b]furanyl carbinol (±)-27-m:
Synthetic procedure 7.3.1.
1H NMR (200 MHz, CDCl3) d = 7.53-7.15 (m 8H), 6.51 (s 1H), 5.91
(d1H, 4.4Hz), 2.53 (d 1H, 4.4 Hz).
IR (CHCl3): n cm-1= 3385,1655,1620.
GC-MS M+ 258(90%), M+ -OH 241 (100%).
M.P.=77-79°C.
(R)-(-)-2-(Isoindonylinyl) butan-1-ol (R)-(-)24:
Synthetic procedure 7.4.
1H-NMR (200 MHz, CDCl3) d =7.20 (s 5H), 4.04 (s 4H), 3.76 (d 1H,
J = 4.1Hz), 3.71 (d 1H, J = 4.1Hz), 2.78 ( s1H), 170-1.49 (m 2H)
0.97 ( t 3H, J= 7.7 Hz).
M.P.= 59-60 °C.
[a]20D -20.01 (c 1.5, CHCl3).
1-Methylimidazole-4,5-dicarbonitrile 33a
Synthetic method 7.7.1
Purified by chromatography (AcOEt) and then recrystallized from
CH2Cl2/hexane.
1H-NMR (200 MHz, CDCl3) d = 3.85 (s, 3H), 7.70 (s, 1H).
IR (CHCl3): n cm-1= 2260
M.P.=  96-98 °C.
Elementary Analysis. calcd. for C6H4N4: C, 54.54; H, 3.05; N,
42.41. Found: C, 54.70; H, 3.00; N, 42.30.
1-(n-Octyl)imidazole-4,5-dicarbonitrile 33b
Synthetic method 7.7.1.
Purified by flash chromatography (AcOEt).
1H-NMR (200 MHz, CDCl3) d = 1.27 (t, J = 5 Hz, 3H), 1.66 (m,
10H), 1.93 (q, J = 5 Hz, 2H), 4.18 (t, J = 6 Hz, 2H), 7.69 (s, 1H).
IR (CHCl3): n cm-1= 2250 cm-1;
M.P. = Colorless oil.
Elementary Analysis. calcd.for C13H18N4: C, 67.79; H, 7.88; N,
24.33. Found: C, 68.08; H, 7.73; N, 24.19.
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(R,S)-(±)-1-(2-Octyl)imidazole-4,5-dicarbonitrile (±)-33c
Synthetic method 7.7.1.
Purified by preparative TLC (hexanes/AcOEt 3:1).
1H-NMR (200 MHz, CDCl3) d = 0.88 (t, J = 5.7 Hz, 3H), 1.28 (m,
8H), 1.65 (d, J = 5.7 Hz, 3H), 1.93 (m, 2H), 4.43 (sextet, J = 5.7 Hz,
1H), 7.75 (s, 1H).
IR (CHCl3): n cm-1= 2240 cm-1.
M.P.= Colorless oil.
Elementary Analysis. calcd. for C13H18N4: C, 67.79; H, 7.88; N,
24.33. Found: C, 67.92; H, 7.93, N, 24.15.
(S)-(+)-1-(2-Octyl)imidazole-4,5-dicarbonitrile (S)-(+)-
33c
Synthetic method 7.7.1:
[a]0546 +1.1 (c 2.91, CHCl3).
Physical and spectral data were identical with those described above
for the racemate (±)-33c.
(R)-(-)-1-(2-Octyl) imidazole-4,5-dicarbonitrile (R)-(-)-
33c
Synthetic method 7.7.1
[a]20546 -1.0 (c 2.18, CHCl3).
Physical and spectral data were identical with those described above
for the racemate (±)-33c.
(R,S)-(±)-1-(1-Phenyl-2-propyl)imidazole-4,5-
dicarbonitrile (±)-33d
Synthetic method 7.7.1.
Purified by flash chromatography (n-hexane/AcOEt 3:1). An
analytical sample was prepared by recrystallization from
benzene/cyclohexane.
1H-NMR (300 MHz, CDCl3) d = 1.48 (d, J = 4.3 Hz, 3H), 2.86 (dd, J
= 14.1, 4.3 Hz, 2H), 2.93 (dd, J = 14.1, 4.3 Hz, 2H), 4.38 (sextet, J =
4.3 Hz, 1H), 6.83 (m, 2H), 7.05 (m, 3H), 7.26 (s, 1H).
IR (CHCl3): n cm-1=2240 cm-1;
M.P.= 138-140 °C.
Elementary Analysis. calcd. for C14H12N4: C, 71.17; H, 5.12; N,
23.71. Found: C, 71.33; H, 5.01; N, 23.57.
(S)-(+)-1-(1-Phenyl-2-propyl)imidazole-4,5-dicarbonitrile
(S)-(+)-33d
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Synthetic method 7.7.1
[a]20D +58.8 (c 0.85, CHCl3).
Physical and spectral data were identical with those described above
for the racemate (±)-33d.
(R,S)-(±)-1-(1-Phenyl-1-propyl)imidazole-4,5-
dicarbonitrile (±)-33e
Synthetic method 7.7.1
Purified by flash chromatography (n-hexane/AcOEt 2:1 ). An
analytical sample was obtained by preparative TLC.
1H NMR (200 MHz, CDCl3) d= 1.05 (t, J = 7.4 Hz, 3H), 2.38
(quintet, J = 7.4 Hz, 2H), 5.23 (t, J = 7.4 Hz, 1H), 7.28 (m, 2H), 7.38
(m, 3H), 7.88 (s, 1H).
IR (CHCl3): n cm-1= 2250 cm-1;
M.P.= Colorless oil.
Elementary Analysis. calcd. for C14H12N4: C, 71.17; H, 5.12; N,
23.71. Found: C, 71.38; H, 5.20; N, 23.42.
(S)-(-)-1-(1-Phenyl-1-propyl)imidazole-4,5-dicarbonitrile
(S)-(-)-33e
Synthetic method 7.7.1
[a]20D -44.3 (c 2.82, CHCl3).
Physical and spectral data were identical with those described above
for the racemate (±)-33e.
1-(_-Phenylbenzyl)imidazole-4,5-dicarbonitrile 33f
Synthetic method 7.7.2
Purified by flash chromatography (n-hexane/AcOEt  2:1) followed
by recrystallization from Et2O.
1H NMR (200 MHz, CDCl3) d = 6.70 (s, 1H), 7.13 (m, 4H), 7.43 (m,
7H).
IR (CHCl3): n cm-1= 2240 cm-1
M.P.= mp 137-138 °C.
Elementary Analysis. calcd. for C18H12N4: C, 76.04; H, 4.25; N,
19.71. Found: C, 76.24; H, 4.18; N, 19.58.
(±)-1-[_-(4-Biphenyl)benzyl]imidazole-4,5-dicarbonitrile
(±)-33g
Synthetic method 7.7.2.
Purified by flash chromatography (n-hexane/AcOEt 5:1 to 3:1). An
analytical sample was prepared by recrystallization from Et2O.
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1H-NMR (200 MHz, CDCl3) d = 6.74 (s, 1H), 7.45 (m, 4H), 7.6 (m,
11H).
IR (CHCl3): n cm-1= 2225 cm-1.
M.P.= 58-59 °C.
Elementary Analysis. calcd. for C24H16N4: C, 79.98; H, 4.47; N,
15.54. Found: C, 80.12; H, 4.39; N, 15.49.
(R,S)-(±)-1-[_-(2-Bromophenyl)benzyl]imidazole-4,5-
dicarbonitrile (±)-33h
Synthetic method 7.7.2
Purified by flash chromatography (n-hexane/AcOEt 2:1) followed by
recrystallization from methanol.
1H-NMR (200 MHz, CDCl3) d = 6.82 (dd, J = 5.7, 2.0 Hz, 1H), 7.05
(s, 1H), 7.10 (m, 2H), 7.38 (m, 3H), 7.45 (m, 3H), 7.70 (dd, J = 5.7,
2.0 Hz, 1H).
IR (CHCl3): n cm-1= 2240 cm-1
M.P.= 176-177 °C.
Elementary Analysis. calcd. for C18H11BrN4: C, 59.52; H, 3.05; N,
15.43. Found: C, 59.43; H, 3.12; N, 15.58.
(R,S)-(±)-1-[_-(2-Bromophenyl)-4-
phenylbenzyl]imidazole-4,5-dicarbonitrile (±)-33i
Synthetic method 7.7.2.
Purified by flash chromatography (n-hexane/AcOEt 3:1) followed by
recrystallization from MeOH.
1H=NMR (200 MHz, CDCl3) d = 6.89 (dd, J = 6.0, 1.8 Hz, 1H), 7.06
(s, 1H), 7.14 (d, J = 7.0 Hz, 2H), 7.41 (m, 6H), 7.65 (m, 5H).
IR (CHCl3): n cm-1= 2230 cm-1
M.P.= 169-171 °C.
Elementary Analysis. calcd. for C24H15BrN4: C, 65.62; H, 3.44; N,
12.75. Found: C, 65.80; H, 3.33; N, 12.91.
(R,S)-(±)-1-{_-[2-Benzo(b)furan]-4-phenylbenzyl}
imidazole-4,5-dicarbonitrile (±)-33 l
Synthetic method 7.7.2.
Purified by flash chromatography (n-hexane/AcOEt 2:1) 1H-NMR (200
MHz, CDCl3) d = 6.68 (s 1H), 6.77 (s1H), 7.47-7.21 (m 8H),
7.55 (1H d, J =6.1Hz), 7.68 (s1H).
IR (CHCl3): n cm-1= 2220 cm-1
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(R,S)-(±)-1-(2-Octyl)imidazole-4,5-dicarboxylic acid (±)-
34a.
Synthetic method 7.8.1
Recrystallized from EtOH.
1H NMR (200 MHz, CDCl3) d = 0.86 (t, J = 6.0 Hz, 3H), 1.28 (m,
8H), 1.70 (d, J = 6.0 Hz, 3H), 1.90 (m, 2H), 5.93 (m, 1H), 8.68 (s,
1H).
IR (CHCl3): n cm-1= 1735 cm-1
M.P. = 188-190 °C.
Elementary Analysis. calcd. for C13H20N204: C, 58.19; H, 7.51; N,
10.44. Found: C, 58.31; H, 7.58; N, 10.29.
(S)-(+)-1-(2-Octyl)imidazole-4,5-dicarboxylic acid (S)-
(+)-34a.
Synthetic method 7.8.1
[a]20D +20.0 (c 0.95, CHCl3).
Physical and spectral data were identical with those described above
for the racemate (±)-34a.
(R,S)-(±)-1-(1-Phenyl-2-propyl)imidazole-4,5-
dicarboxylic acid (±)-34b.
Synthetic method 7.8.1
Recrystallized from EtOH,
1H NMR (200 MHz, DMSO-d6) d= 1.51 (d, J = 6.9 Hz, 3H), 3.10
(dd, J = 13.1, 6.7 Hz, 1H), 3.25 (dd, J = 13.1, 6.7 Hz, 1H), 6.07
(sextet, J = 6.9 Hz, 1H), 7.23 (m, 5H), 9.36 (s, 1H).
IR (nujol mull) n cm-1=1735
M.P.= 210-212 °C.
Elementary Analysis. calcd. for C14H14N204: C, 61.30; H, 5.14; N,
10.22. Found: C, 61.44; H, 5.27; N, 9.98.
(S)-(+)-1-(1-Phenyl-2-propyl)imidazole-4,5-dicarboxylic
acid (S)-(+)-34b.
Synthetic method 7.8.1
[a]20D +2.0 (c 1.40, C6H5N).
Physical and spectral data were identical with those described above
for the racemate (±)-34b.
(R,S)-(±)-1-(1-Phenyl-1-propyl)imidazole-4,5-
dicarboxylic acid (±)-34c.
Synthetic method 7.8.1
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Recrystallized from EtOH/H2O (7:3),
1H-NMR (200 MHz, CDCl3) d =0.98 (t, J = 6.8 Hz, 3H), 2.34
(quintet, J = 6.8 Hz, 2H), 6.83 (t, J = 6.8 Hz, 1H), 7.42 (s, 5H), 8.65
(s, 1H).
IR (nujol mull) n cm-1=1730;
M.P.= 180-182 °C.
Elementary Analysis. calcd. for C14H14N204: C, 61.30; H, 5.14; N,
10.22. Found: C, 61.51; H, 5.00; N, 10.06.
(S)-(-)-1-(1-Phenyl-1-propyl)imidazole-4,5-dicarboxylic
acid (S)-(-)-34c.
Synthetic method 7.8.1
[a]25365 -72.8 (c 2.80, DMF).
Physical and spectral data were identical to those described above for
the racemate (±)-34c.
1-(_-Phenylbenzyl)imidazole-4,5-dicarboxylic acid 34d.
Synthetic method 7.8.1
Recrystallized from EtOH.
1H-NMR (200 MHz, DMSO-d6)  =7.15 (m, 4H), 7.46 (m, 6H), 8.10
(s, 1H), 8.56 (s, 1H).
IR (nujol mull) n cm-1=1730 ;
M.P. = 202-204 °C.
Elementary Analysis. calcd. for C18H14N204: C, 67.07; H, 4.38; N,
8.69. Found: C, 67.30; H, 4.49; N, 8.50.
(R,S)-(±)-1-[_-(4-Biphenylyl)benzyl]imidazole-4,5-
dicarboxylic acid (±)-34e.
Synthetic method 7.8.1
Recrystallized from EtOH (70%)/DMF (98:2),
1H-NMR (200 MHz, DMF-d7) d = 7.45 (m, 10H), 7.85 (m, 4H), 8.41
(s, 1H), 8.95 (s, 1H).
mp 211-213 °C. IR (nujol mull) 1740 cm-1;
Elementary Analysis. calcd. for C24H18N204: C, 72.35; H, 4.55; N,
7.03. Found: C, 72.61; H, 4.38; N, 6.88.
(R,S)-(±)-1-(2-Octyl)imidazole (±)-35a.
Synthetic procedure 7.9.1. or 7.19.
1H-NMR (200 MHz, CDCl3) d = 0.76 (t, J = 7.0 Hz, 3H), 1.19 (br s,
8H), 1.41 (d, J = 7.0 Hz, 3H), 1.65 (q, J = 7.0 Hz, 2H), 4.04 (sextet, J
= 7.0 Hz, 1H), 6.82 (s, 1H), 6.97 (s, 1H), 7.38 (s, 1H).
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M.P. = oil.
Elementary Analysis. calcd. for C11H20N2: C, 73.28; H, 11.18; N,
15.54. Found: C, 73.48; H, 11.26; N, 15.26.
(S)-(+)-1-(2-Octyl)imidazole (S)-(+)-35a.
Synthetic procedure 7.9.1. or 7.19
[a]20D +16.0 (c 1.1, CHCl3).
Physical and spectral data were identical with those described above
for the racemate (±)-35a.
(±)-1-(1-Phenyl-2-propyl)imidazole (±)-35b.
Synthetic procedure 7.9.1.
1H-NMR (200 MHz, CDCl3) d = 1.45 (d, J = 7.0 Hz, 3H), 2.92 (d, J =
7.0 Hz, 2H), 4.30 (sextet, J = 7.0 Hz, 1H), 6.93 (m, 4H), 7.17 (m,
4H).
M.P. = oil.
Elementary Analysis. calcd for C12H14N2: C, 77.38; H, 7.58; N,
15.04. Found: C, 77.51; H, 7.67; N, 14.82.
(S)-(+)-1-(1-Phenyl-2-propyl)imidazole (S)-(+)-35b.
Synthetic procedure 7.9.1.
[]20D +93.3 (c 0.75, CHCl3).
Physical and spectral data were identical to those described above for
the racemate (±)-35b.
(R,S)-(±)-1-(1-Phenyl-1-propyl)imidazole (±)-35c.
Synthetic procedure 7.9.1.
1H-NMR (200 MHz, CDCl3) d =0.94 (t, J = 7.0 Hz, 3H), 2.23 (m,
2H), 5.00 (t, J = 7.0 Hz, 1H), 6.94 (s, 1H), 7.07 (s, 1H), 7.16 (m,
2H), 7.36 (m, 3H), 7.59 (s, 1H).
M.P.= oil.
Elementary Analysis. calcd. for C12H14N2: C, 77.38; H, 7.58; N,
15.04. Found: C, 77.48; H, 7.49; N, 15.03.
Starting from (S)-(-)-34c the racemic compound (±)-35c was
obtained.
(±)-1-(_-Phenylbenzyl)imidazole (±)-35d.
Synthetic procedure 7.9.1.
1H-NMR (200 MHz, CDCl3) d = 6.55 (s, 1H), 6.85 (s, 1H), 7.08 (m,
5H), 7.36 (m, 7H).
M.P. = 88-89 °C (CH3CN).
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Elementary Analysis. calcd. for C16H14N2: C, 82.02; H, 6.02; N,
11.96. Found: C, 81.89; H, 5.95; N, 12.16.
(R,S)-(±)-1-[_-(4-Biphenylyl)benzyl]imidazole [Bifonazole
(±)-6a].
Synthetic procedure 7.9.1.
1H-NMR (200 MHz, CDCl3) d = 6.58 (s, 1H), 6.88 (s, 1H), 7.13 (m,
10H), 7.42 (m, 6H). Anal. Calcd for C22H18N2: C, 85.13; H, 5.84; N,
9.03. Found: C, 85.21; H, 5.80; N, 8.99.
M.P. = 145-147 °C (EtOH) (lit.142 °C, from CH3CN).
Following the same procedure (±)-6a was also obtained in 94%
yield by decarboxylation of (±)-43.
Ethyl 4(5)-imidazol carboxylate 37:
Synthetic procedure 7.10.3
1H-NMR (200 MHz, CDCl3) d = 1.36 (3H, t J=7.13Hz), 4.38 (2H, q
J=7.13 Hz), 7.77 (s1H) 7.82 (s1H), 8.03 (s 1H).
Acetylglycine ethyl ester 38:
Synthetic procedure 7.10.1
1H-NMR (200 MHz, CDCl3) d = 1.28 (3H, Tr J =7.1 Hz), 2.04 (s,
3H), 4.05 (d 2H J=5.4 Hz), 4.21 (q 2H, J=7.4 Hz).
4(5)-(2-Thiol)-imidazol carboxylate 40:
Synthetic procedure 7.10.2
1H-NMR (200 MHz, DMSO) d = 1.29 (3H, t J= 7.06 Hz), 4.24 (2H, q
J= 7.06 Hz) 7.64 (s1H), 12.50 (s 1H), 12,76 (s1H).
(±)-Ethyl-1-[_-(4-biphenylyl)benzyl]imidazole-5-
carboxylate (±)-41a:
Synthetic method 7.11.1 50% yield; Synthetic method 7.11.2
16%yield
1H-NMR (200 MHz, CDCl3) d =1.27 (t, J = 7.1 Hz, 3H), 4.29 (q, J =
7.1 Hz, 2H), 7.13 (m, 4H), 7.36 (m, 7H), 7.58 (m, 5H), 7.85 (s, 1H).
M.P. = 136-137 °C (EtOH).
Elementary Analysis. calcd. for C25H22N2O2: C, 78.51; H, 5.80; N,
7.33. Found: C, 78.70; H, 5.75; N, 7.24.
(±)-Ethyl-1-[_-(4-biphenylyl)benzyl]imidazole-4-carboxy-
late  (±)-41b :
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Synthetic method 7.11.1 16% yield; Synthetic method 7.11.2
16%yield
1H-NMR (200 MHz, CDCl3) d =1.36 (t, J = 6.9 Hz, 3H), 4.34 (q, J =
6.9 Hz, 2H), 6.58 (s, 1H), 7.16 (m, 4H), 7.54 (m, 12H).
M.P.= 149-151 °C (EtOH).
Elementary Analysis. calcd. for C25H22N2O2: C, 78.51; H, 5.80; N,
7.33. Found: C, 78.73; H, 5.84; N, 7.19.
(±)-1-[_-(4-Biphenylyl)benzyl]imidazole-5-carboxylic acid
(±)-43.
Synthetic method 7.12
1H-NMR (200 MHz, DMSO-d6) d =7.41 (m, 4H), 7.62 (m, 6H), 7.69
(m, 7H). Anal. Calcd for C23H18N2O2: C, 77.95; H, 5.12; N, 7.91.
Found: C, 78.12; H, 5.19; N, 7.83.
IR (nujol mull) n cm-1=1740;
M.P.= 163-166 °C (EtOH/H2O).
(±)-5-Amino-1-(2-octyl)imidazole-4-carbonitrile (±)-46
Synthetic method 7.13.
1H-NMR (200 MHz, CDCl3) d =0.87 (t, J = 6.5 Hz, 3H), 1.26 (br s,
8H), 1.46 (d, J = 6.7 Hz, 3H), 1.75 (m, 2H), 3.96 (m, 1H), 7.13 (s,
1H).
IR 3360, 2240 cm-1;
M.P.=110 °C (cyclohexane).
Elementary Analysis. calcd. for C12H20N4: C, 65.41; H, 9.15; N,
25.44. Found: C, 65.67; H, 9.08; N, 25.25.
(±)-5-Amino-1-(2-octyl)imidazole-4-carboxylic acid (±)-
47
Synthetic method 7.14
1H-NMR (200 MHz, DMSO-d6 + D2O) d =0.84 (t, J = 7.3 Hz, 3H),
1.25 (br s, 8H), 1.37 (d, J = 7.4 Hz, 3H), 1.73 (m, 2H), 4.11 (m,
1H), 7.18 (s, 1H).
IR (nujol mull) n cm-1=3350, 1735;
47 was not further purified and was directly used in the next step.
(±)-5-Amino-1-(2-octyl)imidazole (±)-48
Synthetic method 7.15
1H=NMR (200 MHz, CDCl3 + D2O) d = 0.88 (t, J = 6.8 Hz, 3H),
1.30 (br s, 8H), 1.48 (d, J = 7.0 Hz, 3H), 1.75 (m, 2H), 4.04 (m, J =
7.2 Hz, 1H), 4.75 (s, 1H), 7.21 (s, 1H).
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IR (CHCl3) n cm-1 = 3350;
M.P.= Colorless oil.
Elementary Analysis. calcd. for C11H21N3: C, 67.64; H, 10.84; N,
21.52. Found: C, 67.80; H, 10.72; N, 21.35.
(±)-1-(2-Octyl)imidazole-4-carboxamide (±)-49
Synthetic method 7.16.
1H-NMR (200 MHz, CDCl3 + D2O) d =0.86 (t, J = 6.7 Hz, 3H), 1.32
(m, 8H), 1.49 (d, J = 6.8 Hz, 3H), 1.75 (m, 2H), 4.17 (m, 1H), 7.59
(s, 1H), 7.67 (s, 1H).
IR (CHCl3) n cm-1 = 3540, 3420, 1670;
Elementary Analysis. calcd. for C12H21N3O: C, 64.51; H, 9.51; N,
18.81. Found: C, 64.84; H, 9.30; N, 18.48.
(±)-N-[2,2-(Dimethoxy)ethyl]-2-octylamine (±)-52a:
Synthetic method 7.17, 62% yield.
1H-NMR (200 MHz, CDCl3) d =0.88 (t, J = 6.3 Hz, 3H), 1.04 (d, J =
6.2 Hz, 3H), 1.27 (m, 8H), 2.05 (s, 1H), 2.72 (m, 4H), 3.85 (s, 6H),
4.65 (t, J = 6.2 Hz, 1H).
IR (CHCl3) n cm-1 = 3340;
(S)-N-[2,2-(Dimethoxy)ethyl]-2-octylamine (S)-52a:
Synthetic method 7.17, 65% yield
No specific rotation could be measured at different wavelengths.
Physical and spectral data were identical to those described above for
the racemate (±)-52a.
(±)-N-[2,2-(Dimethoxy)ethyl]-1-phenyl-1-ethylamine(±)-
52b:
Synthetic method 7.17, 70% yield.
1H-NMR (200 MHz, CDCl3) d =1.37 (d, J = 6.5 Hz, 3H), 1.65 (s, 1H,
exchangeable with D2O), 2.55 (dd, J = 12.1, 6.3 Hz, 1H), 2.65 (dd, J
= 12.1, 6.3 Hz, 1H),  3.29 (s, 3H), 3.34 (s, 3H), 3.76 (q, J = 6.5 Hz,
1H), 4.45 (t, J = 6.5 Hz, 1H), 7.35 (m, 5H).
IR (CHCl3) n cm-1 = 3345;
(S)N-[2,2-(Dimethoxy)ethyl]-1-phenyl-1-ethylamine
(S)-(-)-52b:
Synthetic method 7.17
[a]20D -31.0 (c 2.09, CHCl3).
Physical and spectral data were identical to those described above for
the racemate (±)-52b
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(±)-N-1-(2-Octyl)-2-thiol-imidazole (±)-53a:
Synthetic method 7.18,84% yield;
1H NMR (200 MHz, CDCl3) d= 0.82 (t, J = 7.0 Hz, 3H), 1.25 (m,
8H), 1.33 (d, J = 7.0 Hz, 3H), 1.70 (m, 2H), 4.92 (m, J = 7.0 Hz,
1H), 6.69 (s, 1H), 6.75 (s, 1H), 11.40 (br s, 1H, exchangeable with
D2O).
IR (CHCl3) n cm-1 = 2580;
M.P.= 84-85 °C (Et2O).
Elementary Analysis. calcd. for C11H20N2S: C, 62.21; H, 9.49; N,
13.19. Found: C, 62.41; H, 9.53; N, 13.25.
(S)-(-)-N-1-(2-Octyl)-2-tiol-imidazole (S)-(-)-53a:
Synthetic method 7.18
[a]20D -35.6 (c 0.45, CHCl3).
Physical and spectral data were identical to those described above for
the racemate (±)-53a.
(±)-N-1-(1-Phenylethyl)-2-thiol-imidazole-(±)-53b:
Synthetic method 7.18, 84% yield;
1H-NMR (200 MHz, CDCl3) d =1.74 (d, J = 7.4 Hz, 3H), 6.20 (q, J =
7.4 Hz, 1H), 6.58 (s, 1H), 6.70 (s, 1H), 7.32 (m, 5H), 11.93 (br s,
1H, exchangeable with D2O).
IR (CHCl3) n cm-1 = 2585;
M.P.=124-127 °C (Et2O).
Elementary Analysis. calcd.for C11H12N2S: C, 64.66; H, 5.92; N,
13.72. Found: C, 64.52; H, 5.88; N, 13.80.
(S)-(-)-N-1-(1-Phenylethyl)-2-thiol-imidazole (S)-(-)-53b:
Synthetic method 7.18
[a]20D -239.2 (c 4.10, CHCl3).
Physical and spectral data were identical to those described above for
the racemate (±)-53b
(±)-N-1-Phenyl-1-ethyl imidazole (±)-54:
Synthetic method 7.19
1H-NMR (200 MHz, CDCl3) d =1.87 (d, J = 8.0 Hz, 3H), 5.34 (q, J =
8.0 Hz, 1H), 6.90 (s, 1H), 7.08 (s, 1H), 7.14 (m, 2H), 7.30 (m, 3H),
7.58 (s, 1H).
M.P. =yellow oil.
Anal. Calcd for C11H12N2: C, 76.71; H, 7.03; N, 16.27. Found: C,
76.86; H, 7.10; N, 16.04.
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(S)-(+)-1-Phenyl-1-ethyl imidazole (S)-(+)-54:
Synthetic method 7.19
[a]20D +5.20 (c 3.84, CHCl3). e.e. > 98%.
Physical and spectral data were identical to those described above for
the racemate (±)-54.
(±)-55a:
Synthetic method 7.20.1
1H-NMR (200 MHz, CDCl3) d = 4.95 (s 1H), 7.14-7.27 (m 14H).
IR (CHCl3) n cm-1 = 2120;
MP: Oil
(±)-55b:
Synthetic method 7.20.1 or 7.20.2
1H-NMR (200 MHz, CDCl3) d = 6.1 (s1H),7.13-7.29 (m3H), 7.31-
7.59 (m10H).
IR (CHCl3): n cm = 2105 cm-1;
MP: Oil
(±)-55c:
Synthetic method 7.20.1 or 7.20.2
1H-NMR (200 MHz, CDCl3) d = 5.34 (s1H), 6.25 (s1H), 7.23-7.30
(m 3H), 7.41-7.60 (m 6H).
IR (CHCl3) n cm-1 = 2105;
MP: Oil
(±)-55d:
Synthetic method 7.20.1 or 7.20.2
1H-NMR (200 MHz, CDCl3) d = 6.22 (s 1H), 6.58 (s 1H), 7.17- 7.39
(m 3H), 7.43-7.54 (m 4H).
IR (CHCl3) n cm-1 = 2125;
MP: Oil
(+)-55d:
Synthetic method 7.20.2
[a]20D = +0.5 (c  4, CHCl3). e.e. ND
Physical and spectral data were identical to those described above for
the racemate (±)-55d.
(±)-56a
Synthetic method 7.21.1 or 7.21.2
1H-NMR (200 MHz, CDCl3) d = 1.98 (s 2H), 5.38 (s 1H), 7.28-7.55
(m14H).
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IR (CHCl3) n cm-1 = 420,3020,1620, 1600;
MP: Oil
(±)-56b:
Synthetic method 7.21.1 or 7.21.2
1H-NMR (200 MHz, CDCl3) d = 2.55 (s 2H), 5.22 (s 1H), 7.33-7.65
(m13H).
IR (CHCl3) n cm-1 = 3080,3020,1610, 1590;
MP: Oil
(±)-56c:
Synthetic method 7.21.1 or 7.21.2
1H-NMR (200 MHz, CDCl3) d = 2.28 (s 2H), 5.21 (s1H), 6.45 (s1H),
7.10-7.21 (m 3H), 7.27-7.47 (m 6H).
IR (CHCl3) n cm-1 = 3420,3120,1620, 1600;
MP: Oil.
(±)-56d:
Synthetic method 7.21.1 or 7.21.2
1H-NMR (200 MHz, CDCl3) d = 1.91 (s 2H), 5.69 (s 1H), 6.55 (s
1H), 7.15-7.7.27 (m 3H), 7.39-7.52 (m 4H).
IR (CHCl3) n cm-1 = 3390,3120,1620, 1600;
MP: Oil.
(+)-56d:
Synthetic method 7.21.1 or 7.21.2
[a]20D = not measurable  20%e.e. by chiral HPLC(Chiracel OD).
Physical and spectral data were identical with those described above
for the racemate (±)-56d.
(±)-57a as mixture of diasteroisomers:
Synthetic method 7.22.
1H-NMR (300 MHz, CDCl3) d = 1.63 (d 3H J =6.7 Hz), 5.94 (m 1H),
6.25 (s 1H), 7.06-7.28 (m 4H), 7.33-7.59 (m19H), 7.68-7.91 (m 4H).
57b:
Synthetic method 7.22.
1H-NMR (300 MHz, CDCl3) d = 1.75 (d 3H J =7.0 Hz), 1.85 (d3H J
=7.0 Hz), 6.05 (q J =7.0 Hz, dq J =6.17 Hz and J =8.8 Hz) 7.05-804
m, 8.13 (d 1H, J =8.8 Hz), 11.95 (d 1H, J =7.0 Hz).
FAB MS= 705 M+.
HPLC: Lichrocart 250X4, Lichrospher n-hexane/EtAc gradient rt
16.40 min
Chapter 8 198
57c:
Synthetic method 7.22.
1H-NMR (300 MHz, CDCl3) d = 1.75 (d 3H J =7.0 Hz), 1.85 (d3H J
=7.0 Hz), 6.05 (q J =7.0 Hz, dq J =6.17 Hz and J =8.8 Hz) 7.05-804
m, 8.05 (d 1H, J =8.8 Hz), 11.88 (d 1H, J =7.0 Hz).
FAB MS= 705 M+.
HPLC: Lichrocart 250X4, Lichrospher n-hexane/EtAc gradient rt
17.66 min
(±)-57d mixture of diasteroisomers:
Synthetic method 7.22.
1H-NMR (200 MHz, CDCl3) d = 1.52 (d 3H J =7.10 Hz), 1.62 (d 3H
J =7.10 Hz), 5.13 (m 1H), 5.32 (m m1H), 7.03-7.58 (m 24H), 8.01
(d 1H J=8.5 Hz) 8.27 (s 1H) 11.62 (m2H).
FAB MS= 604 M+.
(±)-1-Phenyl-2-propyn-1-ol (±)-58a:
Synthetic methods 7.23.1, 7.23.3.1, 7.23.3.2, 7.23.4. The compound
is commercially available.
1H-NMR (200 MHz, CDCl3) d = 2.28 (d 1H, 6.23 Hz), 2.69 (d 1H, J =
2.17 Hz), 5.48 (dd 1H, J=2.17 Hz; J=6.21 Hz), 7.59-7.32 (m3H).
13C NMR (CDCl3) n = 64.05, 74.65, 83.36, 126.43, 128.27, 128.42,
139.81.
IR (CHCl3) n cm-1 = 3510, 3320, 3080, 2840, 2120.
MP =oil.
(±)-1-(4-Methylphenyl)-2-propyn-1-ol (±)-58b:
Synthetic method 7.23.3.1 or 7.23.4.
1H-NMR (200 MHz, CDCl3) d = 2.19 (d 1H, J =4.12 Hz), 2.40
(s 3H), 2.69 (d 1H, J = 2.2 Hz), 5.48 (d 1H, J = 4.12 Hz), 7.24 (d 2H,
J= 8.12 Hz), 7.48 (d 2H, J= 8.12 Hz).
13C NMR (CDCl3) d = 21.29, 64.49, 74.72, 83.85, 126.71, 129.51,
137.42, 138.59.
IR (CHCl3) n cm-1 = 3540, 3380, 3280, 2120, 1610, 1510.
MP = oil.
(R)-(-)-1-(4-Methylphenyl)-2-propyn-1-ol (R)-(-)-58b:
Synthetic methods 7.28.1, 7.28.2
[a]20D -27.9 (c  3.05, CHCl3). 75.7% ee.
Physical and spectral data were identical to those described above for
the racemate (±)58b.
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(±)-1-(4-Fluorophenyl)-2-propyn-1-ol (±)-58c:
Synthetic methods 7.23.3.1, 7.23.3.2, 7.23.4.
1H-NMR (200 MHz, CDCl3) d = 2.71 (d 1H, J= 2.9 Hz), 2.73 (s1H),
5.47 (d1H, J =2.90 Hz), 7.12-7.07 (m 2H), 7.57-7.53 (m 2H).
13C NMR (CDCl3)  = 63.85, 75.25, 83.53, 115.79, 116.23, 128.69,
136.9, 161.71, 164.166.
IR (CHCl3) n cm-1 = 3400, 3390, 3280, 2120, 1610, 1520.
GC-MS = M+ 149 (45%) 133.7 (73%), 101.8 (100%)
MP = oil.
(R)-(-)-1-(4-Fluorophenyl)-2-propyn-1-ol (R)-(-)-58c:
Synthetic method 7.28.2
[a]20D -28.3 (c  2.11, CHCl3). 83.2% ee.
Physical and spectral data were identical to those described above for
the racemate (±)-58c.
(±)-1-(4-Chlorophenyl)-2-propyn-1-ol (±)-58d:
Synthetic method 7.23.3.1
1H-NMR (200 MHz, CDCl3) d = 2.20 (s1H), 2.65 (d 1H, J = 1.91
Hz), 5.44 (d 1H, J = 1.91 Hz), 7.28 (d 2H, J = 8.51 Hz), 7.38 (d 2H,
J= 8.51 Hz).
13C NMR (CDCl3) n = 63.77, 75.13, 83.41, 128.16, 128.91, 134.47,
138.83.
MP = oil.
(±)-1-(4-Cyanophenyl)-2-propyn-1-ol (±)-58e:
Synthetic method 7.23.4
1H-NMR (200 MHz, CDCl3) d = 2.72, (d 1H, J=6.10 Hz), 2.74 (d 1H,
J=2.10 Hz), 5.56 (dd 1 H, J=2.10 Hz, J = 6.10 Hz), 7.71 (s 4H).
13C NMR (CDCl3) d = 63.10, 75.47, 82.39, 111,68, 118.43, 127.07,
132.23, 145.12.
GC-MS = 157 M+ (100%).
IR (CHCl3) n cm-1 = 3445,3300, 2235, 1660, 1408.
MP= 79.5-80.5.
(R)-(-)-1-(4-Cyanophenyl)-2-propyn-1-ol (R)-(-)-58e:
Synthetic methods 7.28.1,7.28.2
[a]20D -20.8 (c  0.60, CHCl3). 85.5% ee .
Physical and spectral data were identical to those described above for
the racemate (±)-58e.
(±)-1-(3,4-Dimethoxyphenyl)-2-propyn-1-ol (±)-58g:
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Synthetic method 7.23.3.3.
1H-NMR (200 MHz, CDCl3) d =2.52 ( d 1H, J=5.7 Hz), 2.69 ( d 1H,
J=2.1 Hz), 3.89 (s 3H), 3.91 (s 3H), 5,42 (dd 1H, J=2.1Hz, J=5.7 Hz),
6.87 ( d 1H, J=8.7 Hz), 7.09 (d 1H, J=8.7 Hz), 7.11 (s 1H).
13C NMR (CDCl3) d = 56,12, 64.35, 74.78, 83.90, 110. 12, 111.24,
119.22, 128.95, 131.01, 133.02, 149.33.
MP= oil.
(±)-1-(3-Methylphenyl)-2-propyn-1-ol (±)-58h:
Synthetic method 7.23.4.
1H-NMR (200 MHz, CDCl3) d =2.33 (d 1H, J= 6.1 Hz), 2.42 (s 3H),
2.70 (d 1H, J= 2.21 Hz), 5.46 (dd 1H, J= 6.1 Hz,J= 2.21 Hz), 7.20 (d
1H, J= 8.1 Hz), 7.32 ( t 1H, J=8.1Hz), 7.39 (d 1H, J=8.1 Hz), 7.41 (s
1H).
13C NMR (CDCl3) d = 21.54, 64.63, 74.87, 83.83, 123.816, 127.42,
128.76, 129.48, 138.61, 140.19.
IR (CHCl3) n cm-1 = 3380, 3280, 2120, 1620, 1480.
GC-MS= 146 M+ (56%), 131 (100%).
MP= oil.
(R)-(-)-1-(3-Methylphenyl)-2-propyn-1-ol (R)-(-)-58h:
Synthetic method 7.28.2
[a]20D -27.5 (c  0.65, CHCl3). 92.1% ee .
Physical and spectral data were identical to those described above for
the racemate (±)-58h.
(±)-1-(3-Fluorophenyl)-2-propyn-1-ol (±)-58i:
Synthetic method 7.23.4
1H-NMR (200 MHz, CDCl3) d =2.45 (d 1H, J=6.10 Hz), 2.72 (d 1H,
J= 2.10 Hz), 5.50 (dd 1H, J= 2.1Hz, J= 6.10 Hz) 7.09-7.04 (m 1H)
7.42-7.30 (m 3H).
13C NMR (CDCl3) d = 63.89, 75.32, 83.14, 113.91, 115.65, 230.37,
142.66, 161.85, 164.29.
IR (CHCl3) n cm-1 = 3340, 3300, 2120, 1640, 1590.
GC-MS= 150 M+ (100%), 133 (70%).
MP= oil.
(R)-(-)1-(3-Fluorophenyl)-2-propyn-1-ol (R)-(-)-58i:
Synthetic method 7.28.2
[a]20D -21.1 (c  1.44, CHCl3). 91.5% ee .
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Physical and spectral data were identical to those described above for
the racemate (±)-58i.
(±)-1-(2-Methylphenyl)-2-propyn-1-ol (±)-58 l:
Synthetic method 7.23.4
1H-NMR (200 MHz, CDCl3) d =2.38 (d 1H, J=51 Hz) 2.49 (s 3H),
2.68 (d 1H, J=2.1 Hz), 5.65 (dd 1H, J=2.1 Hz, J= 5.03 Hz), 7.24-7.22
(m 1H), 7.31-7.27 (m 2 H), 7.72-7.70 (m 1H).
13C NMR (CDCl3) n = 19.04, 62.39, 74.84, 83.52, 126.42, 126.57,
128.72, 130.95, 136.07, 138.042.
GC-MS= 145 M+ (18%), 121 (100%).
MP= 30.6-32.0.
(R)-(-)-1-(2-Methylphenyl)-2-propyn-1-ol (R)-(-)-58 l:
Synthetic method 7.28.2
[a]20D -18.1 (c  0.65, CHCl3). 80.4% ee .
Physical and spectral data were identical to those described above for
the racemate (±)58 l.
(±)-1-(2,4 Dichlorophenyl)-2-propyn-1-ol (±)-58 m:
Synthetic method 7.23.4
1H-NMR (200 MHz, CDCl3) d =22.68 (d 1H, J=5.43 Hz), 2.71 (d 1H,
J=2.04 Hz), 5.79 (dd 1H, J=5.43 Hz,J=2.04 Hz), 7.33 (d 1H, J=8.35
Hz), 7.43 (s 1H), 7.73 (d 1H J=8.35 Hz).
13C NMR (CDCl3) d = 61.29, 75.29, 82.18, 127.73, 129.31, 129.68,
133.56, 135.18, 136.22.
MP=oil.
(±)-1-Phenyl-2-propyn-3-trimethylsilyl-1-ol (±)-59a:
Synthetic method 7.23.2
1H-NMR (200 MHz, CDCl3) d = 0.00 (s 9H), 2.40 (s1H), 5.65 (s1H),
7.67-7.23 (m5H).
IR (CHCl3) n cm-1 = 3620, 3450,3020,2090.
MP = oil.
(±)-1-(4-Methylphenyl)-2-propyn-3-trimethylsilyl-1-ol
 (±)-59b:
Synthetic method 7.23.2
1H-NMR (200 MHz, CDCl3) d = 0.00 (s 9H), 2.12 (s 1H), 2.34 (s 3H),
5.39 (s 1H), 7.16 (d 2H, J =8.02 Hz), 7.41 (d 2H, J = 8.02 Hz).
IR (CHCl3) n cm-1 = 3600, 3470,3020,2100.
MP = oil
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(±)-1-(4-Fluorophenyl)-2-propyn-3-trimethylsilyl-1-ol
(±)-59c:
Synthetic method 7.23.2
1H-NMR (200 MHz, CDCl3) d = 0.00 (s 9H), 2.16 (d 1H, J = 5.1 Hz),
5.42 (d 1H, J = 5.1 Hz), 7.06 (t 2H, 9.1 Hz), 7.51 (dd 2H, J= 6.1 Hz,
9.1 Hz).
IR (CHCl3) n cm-1 = 3580, 3460,3010,2080.
MP = oil
(±)-1-(4-Chlorophenyl)-2-propyn-3-trimethylsilyl-1-ol
(±)-59d:
Synthetic method 7.23.2
1H-NMR (200 MHz, CDCl3) d = 0.00 (s 9H), 2.01 (s 1H), 5.40 (s
1H). 7.30 (d 2H, J = 8.24 Hz), 7.46 (d 2H, J = 8.24 Hz).
IR (CHCl3) n cm-1 = 3580, 3460,3010,2080.
MP = oil
(±)-1-(4-Cyanophenyl) – 2 – propyn – 3 – trimethylsilyl – 1 - ol (±)-
59e:
Synthetic method 7.23.2
1H-NMR (200 MHz, CDCl3) d = 0.00 (s 9H), 2.31 (s 1H), 5.50 (s
1H), 7.66 (m 4H).
IR (CHCl3) n cm-1 = 3544, 3425, 2960, 2232, 2173, 1608.
MP = oil
(±)-1-(4-Nitrophenyl)-2-propyn-3-trimethylsilyl-1-ol (±)-
59f:
Synthetic method 7.23.2
1H-NMR (200 MHz, CDCl3) d = 0.00 (s 9H), 2.27 (s 1H), 5.54 (s1H),
7.71 (d 2H, J= 8.73 Hz), 8,22 (d 2H, J= 8.73 Hz).
MP = oil.
(±)-1-(3,4-Dimethoxyphenyl)-2-propyn-3-trimethylsilyl-1-
ol (±)-59g:
Synthetic method 7.23.2
1H-NMR (200 MHz, CDCl3) d = 0.00 (s 9H), 2.20 (d 1H, J = 4.42
Hz), 3.92 (s 3H), 3.96 (s 3H), 5,44 (d 1H, J = 4.42 Hz), 6.90 (d 1H, J
= 8.17 Hz) 7.11 (d 1H, J = 8.17 Hz), 7.15 (s 1H).
13C NMR (CDCl3) d = 0.000, 55.98, 56.14, 91.67, 105.312, 110.29,
111,22, 119,36, 133.25, 145.68, 149.37.
MP= oil.
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(±)-1-(Phenyl)-2-propyn-1-ol acetate (±)-60a:
Synthetic method 7.26.1 or 7.26.2.
1H-NMR (200 MHz, CDCl3) d =2.13 (s 3H), 2.67 (d 1H, J=2.29 Hz),
6.43 (d 1H, J =2.29 Hz) 7.57-7.34 (m5H).
13C NMR (CDCl3) d = 20.74, 65.04, 75.04, 80.04, 127.46, 128.47,
128.85, 136.25, 169.39.
IR (CHCl3) n cm-1 = 3320, 3080, 2120, 1760.
GC-MS 174 M+ (100%)
(±)-1-(4-Methylphenyl)-2-propyn-1-ol acetate (±)-60b:
Synthetic method 7.26.2
1H-NMR (200 MHz, CDCl3) d = 2.14 (s 3H), 2.41 (s3H), 2.67 D 1H,
J=2.9 HZ), 6.46 (d 1H J=2.19 Hz), 7.23 (d 2H, J=8.2 Hz), 7.46 (d
2H, J=8.2 Hz).
13C NMR (CDCl3) d = 21.34, 31.01, 65.36, 75.27, 80.61, 127.83,
129,52, 133.79, 139.22, 169.84.
(±)-1-(4-Cyanolphenyl)-2-propyn-1-ol acetate (±)-60c:
Synthetic method 7.26.2
1H-NMR (200 MHz, CDCl3) d =2.17 (s 3H), 2.73 (d 1H, J=2.28 Hz),
6.51  (d 1H, J=2.28 Hz), 7.68 (d 2H J=8.40 Hz), 7.73 (d 2H J=8.40
Hz).
13C NMR (CDCl3) d = 31.01, 65.01, 76.84, 78.30, 111.62, 118.25,
128.51, 132.79, 140.54, 169.73.
(±)-1-(4Methylphenyl)-2-propyn-1-chloroacetate (±)-61b:
Synthetic method 7.27.
1H-NMR (200 MHz, CDCl3) d = 2.47 (s 3H), 2.74 (s1H), 4.12 (dd
2H, J=4.9 Hz, J=7.2 Hz), 6.52 (s 1H), 7.26 (d2H, J= 8.1 Hz), 7.49
(d2H, J= 8.1 Hz).
13C NMR (CDCl3) d = 21.38, 40.95, 67.29, 76.58, 79.88, 128.01,
129.64, 132.88, 139.73, 166.31.
IR (film)cm-1 = 3090, 2120, 1780, 1760, 1520.
GC-MS = 218 M+ (18%), 128 (100%).
MP= oil
(S)-(-)-1-(4-Methylphenyl)-2-propyn-1-chloroacetate (S)-
(-)-61b:
Synthetic method 7.28.2
[a]20D - 23.3 (c  1.12, CHCl3). 97.8% ee .
Physical and spectral data were identical to those described below for
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the racemate (±)-61 b.
(±)-1-(4-Fluorophenyl)-2-propyn-1-chloroacetate (±)-61c:
Synthetic method 7.27.
1H-NMR (200 MHz, CDCl3) d = 2.77 (d 1H, J= 2.25 Hz), 4.11 (dd
2H, J=5.1Hz, J=10.8 Hz), 6.51 (d 1H, 2.25 Hz), 7.11 (t 2H, J=6.66
Hz), 7.57 (m 2H).
13C NMR (CDCl3) d = 38.94, 66.63, 76.80, 79.28, 116.06, 130.12,
131.76, 145.65, 162.19, 164.67, 166.25.
IR (film): n cm-1= 3290, 2980, 2120, 1780-1740,1610.
MP= oil.
(S)-(-)-1-(4-Fluorophenyl)-2-propyn-1-chloroacetate (S)-
(-)-61c:
Synthetic method 7.28.2
[a]20D - 11.8 (c  1.01, CHCl3). 96.8% ee .
Physical and spectral data were identical to those described below for
the racemate (±)-61c.
(±)-1-(4-Cyanophenyl)-2-propyn-1-chloroacetate (±)-61e:
Synthetic method 7.27.
1H-NMR (200 MHz, CDCl3) d = 2.80 (d 1H, J=2.34 Hz), 4.14 (m
2H), 6.56 (d 1H, J=2.34 Hz), 7.70 (d 2H, J=8.11 Hz), 7.75 (d 2H,
8.51 Hz).
13C NMR (CDCl3) d = 40.65, 66.25, 76.84, 78.30, 113.62, 118.23,
128.51, 132.80, 140.58, 166.10.
IR (CHCl3): n cm-1 = 3290, 2220, 2120, 1740,1620, 1510.
MP= 61-62 °C.
(S)-(-)-1-(4-Cyanophenyl)-2-propyn-1-chloroacetate  (S)-
(-)-61e:
Synthetic method 7.28.2
[a]20D - 31.3 (c  0.98, CHCl3). 96.6% ee .
Physical and spectral data were identical to those described below for
the racemate (±)-61e.
(±)-1-(3-Methylphenyl)-2-propyn-1-chloroacetate (±)-61h:
Synthetic method 7.27.
1H-NMR (200 MHz, CDCl3) d = 2.42 (s 3H), 2.74 (d 1H, J=2.15 Hz),
4.13 (dd 2H, J= 6.6Hz; J=15.10 Hz), 6.52 (d 1H, J=2.15 Hz), 7.24 (d
1H J=7.6 Hz), 7.39 (m 3H).
13C NMR (CDCl3) d = 21.94, 40.94, 67.40, 76.41, 79.58, 125.05,
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128.61, 128.87, 130.39, 135.66, 138.81, 166.28.
IR (film): __cm-1= 3290, 2135, 1785,1740,1610.
GC-MS = 222 M+ (18%), 128 (100%).
MP= oil
(S)-(-)1-(3-Methylphenyl)-2-propyn-1-chloroacetate  (S)-
(-)-61h:
Synthetic method 7.28.2
[a]20D - 13.9 (c  0.84, CHCl3). 99.2% ee .
Physical and spectral data were identical to those described below for
the racemate (±)-61 h.
(±)-1-(3-Fluorophenyl)-2-propyn-1-chloroacetate (±)-61i:
Synthetic method 7.27.
1H-NMR (200 MHz, CDCl3) d = 2.77 (d 1H, J=2.22 Hz), 4.15 (m
2H), 6.53 (d 1H; 2.22 Hz), 7.13 (m 1H), 7.36 (m 3H).
13C NMR (CDCl3)  = 40.79, 66.48, 78.89, 115.11, 116.72, 123.56,
130.61, 161.73, 164.19, 166.19.
IR (film): n cm-1=  2980, 2135, 1745,1590.
MP= oil.
(S)-(-)1-(3-Fluorophenyl)-2-propyn-1-chloroacetate  (S)-(-
)-61 i:
Synthetic method 7.28.2
[a]20D - 5.3 (c  1.33, CHCl3). 99.4% ee .
Physical and spectral data were identical to those described below for
the racemate (±)-61 i.
1-(2-Methylphenyl)-2-propyn-1-chloroacetate (±)-61 l:
Synthetic method 7.27.
1H-NMR (200 MHz, CDCl3) d = 2.48 (s 3H), 2.73 (d 1H, J=2.2Hz),
4.15 (m2H), 6.67 (d 1H, J=2.2Hz), 7.36-7.24 (m 3H), 7.66 (d 1H,
J=7.82).
13C NMR (CDCl3) d = 19.85, 40.84, 65.44, 76.44, 79.37, 126.57,
128.25, 129.61, 131.11, 133.87, 166.21.
IR (film): n cm-1= 3290, 2120, 1770,1730.
MP= oil.
(S)-(+)1-(2-Methylphenyl)-2-propyn-1-chloroacetate (S)-
(+)-61 l:
Synthetic method 7.28.2
[a]20D + 16.2 (c  1.25, CHCl3). 94.0% ee .
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Physical and spectral data were identical to those described below for
the racemate (±)-61 b.
1-(2,4-Dichlorophenyl)-2-propyn-1-chloroacetate (±)-61m:
Synthetic method 7.27.
1H-NMR (200 MHz, CDCl3) d = 2.77 (d 1H, J=2.21 Hz), 4.14 (m
2H), 6.78 (d 1H, J=2.21 Hz), 7.36 (d 2H, J=8.51 Hz), 7.46 (s 1H),
7.77 (d 1H, J=8.51 Hz).
MP= oil.
(2'-HydroxyPhenyl)-2-propyn-1-phenyl-1-ol (±)-62.
Synthetic method 7.35
1H NMR (CDCl3) d =2.90 (s, 1H), 5.65 (s, 1H), 6.85 (m,3H), 7.32
(m,4H), 7.68 (m, 2H).
13C NMR (CDCl3) d= 65.165, 81.590, 98.845, 108.809, 115.346,
120.174, 126.708, 128.568, 128.722, 130.589, 131.951, 140.068,
157.028.
13C J MOD NMR (CDCl3) d= (+)65.165, (-)81.590, (-)98.845, (-)
108.809, (+)115.346, (+)120.174, (+)126.708, (+)128.568,
(+)128.722, (+)130.589, 131.951, (-) 140.068, (-)157.028.
GC-MS M+ 224(100%), M+ -OH 207 (80%).
M.P.: oil.
(±)-(4'-Methylphenyl)-2-benzo[b]furanyl carbinol (±)-63a:
Synthetic method 7.30
1H NMR (CDCl3) d= 2.35 (s,3H), 2.44 (d, 2H, 4.5Hz), 5.90 (d, 2H,
4.5Hz), 6.52 (s,1H), 7.27-7.14 (m 5H), 7.51-7.34 (m 3H);
13C NMR (CDCl3) d= 21.076, 70.388, 103.729, 111.224, 121.002,
122.673, 124.078, 126.706, 128.032, 129.150, 137.392, 137.957,
155.003, 158.743;
13C J MOD NMR (CDCl3) d= (+)21.076, (+)70.388, (+)103.729,
(+)111.224, (+)121.002, (+)122.673, (+)124.078, (+)126.706, (-)
128.032, (+)129.150, (-)137.392, (-)137.957, (-)155.003, 1(-)
58.743;
GC-MS M+ 238 (100%); M+-OH 221.
(R)-(-)-4'-Methylphenyl- 2 benzo[b]furanyl carbinol (R)-(-
)-63a:
Synthetic method 7.30
[a]20D -8.05, (c 1.6 CHCl3); 99.0% ee (Chiracel OD n-
hexane/isopropanole), rt (S)-(+)-2b 55.28 min., (R)-(-)-2b 59.44
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 min.
Physical and spectral data were identical to those described above for
the racemate (±)-63a.
(±)-(3'-Methylphenyl)-2 benzo[b]furanyl carbinol (±)-63b:
Synthetic method 7.30.
1H NMR (CDCl3) d= 2.39 (s,3H), 2.53 (d, 4.3 Hz, 1H), 5.93 (d, 4.3
Hz, 1H), 6.57 (s, 1H), 7.32-7.18 (m,6H), 7.72-7.45 (m,2H).
13C NMR (CDCl3) d= 21.294, 70.509, 103.744, 111,219, 121.000,
122.664, 123.816, 124.075, 127.358, 128.003, 128.356, 128.957,
138.136, 140.211, 154.980, 158.653.
13C J MOD NMR (CDCl3) d= (+)21.294, (+)70.509, (+)103.744,
(+)111,219, (+)121.000, (+)122.664, (+)123.816, (+)124.075,
(+)127.358, (-) 128.003, (+)128.356, (+)128.957, (-)138.136, (-
)140.211, (-)154.980, (-) 158.653.
GC-MS M+ 238(100%), M+ -OH 221.
M.P: oil
(R)-(-)-(3'-Methylphenyl)-2benzo[b]furanyl carbinol (R)-(-
)-63b:
Synthetic method 7.30.
[a]20D -3.55, (c 2.81 CHCl3), 98.11% ee (Chiracel OD n-
hexane/isopropanole), (S)-(+)-2d rt= 15.38 min., (R)-(-)-2d rt =
17.86 min.
Physical and spectral data were identical to those described above for
the racemate (±)-63b.
(±)-3'-Fluorophenyl-2 benzo[b]furanyl carbinol (±)-63c:
Synthetic method 7.30.
1H NMR (CDCl3) d= 2.55 (d,4.2Hz,1H), 5.94 (d,4.2Hz,1H) 6.54
(s,1H), 7.37-6.98 (m,4H), 7.53-7.40 (m, 3H).
13C NMR (CDCl3) d= 69.745d, 104.097, 111.233, 113.435, 113878,
114.794, 115,215, 121.144, 122.236d, 124.390, 127.802, 130.014d,
142.757d, 154.979, 157.728, 160.334, 165.226.
13C J MOD (CDCl3) NMR  (+)69.745d, (+)104.097, (+)111.233,
(+)113.435, (+)113878, (+)114.794, (+)115,215, (+)121.144,
(+)122.236d, (+)124.390, (-)127.802, (+)130.014d, (-)142.757d, (-)
154.979, (-)157.728, (-)160.334, (-)165.226.
GC-MS M+ 242(100%), M+ -OH 225.
M.P: oil
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(R)-(+)-3'-Fluorophenyl-2 benzo[b]furanyl carbinol (R)-
(+)-63c:
Synthetic method 7.30.
[20D +6.23, (c 2.41 CHCl3) 98.50% ee (Chiracel OD n-
hexane/isopropanole), (S)-(-)-2e rt=73.36 min., (R)-(+)-2e
rt=83.54 min.
Physical and spectral data were identical to those described above for
the racemate (±) 63c.
(±)-2'-Methylphenyl-2benzo[b]furanyl carbinole (±)-63d:
Synthetic method 7.30.
1H NMR (CDCl3) d= 2.02 (s,1H), 2.48 (d,4.2Hz, 1H), 6.13 (d,4.2Hz,
1H), 6.40 (s,1H), 7.27-7.15 (m, 5H), 7.57-7.42 (m,3H).
13C NMR (CDCl3) d= 18.933, 67.475, 104.130, 111.253, 121.037,
122.718, 124.184, 126.219, 126.380, 128.083, 130.445, 135.512,
138.288, 155.036, 158.217.
13C J MOD NMR (CDCl3) d= (+)18.933, (+)67.475, (+)104.130,
(+)111.253, (+)121.037, (+)122.718, (+)124.184, (+)126.219,
(+)126.380, (-) 128.013, (+)128.083, (+)130.445, (-)135.512, (-
)138.288, (-)155.036, (-) 158.217.
GC-MS M+ 238(100%), M+ -OH 221.
M.P: oil
(R)-(-)-2'-Methylphenyl-2-benzo[b]furanyl carbinol (R)- (-
) 63d:
Synthetic method 7.30.
[a]20D -32.53, (c 1.076 CHCl3) 93.26% ee (Chiracel OD n-
hexane/isopropanole), (S)-(+)-2f rt=30.56 min., (R)-(-)-2f
rt=33.92 min.
Physical and spectral data were identical to those described above for
the racemate (±) 63d.
(±)-Phenyl-2-(N-mesyl)indolyl carbinol (±)-64a:
Synthetic method 7.33:
1H NMR (CDCl3) d= 3.02 (s,3H), 3.24 (d, 5.7 Hz,1H), 6.27 (s,1H),
6.37 (d,5.7Hz,1H), 7.51-7.24 (m,8H), 7.98 (7.56Hz,1H).
13C NMR (CDCl3) d= 40.772, 69.230, 111.256, 113.9912, 121.348,
123.677, 125.083, 127.122, 128.097, 128.351, 128.568, 137.134,
140.767, 143.037.
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13C J MOD NMR (CDCl3) d= (+)40.772, (+)69.230, (+)111.256,
(+)113.912, (+)121.348, (+)123.677, (+)125.083, (+)127.122,
(+)128.097, (+)128.351,(-)128.568, (-)137.134, (-)140.767, (-
)143.037.
GC-MS M+ 301(75%), M+ -OH 284 (30%), M+ -Ms 221 (100%)
M.P: 131.7-131.9 (DCM-Petroleum ether)
(S)-(+)-Phenyl-2-(N-mesyl)indolyl carbinol (S)-(+)-64a:
Synthetic method 7.33
[a]20D +22.3, (c 2.02 CHCl3) 96.74% ee (Chiracel OD n-
hexane/isopropanole), (R)-(-)-64a rt=12.69 min., (S)-(+)-64a
rt=15.13 min.
(±)-4'-Methylphenyl-2-(N-mesyl)indolyl carbinol (±)-64b:
Synthetic method 7.33
1H NMR (CDCl3) d= 2.37 (s,3H), 3.01 (s,3H), 3.15 (d,5.4 Hz, 1H),
6.29 (s,1H), 6.33 (d,5.4 Hz, 1H), 7.40-7.17 ( m,5H), 7.45 (d,8.49 Hz,
1H), 7.98 (d,8.64 Hz, 1H).
13C NMR (CDCl3)  21.106, 40.735, 69.040, 110.950, 113,859,
121.257, 123.576, 124.924, 127.036, 128.553, 128.982, 137.095,
137.786, 137.904, 143.205.
13C J MOD NMR (CDCl3) d= (+)21.106, (+)40.735, (+)69.040,
(+)110.950, (+)113,859, (+)121.257, (+)123.576, (+)124.924,
(+)127.036, (-)128.553, (+)128.982, (-)137.095, (-)137.786, (-
)137.904, (-)143.205.
GC-MS M+ 315(56.5%), M+ -OH 298 (20%), M+ -Ms 235 (100%)
M.P: 131.0-131.6 (DCM-Petroleum ether).
(R)-(-)-4'Methylphenyl-2-(N-mesyl)indolyl carbinol (R)-
(-)-64b:
Synthetic method 7.33
95.97% ee (Chiracel OD n-hexane/isopropanole), (R)-(-)-64b
rt=12.64 min., (S)-(+)-64b rt=16.08 min.
(±)-4'-Fluorophenyl-2-(N-mesyl)indolyl carbinol (±)-64c:
Synthetic method 7.33.
1H NMR (CDCl3) d= 2.98 (s,3H), 3.30 (d,5.38 Hz, 1H), 6.29 (s,1H),
6.34 (d,5.38 Hz, 1H), 7.05 (m,2H), 7.55-7.21 (m,6H).
GC-MS M+ 319(63%), M+ -OH 302 (12%), M+ -Ms 239 (100%)
M.P: oil.
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(R)-(-)-4'-Fluorophenyl-2-(N-mesyl)indolyl carbinol (R)-
(-) -64c:
Synthetic method 7.33
98.20% ee (Chiracel OD n-hexane/isopropanole), (R)-(-)-64c
rt=33.14 min., (S)-(+)-64c rt=39.78 min.
(3-Methylphenyl)-2-(N-mesyl)indolyl carbinol (±)-64e:
Synthetic method 7.33.
1H NMR (CDCl3) d= 2.36 (s,3H), 3.03 (s,3H), 3.17 (d,5.5Hz,1H),
6.27 (s,1H), 6.34 (d,5.5Hz,1H),7.35-7.14 (m,6H), 7.46 (d,8.1Hz,1H),
7.98 (d, 8.0Hz,1H).
13C NMR (CDCl3) d= 21.386, 40.770, 69.211, 111.236, 113.897,
121.313, 123.639, 124.165, 125.024, 127.719, 128.218, 128.582,
128.823, 137.115, 138.049, 140.752, 143.102.
13C J MOD NMR (CDCl3) d = 21.386, ___40.770, ___69.211,
___111.236, ___113.897, ___121.313, ___123.639, ___124.165,
___125.024, ___127.719, ___128.218, ___128.582, ___128.823,
____137.115, ___138.049, ___140.752, ___143.102.
GC-MS M+ 315(56.34%), M+ -OH 298 (12%), M+ -Ms 235 (100%)
M.P: 119.4-120.4 (DCM-Petroleum ether).
(R)-(-)-(3'-Methylphenyl)-2-(N-mesyl)indolylcarbinol  (R)-
(-)-64e:
Synthetic method 7.34.
[a]20D -16.7, (c 1.45 CHCl3) 99.12% ee (Chiracel OD n-
hexane/isopropanole), (R)-(-)-64e rt=10.76 min., (S)-(+)-64e
rt=13.16 min.
(±)-3'-Fluorophenyl-2-(N-mesyl)indolyl carbinol (±)-64f:
Synthetic method 7.34
1H NMR (CDCl3) d = 2.98 (s,3H), 3.32 (d,5.38Hz, 1H), 6.21 (s,1H),
6.34 (d,5.38Hz, 1H), 7.53-6.98 (m,7H), 7.98 (d, 8.5 Hz,1H).
GC-MS M+ 319(46.34%), M+ -Ms 239 (100%)
M.P: 109.4-110.6 (DCM-Petroleum ether).
(R)-(-)-3'-Fluorophenyl-2-(N-mesyl)indolyl carbinol (R)-
(-)-64f:
Synthetic method 7.34
[a] 20D-22.46, (c 1.50 CHCl3) 99.55% ee (Chiracel OD n-
hexane/isopropanole), (R)-(-)-64f rt=12.50 min., (S)-(+)-64f
rt=16.00 min.
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(±)-2'-Methylphenyl-2-(N-mesyl)indolyl carbinol (±)-64g:
Synthetic method 7.34.
1H NMR (CDCl3) d = 2.24(s,3H), 3.18 (s,3H), 6.58(d, 5.3 Hz,1H),
7.47-7.18 (m,6H), 7.63 (m,1H) 8.03 (d, 8.8 Hz).
13C NMR (CDCl3) d= 18.903, 40.898, 65.742, 110.980, 113.933,
121.342, 123.651, 125.087, 126.065, 126.200, 127.921, 128.582,
130.308, 135.395, 137.192, 139.229, 142.456.
13C J MOD NMR (CDCl3) d= (+)18.903, (+)40.898, (+)65.742,
(+)110.980, (+)113.933, (+)121.342, (+)123.651, (+)125.087,
(+)126.065, (+)126.200, (+)127.921, (-) 128.582, (+)130.308, (-)
135.395, (-)137.192, (-)139.229, (-)142.456.
GC-MS M+ 315(32.34%),, M+ -Ms 235 (100%)
M.P: 142.4-144.4 (DCM-Petroleum ether).
(R)-(-)-2'-Methylphenyl-2-(N-mesyl)indolyl carbinol (R)-
(-)-64g:
Synthetic method 7.34.
93.21% ee (Chiracel OD n-hexane/isopropanole), (R)-(-)-64g
rt=54.69 min., (S)-(+)-64g rt=63.38 min.
(±)-1-Phenyl-3-(2'aminophenyl)-2-propyn-1-ol (±)-65:
Synthetic method 7.32
1H NMR (CDCl3) d= 5.74 (s,1H), 6.66 (m,2h), 7.13 (t, 7.8Hz, 1H),
7.45-7.26 (m, 4H), 7.65 (d, 7.8 Hz, 2H).
13C NMR (CDCl3) d= 64.733, 83.047, 94.450, 107.241, 114.539,
117.850, 126.548, 128.080, 128.449, 129.738, 132.068, 140.733,
147.835.
13C J MOD NMR (CDCl3) d= (+)64.733, (-)83.047, (-)94.450, (-)
107.241, (+)114.539, (+)117.850, (+)126.548, (+)128.080,
(+)128.449, (+)129.738, (+)132.068, (-)140.733, (-)147.835.
M.P: oil.
N-Mesyl-2-iodoaniline 66:
Synthetic method 7.33:
1H NMR (CDCl3) d= 2.98 (s, 3H), 6.61 (s,1H), 6.91 (t, 7.9 Hz, 1H),
7.36 (t, 7.9 Hz, 1H), 7.63 (d, 7.9 Hz, 1H), 7.81 (d, 7.9 Hz, 1H).
GC-MS M+ 297(100%), M+ -Ms 218(75%).
(±)-1-Phenyl-3-(2'acetoxyphenyl)-2-propyn-1-ol (±)-71.
Synthetic method 7.36
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1H NMR (CDCl3) d = 2.13 (s,3H), 2.53 (s,3H), 5.65 (s,1H), 7.45-
6.90 (m,9H).
13C NMR (CDCl3) d= 20.551, 64.772, 81.287, 94.138, 116.661,
122.169, 125.860, 126.612, 128.281, 1288.556, 129.734, 133.045,
140.617, 151.727, 169.177.
13C J MOD NMR (CDCl3) d=  (+)20.551, (+)64.772, (-)81.287, (-)
94.138, (-)116.661, (+)122.169, (+)125.860, (+)126.612,
(+)128.281, (+)1288.556, (+)129.734, (+)133.045, (-)140.617, (-
)151.727, (-) 169.177.
GC-MS M+ 266(100%), M+ -OH 249 (39%), M+ -Ac 223 .
IR(film) n cm-1= 3500, 2900, 1760.
M.P. :oil
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